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ABSTRACT
An Analysis of Treatment Patterns, Receipt of Guideline-Concordant Care, and Survival
Outcomes among Elderly Women with Non-Metastatic Breast Cancer Using the SEERMedicare Linked Dataset
Traci LeMasters
Breast cancer (BC) is the 2nd most commonly diagnosed type of cancer in the United States (US)
and the 1st among women, with 57% of incident cases in those age > 60 years. Relative to other
cancers, BC has high survival rates, with a 89% 5-year overall survival rate. High survival rates are
due to improvements in disease understanding, treatment, and earlier stage at diagnosis from
increased routine BC screening. Yet, disparities in treatment and survival outcomes persist.
Epidemiologic studies suggest that elderly women experience disparities uniquely associated with
increasing age and comorbidity, in addition to those associated with socio-demographic
characteristics, access to oncology care resources, and clinical prognostic factors. This sequence of
retrospective database studies sought to characterize and examine associations with initial locoregional treatment for stage I and II BC, receipt of guideline-concordant care (GCC) and individual
tests and treatments for stage I-III BC, and overall 5-year survival among using the first two study
cohorts and a third, more broadly inclusive cohort of elderly women with stage I-III BC. Cohorts of
women age > 66 years diagnosed in 2003-2009 were selected from the Surveillance, Epidemiology,
and End Results-Medicare (SEER-Medicare) linked dataset. Regarding the 1st study, 55% of women
had breast-conserving surgery (BCS) plus radiation therapy (RT), 23% has mastectomy, and 22%
had BCS without RT as their initial loco-regional treatment. Compared to women who received BCS
plus RT, those who were older, of greater comorbidity, later stage, or non-white race were more
likely to have had mastectomy or BCS without RT. Women who were less likely to have had
mastectomy or BCS without RT were those treated by an oncology surgeon or both an oncology and
general surgeon vs. a general surgeon only, from areas of less education, lower income, or lived in
metro areas. Regarding the 2nd study, only 34% received GCC, 61% had RT, and 25% had
chemotherapy but, most women had their hormone receptor (HR) statuses and lymph nodes tested.
Women who were older, of greater comorbidity, stage II vs. I, lymph node negative, or non-white
race were less likely to receive GCC, while those who were HR negative or treated by an oncology
surgeon or both an oncology and general surgeon, vs. a general surgeon only were more likely to
receive GCC. Regarding the 3rd study, overall 5-year survival ranged from 82%-88% among the
three cohorts. The risk of death was greater for women who were older, of greater comorbidity,
diagnosed at a later stage, HR negative, treated by mastectomy, BCS without RT, did not received
GCC, RT, or chemotherapy, but was lower for women treated by an oncology surgeon or both an
oncology and general surgeon vs. a general surgeon only. Despite recommended treatment
guidelines, increasing age and comorbidity are strongly associated with less aggressive BC among
elderly women. Older women with BC should receive treatment according to guidelines as it would
be otherwise given to younger women, health permitting. While the increased risk of death
associated with increasing age is inevitable, targeting health behaviors to decrease comorbidity and
continued routine BC screening for earlier stage at diagnosis may go a long way to improve survival.
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CHAPTER 1
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CHAPTER 1
Background
Epidemiology
Female breast cancer is the second most prevalent type of cancer diagnosed in the United
States (US) population and the first among women.1 It is estimated that in 2014, 232,670 incident
diagnoses and 40,000 deaths will be attributed to breast cancer. It is estimated that about 1/8
women will develop breast cancer in their lifetime and as of January 1st, 2012, over 2.9 million
women with a history of breast cancer were living in the US. 2 The average age at diagnosis is 61
years. About 20% of breast cancer cases occur in women age < 50 years, 40% among women
age 50 – 64 years, and 40% among women age > 65 years. 3 Although breast cancer can occur in
men, it only accounts for about 1% of incident cases. 4
Risk Factors
Non-modifiable risk factors include gender, age, genetic mutations, race, family history
of breast cancer, personal history of breast cancer, history of DCIS or LCIS, age at menarche,
age at menopause, and radiation to the chest. Female gender, age > 55 years, and genetic
mutations increase the risk for breast cancer. Non-Hispanic White women have slightly higher
rates of breast cancer overall, but in women age < 45 years, rates are higher among non-Hispanic
Blacks. Although 85% of women who develop breast cancer do not have an immediate family
history of the disease (mother, sister, or daughter), women with an immediate family history are
almost twice as likely to develop breast cancer. Women who begin their menstrual cycle at age <
12 years and experience menopause at age > 55 years are at increased risk of developing breast
cancer due to prolonged exposure to the female hormones estrogen and progesterone, which can
stimulate malignant cell growth in breast tissue. Radiation to chest area, for treatment of an
earlier cancer, increases a woman’s chance of breast cancer if radiation was received earlier in
2

life, especially during the teenage years of breast development, but does not appear to increase
breast cancer risk if radiation treatment was received after the age of 40 years. 2, 5, 6 About 5% 10% of incident cases of breast cancer are attributable to inheritable genetic mutations, with
about 15% - 20% of those mutations to the BRCA1 and BRCA2 genes. While genetic mutations
are present in less than 1% of the population, they are more common among women of certain
ethnic groups, particularly those of Ashkenazi (Eastern European) Jewish descent. Genetic
testing for mutations to several genes that increase the risk of breast cancer are available, but
interpretation of results and subsequent treatment decisions remains challenging. The United
States Preventive Services Task Force (USPSTF) recommends that women with a very strong
family history of breast cancer be tested for BRCA mutations, while the American Cancer
Society (ACS) and American Society for Clinical Oncology (ASCO) recommend that any
women wanting genetic testing first meet with a genetic counselor to assess individual level of
risk for mutations, and the benefits and harms of testing. 4
Modifiable risk factors include age at first childbirth, history of breast feeding, use of oral
contraception, use of hormone replacement therapy, alcohol consumption, weight, and exercise.
Women who have not had children, or had children after the age of 30 years, are at a slightly
higher risk of breast cancer due to prolonged estrogen and progesterone exposure. Similarly, use
of oral contraceptives or combination estrogen/progesterone hormone replacement therapy after
menopause increases breast cancer risk. Also, since breast feeding lowers a woman’s total
number of menstrual cycles, women who do not breast feed are at an increased risk for breast
cancer. Elevated risk for breast cancer is also associated with a lack of exercise and being
overweight or obese. Although the relationship between weight and breast cancer is not well
understood, it is thought that women with higher percentages of body fat, particularly in the
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abdomen, have higher levels of estrogen in their bodies. Finally, women who consume 2 – 5
alcoholic drinks a day are about 1.5 times more likely to develop breast cancer, compared to
women who do not drink alcohol. 2, 5
Types of Breast Cancer
Female breast cancer, from here on referred to as “breast cancer”, can be classified into
two general categories, non-invasive and invasive. Non-invasive breast cancers, called “in situ”
are confined to either the ductal (ductal carcinoma in situ or DCIS) or lobular (lobular carcinoma
in situ or LCIS) regions of the breast tissue and are benign masses. Ductal carcinoma in situ
accounts for the majority (83%) of non-invasive breast cancer diagnoses. Together, DCIS and
LCIS comprise less than 11% of all breast cancer cases, but may increase the risk for developing
invasive breast cancer. The majority of breast cancer cases are invasive and can spread to areas
outside the breast tissue. Inflammatory breast cancer (IBC) is a rare form of invasive breast
cancer and accounts for 1% - 3% of all breast cancer cases. It is not characterized by any single
lump or tumor, making it hard to detect at an early stage. 2, 4
Breast Cancer Screening
Methods of breast cancer screening include mammography, magnetic resonance imaging
(MRI), ultrasound, and clinical breast exam (CBE). However, mammography is used at the
primary method to detect breast cancer. Recommended guidelines for the use of mammography
screening vary across agencies and remain controversial.
The American Cancer Society (ACS) and the National Comprehensive Cancer Network
(NCCN) recommend annual mammograms for women age > 40 years. 2, 7 The United States
Preventive Services Task Force (USPSTF) had previously recommended biennial screening
mammography in women age > 40 years. However, in 2009 the USPSTF released an updated
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statement that recommended against routine screening mammography in women 40 – 49 years of
age, biennial screening mammography for women 50 – 74 years of age, and rescinded any
recommendation for screening mammography among women age > 75 years. Changes to
recommended screening mammography guidelines were due to an internal USPSTF review of
evidence concluding that mammography resulted in only a small net benefit among women 40 –
49 and benefits were inconclusive evidence among women age > 75 years. 8
The sensitivity and specificity of mammography varies by study and patient
characteristics. The overall sensitivity of mammography ranges from 67.8% - 84.1%. 9 - 12
Mammography has been found to be less sensitive in younger women with denser breast tissue
(33% - 50%), compared to more fatty breast tissue (75% - 100%). 2, 4, 9 The overall specificity of
mammography ranges from 75% - 92%, but is also lower in younger women with more dense
breast tissue. 9, 11, 12 Additionally, longer intervals between mammography have been associated
with increased sensitivity and decreased specificity. 13
Reasons for false-positive mammography results include dense breast tissue, reading by a
less experienced radiologist, time since last screening, and availability of prior mammography
film for comparison. Additionally, benign breast abnormalities such as micro calcifications,
fibro adenomas, and cysts can make it difficult to distinguish between benign and cancerous
lesions.
Diagnosis & Characterization
Women with screening mammography results found to be normal, require no additional
testing and should continue routine screening. However, if a suspicious image cannot be
determined as benign or malignant, then a diagnostic mammogram should be performed, with or
without a breast ultrasound. Although, breast ultrasound is a complementary method to
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mammography, it does not detect the majority of micro calcifications. Mammography results
determined to be positive for breast cancer will require additional imaging and tests that may
include diagnostic mammography, breast ultrasound, MRI, and breast biopsy. Methods for a
breast biopsy include Fine Needle Aspiration Biopsy (FNA), Core Needle Biopsy (CNB), and
Excisional Biopsy.
Additional characteristics used to classify the type of cancer are the presence or absence of
certain hormone receptors. If receptors for estrogen or progesterone are present in the tumor,
they can also stimulate the growth of the tumor. Similarly, when the growth promoting protein
HER-2/neu is present, tumors will grow and spread more rapidly. Hormone receptor assay tests
identify the presence or absence of these hormone receptors. If a hormone receptor is present the
breast cancer is further classified as estrogen-receptor positive (ER-positive), progesteronereceptor positive (PR-positive), and/or HER-2 positive. These hormone classifications, in
conjunction with staging, determine the appropriate course of treatment. 14
Staging
Once a case of breast cancer has been diagnosed, the stage of cancer development is used
to characterize the severity and/or extent that the cancer has spread. Two commonly used
systems of staging are the American Joint Committee on Cancer (AJCC) TNM (See Tables 1 &
2) and the Surveillance Epidemiology End Results (SEER) Summary Stage systems. 14, 15
The SEER Summary Stage system for breast cancer is a more general system of staging breast
cancer. Under this system, stages are categorized into three groups: local-stage, regional-stage,
and distant-stage. In the local-stage, the cancer is confined to the breast tissue. In the regionalstage, the breast cancer has spread to surrounding tissue and lymph nodes. In the distant-stage,
the breast cancer has metastasized to distant organs. 4

6

Treatment
Local treatment focuses only on the area of the breast where the cancer is confined to,
while systematic treatment is given throughout the entire body to treat cancer that has spread
beyond the breast. Local treatment includes surgery and radiation therapy. The two primary
surgeries used to remove breast cancer are breast conserving surgery (BCS), i.e. lumpectomy,
and mastectomy. Many women may also undergo a lymphadenectomy to remove affected lymph
nodes. BCS removes the cancerous tumor and a small rim of healthy tissue surrounding the
tumor for earlier stage breast cancer. Surgical mastectomy removes the entire breast for later
stage diagnoses, or upon patient request. Two forms of lymphadenectomy are used to remove
affected lymph nodes. A sentinel lymph node biopsy examines lymph nodes when there is no
evidence that the cancer has spread to the nodes. A radioactive dye is injected into the breast, and
as the dye leaves the breast and travels through the lymph system, it leaves a path identifying the
first node nearest the breast. This node is removed and tested for cancer. If the test is negative,
no further node removal is necessary, otherwise more nodes will be removed. The number of
affected nodes influences the course of treatments. An axillary lymph node dissection is used to
remove lymph nodes under the armpit when there is sufficient evidence of malignancy.
Radiation therapy, another form of local treatment, directs a beam of high-energy rays to the
chest and breast area. External beam radiation therapy (EBRT) is most often used after BCS 5
days of week for 6 to 7 weeks to destroy any remaining cancerous cells. Radiation therapy is
recommended after BCS and after mastectomy if the tumor is > 5 cm. Radiation is also used to
treat the area where affected lymph nodes were removed.
Systematic treatment can be chemotherapy, hormone therapy, and targeted therapy.
Chemotherapy is a single drug or a mix of drugs used to kill cancerous cells that can be
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administered intravenously or orally with a pill. Chemotherapy is used if cancerous cells have
spread throughout the body in early stage breast cancers, or when the cancer has metastasized to
other parts of the body in later stages, to control the tumor growths. Chemotherapy can also be
used as neoadjuvant treatment to shrink tumors > 5 cm before surgery to remove the tumor.
Treatment is given in cycles of 14, 21, or 28 days, with days of rest in between over a period of 3
to 6 months.
Hormone therapy treats tumors that test positive for estrogen and/or progesterone
receptors. Estrogen and progesterone are hormones that promote the growth of normal breast
tissue in women, but can also promote the growth of cancerous cells when present in breast
tumors. Hormone therapies work by either blocking the receptors from receiving the hormones
or by reducing the body’s hormone production. Adjuvant hormone therapy is typically
prescribed for 5 years to women with early stage breast cancers after primary treatment to
prevent recurrence. Hormone therapy may be given as the first line of treatment for advanced
staged breast cancer.
Targeted therapy is form of systematic treatment that targets only cancerous cells. When
the protein for the Human Epidermal Growth Factor Receptor 2 is found in breast tumors, the
breast cancer is classified as HER-2/neu positive. Trastuzumab is a targeted intravenous drug
therapy that may be given as a neo-adjuvant to shrink the tumor before surgery, but it is most
often given as an adjuvant treatment for 1 year. It is commonly started when chemotherapy is
initiated. 14
Stage 0 (LCIS)
LCIS is usually not treated with any surgery other than a surgical biopsy. Depending on
individual preference and level of risk, a woman may choose to take hormone therapy for 5 years
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to reduce the risk of recurrence. Some women may also choose to have a prophylactic
mastectomy, but this option should only be chosen for high risk women who first undergo
genetic counseling. 14
Stage 0 (DCIS)
DCIS is most often treated with BCS. If there is only 1 tumor and the margin is
noncancerous, radiation therapy may not be necessary, depending on the patient’s risk for
recurrence. If the rim of tissue removed around the tumor is positive for cancerous cells, the
patient may require another excision or a mastectomy if the cancer cannot be completely
removed or continues to return. BCS should be followed up with radiation therapy, but if a
mastectomy is performed, then radiation therapy is not necessary. Some patients may choose to
have a mastectomy when it is not necessary for preventive reasons. However, studies have
shown that women who receive BCS with radiation have the same survival rates as women
treated with mastectomy. If primary treatment includes BCS, adjuvant hormone therapy should
be given to prevent recurrence if the tumor is estrogen or progesterone receptor positive. 14
Stages I - IIIA
Women diagnosed with breast cancer Stage IA, IB, IIA, IIB, and some cases of Stage
IIIA will have the option for BCS. Patients with tumors > 2 cm, and who desire to have BCS vs.
mastectomy should consider neo-adjuvant chemotherapy to shrink the tumor. BCS should be
followed by radiation therapy. Patients with tumors > 2 cm that do not shrink with first or second
rounds of chemotherapy will require a mastectomy. Depending on the degree of nodal
involvement, patients will have any necessary lymph node removal at the time of tumor removal
or shortly after. Adjuvant chemotherapy may be given for patients with tumors > 1 cm, have 2 or
more cancerous lymph nodes, or at high risk of recurrence. If the patient’s tumor was found to be
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HER-2/neu positive, they will start targeted therapy at the time of diagnosis. If the patient’s
tumor is estrogen or progesterone receptor positive, they will begin adjuvant hormone therapy
after radiation. 14
Stages IIIA – IV
Some patients diagnosed with Stage IIIA breast cancer may still have the option of BCS
if the tumor can be shrunk with neo-adjuvant chemotherapy. However, most patients with Stage
IIIA and beyond will undergo mastectomy. Patients in these stages will most likely also require
radiation therapy after surgery, regardless of which type of surgery they receive, due to the
advanced stage of the disease and lymph node involvement. Moreover, patients in theses stages
will most likely undergo neo-adjuvant and adjuvant chemotherapy. Targeted therapy and
adjuvant hormone therapy will also be given if tumors are receptor positive for either type of
hormones. Patients with Stage IV breast cancer that has metastasized to other areas of their body
may have inoperable tumors, but may still elect for mastectomy to relieve pain. Combinations of
radiation therapy, chemotherapy, targeted therapy, and hormone therapy can be used to shrink
and slow cancer growth and spread in order to prolong life. 14
Treatment Considerations
While these are recommended guidelines for breast cancer treatment put forth by the
NCCN, treatment should and may vary according to individual patient characteristics such as
age, health, and menopausal status. Women who may consider BCS without radiation therapy
are those whose age > 70 years, tumor < 2cm, tumor was completely removed, tumor contained
hormone receptors, had no lymph node involvement, and received hormone therapy.
Chemotherapy should be given on a case-by-case basis for women age > 70 years, considering
patient health. Lymph node removal may be optional for small tumors and for whom lymph node
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spread is unlikely, elderly women, and those with poor health. Pregnant women should not
undergo radiation therapy or chemotherapy. Women who are elderly or in poor health may also
be recommended to not receive chemotherapy. Choice of adjuvant hormone therapy, if needed,
should consider the woman’s menopausal status and future pregnancy plans. 4, 14
Patterns of Care
In 2008, among women with early stage breast cancer (Stages I – II), 10% had BCS only,
30% had BCS and radiation therapy, 17% had BCS, radiation therapy, and chemotherapy, 17%
had mastectomy alone, 14% had mastectomy and chemotherapy, 1% had mastectomy and
radiation therapy, 4% had mastectomy, radiation therapy, and chemotherapy, 6% had
nonsurgical treatment, and 1% received no treatment at all. Overall, 57% had BCS either alone
or in combination with some other form of treatment, and 36% had mastectomy alone or in
combination with some other treatment. Among women with late stage breast cancer (Stages III
– IV), 2% had BCS only, 1% had BCS and radiation therapy, 10% had BCS, radiation therapy,
and chemotherapy, 7% had mastectomy only, 20% had mastectomy and chemotherapy, 2% had
mastectomy and radiation therapy, 31% had mastectomy, radiation therapy, and chemotherapy,
18% had nonsurgical treatment, and 7% received no treatment at all. 3
Variations in treatment patterns among women with breast cancer occur for a variety of reasons.
It may seem intuitive that women with early stage breast cancer who have the choice of BCS vs.
mastectomy would choose BCS in order to preserve their physical appearance and upper body
functioning. However, over 1/3 of women with early stage breast cancer receive a mastectomy.
In fact, several recent studies have shown that the rates of elective mastectomy have been on the
rise since about the mid 2000’s among women who are candidates for BCS. 16-18 Many women
may choose mastectomy over BCS due to fear of side effects from radiation therapy,
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inconvenience and time to comply with the radiation therapy schedule, advances in surgical
techniques for reconstructive surgery, and fear of recurrence. 19, 20 Similarly, higher rates of
mastectomy among early stage breast cancer patients have been observed among women residing
in rural locations (60% vs. 45%), as compared to metro or urban areas. 21, 22 Women residing in
rural areas may elect to have mastectomy over BCS because of the time and distance to travel for
radiation therapy after BCS, out-of-pocket expenditures for travel for radiation therapy,
opportunity cost of time off work for radiation therapy, the increased demand for coordination of
care with BCS and radiation therapy, and lack of radiation oncologist in or near rural areas.

22-24

Additional reasons for receipt of mastectomy vs. BCS among women with early stage breast
cancer include reasons commonly associated with health disparities in general. Higher rates of
mastectomy vs. BCS among early stage breast cancer patients have been observed in women
who are white, or a race other than white or black, unmarried women, lower levels of education,
women insured by Medicaid or uninsured, had a male surgeon, are younger than 40 or older than
70 years of age, since breast cancer is usually more aggressive among younger women, and the
risks and side effects of additional and extensive treatments may outweigh the benefits for
women of older age . 17, 18, 21, 24, 25 Women who are of low income and/or socio-demographically
disadvantaged with early stage breast cancer may have higher rates of mastectomy than higher
income women due to the additional costs of treatment associated with BCS. 23, 26-29 Similar
factors have been associated with lack of lymph node biopsy among early stage breast cancer
patients, lack of radiation therapy following BCS, lack of radiation therapy and chemotherapy
among patients with local-regionally advanced, or later staged breast cancers, and non-initiation
or early discontinuation of adjuvant hormone therapy. 30-46
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Survival & Recurrence
Five-year survival rates have improved substantially since 1975. In 1975 – 1977, the
average 5-year survival rate for women of all ages and race/ethnicities in the US was 75.1% and
has increased to 90.0% for 2001 – 2007. 3 Increased survival rates can be attributed to treatment
advancements and more cases diagnosed at an earlier stage due to widespread adoption of
mammography screening. Additionally, in 2008, 82% of breast cancer survivors were alive after
10 years, and 77% after 15% years. 4 However, survival rates vary greatly according to stage at
diagnosis, age, and race/ethnicity. Five-year survival rates decrease with advancing stage at
diagnosis. 2 See Table 3. Similarly, breast cancer mortality tends to increase with age. 47 See
Table 4. Although 5-year survival rates have improved for all race/ethnicity groups, disparities
persist, especially between whites and blacks. See Table 5. These differences are largely
attributable to later stage at diagnosis and poorer stage-specific survival, and aggressive tumor
characteristics among black women. 4 Other factors associated with poor breast cancer survival
are low levels of education and income, being uninsured or insured through Medicaid, receipt of
guideline appropriate care, and number of comorbidities. 48-53
Among women diagnosed with Stage I, II, and III breast cancer, about 11% will
experience recurrence within 5 years and 20% within 10 years. Recurrence rates are higher
among survivors diagnosed at advanced stages with recurrence rates of 7% among Stage I, 11%
among Stage II, and 13% among those diagnosed at Stage III. 54 The likelihood of recurrence has
been found to increase among survivors that had large tumors, poorly differentiated tumors,
greater nodal involvement, estrogen receptor positive tumors, did not receive radiation therapy
after BCS, and did not receive adjuvant hormone therapy. 54-57 Additionally, unhealthy lifestyle
factors such as obesity, lack of physical activity, poor diet, heavy alcohol consumption, and
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smoking have been associated with poorer breast cancer survival and greater risk of recurrence.
Although, it should be noted that studies of the association between diet, physical activity, and
breast cancer survival and recurrence have not yielded consistent findings. 58-66
Statement of the Problem
Despite advances in breast cancer treatment and survival, disparities in treatment patterns
and survival outcomes persist. The most common disparities in treatment are the omission of
recommended treatments and services or receiving non-preferential treatments. The most
commonly omitted treatments are radiation therapy (RT) following breast-conserving surgery
(BCS) or mastectomy when indicated, chemotherapy, adjuvant hormone therapy, and lymph
node sampling. The appropriate course of treatment for each women is determined by tumor size,
lymph node invasion, and hormone receptor status. However, when diagnosed at an early-stage,
women often have an option for the type of local treatment received. Women with tumors < 5 cm
have the option of mastectomy or BCS followed by RT. Multiple randomized clinical studies
have shown BCS followed by RT to be as equally effective as mastectomy for long-term survival
of invasive early-stage breast cancer.67-70 Since the National Institutes of Health's (NIH) 1991
endorsement of BCS plus RT as an appropriate alternative to mastectomy for treatment of
invasive early-stage breast cancer, mastectomy rates have decreased while rates of BCS plus RT
have steadily increased.71 In fact, BCS, with or without RT, has become the preferred choice of
primary surgical treatment among women with early-stage breast cancer, with ~ 60% or more
receiving BCS. 18,72,73 Yet, in recent years, rates of mastectomy have started to slowly
increase.18,73,74 Associations with receipt of mastectomy when BCS is an option, include a desire
to avoid radiation therapy due to side effects, fear of recurrence, larger tumor size, positive
lymph nodes, tumors with negative hormone receptors, moderately or poorly differentiated
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tumors, lower income, being insured by Medicaid or uninsured, residing in a rural location,
increased travel distance for RT, the increased cost of BCS plus RT vs. mastectomy, and surgeon
characteristics that include being male, not trained in the U.S., and less recent training.18,73,75-79
In fact, many of the same factors are associated with treatment disparities at all stages of
diagnosis and include age, health, socio-demographic characteristics, and access to specialty
care. Age and comorbidity are two inter-related factors that are strongly associated with
treatment. While increasing age has its own associated frailty, it is also associated with
increasing comorbidity, that together, may make some treatments with adverse and toxic effects
intolerable for some women, to the point that the harms of such treatments outweigh the benefits.
80-85

In fact, clinical evidence-based treatment guidelines put forth by the National

Comprehensive Cancer Network (NCCN) do not make recommendations for or against
chemotherapy in women age > 70 years, but suggest chemotherapy be given on a case-by-case
basis, depending on the patient's health.86 Additionally, guidelines specify that RT following
BCS may be omitted among women meeting the following requirements: age > 70 years, tumors
< 2 cm, node negative, estrogen-receptor positive, and receiving adjuvant hormone therapy.87
This change to recommended treatment guidelines that had previously recommended RT
following BCS for all age groups, was made after the 2004 publication of the Cancer and
Leukemia Group B (CALGB) C9343 trial study results were demonstrating similar 5-year
survival between women with these clinical characteristics who received BCS plus RT or BCS
alone. However, since this change in treatment recommendations, evidence suggests that a
greater number of elderly women do not receive RT or chemotherapy, than those that meet
exemption requirements from RT or who are in too poor of health to undergo chemotherapy. 88-90
The course of breast cancer care is often affected by the woman's access to oncology services
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due to their location of residence and socio-demographic characteristics. Women residing in
rural vs. urban areas, in areas with a lower density of oncology service providers, and that have
greater distances to travel for care are more likely to not receive adjuvant treatments such as RT
and chemotherapy, or delay the initiation of treatment. 80,90-92 Lastly, as frequently observed with
many health disparities, women who are of black or non-white Hispanic race, lower income,
lower education, publically insured or uninsured are more likely to experience breast cancer
treatment disparities. 81,93,94
In similar fashion, these factors, as well as clinical prognostic characteristics are also
associated with overall breast cancer survival. Clinical characteristics associated with greater
survival are earlier stage at diagnosis, smaller tumor size, less or no lymph node invasion, well
differentiated tumor grade, and estrogen and progesterone positive tumors. 1,96-98 Receiving
guideline-concordant care (GCC) is associated with greater breast cancer survival, while
treatment disparities, i.e. guideline-discordant care (GDC), are associated with poorer survival.
99-102

While age and comorbidity are inherently associated with poorer overall survival, survival

differences have also been observed between different races. Black women have markedly worse
survival outcomes, as compared to white women, such that 5-year survival for white and black
women is 90% and 79%, respectively. 103-105 Aside from being less likely to receive GCC due to
various socio-demographic factors, black women diagnosed with breast cancer are more likely to
have tumors with less favorable characteristics and aggressive cancers. 106,107
In order to address gaps in the literature and build upon existing knowledge this series of
studies will focus upon the treatment patterns and survival of elderly women with invasive breast
cancer, a population with the highest incidence of the disease, but for whom many are
undertreated due to age. These studies will also determine how age, health, clinical prognostic
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factors, oncology care resources, and socio-demographic characteristics are associated with these
outcomes. The first study will investigate the initial type of loco-regional treatment received for
early-stage breast cancer. Most studies reporting on treatment patterns for early-stage breast
cancer present rates that reflects the end result of multiple surgeries, such that a woman who first
had BCS with or without RT, but eventually had a mastectomy, would be classified as having a
mastectomy and not BCS. This study will capture, the initial treatment, may reflect treatment
preferences of elderly women with early-stage breast cancer, as many women with this diagnosis
have a choice of treatment. The second study will determine to what degree women with stage I,
II, and III breast cancer receive GCC according to NCCN and ASCO treatment guidelines, by
comprehensively comparing clinical characteristics and the care received by each women,
including individual diagnostic tests and treatment. This will address gaps in previous studies
that have only studied early stages or loco-regional treatment. The third study will examine
overall 5-year survival among the two previously described study populations and how each of
those study outcomes (initial loco-regional treatment and receipt of GCC) and independent
variables are associated with survival. Additionally, overall 5-year survival will be examined
among a third, more broadly inclusive sample of women with stage I, II, III breast cancer, to gain
a baseline understanding of overall survival of elderly women with invasive non-metastatic
breast cancer.
Using samples of female fee-for-service Medicare beneficiaries diagnosed with breast
cancer in the SEER-Medicare dataset, the goals of this study are to determine 1) rates and factors
associated with receipt of BCS plus RT, mastectomy, and BCS only among elderly women with
stage I and II breast cancer; 2) rates and factors associated with receipt of guideline-concordant
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care among elderly women with stage I, II, and III breast cancer; and 3) 5-year survival rates and
associated factors among elderly women with stage I, II, and III breast cancer.
Specific Aims & Objectives
Specific Aim 1: To determine patterns of initial loco-regional treatment following an
incident diagnosis of stage I and II breast cancer among female fee-for-service Medicare
beneficiaries identified in the SEER-Medicare linked dataset.
Objective 1.1: To determine the proportion of women who received breast-conserving surgery
plus radiation therapy, mastectomy, or breast-conserving surgery only following an incident
diagnosis of stage I and II breast cancer among fee-for-service Medicare beneficiaries in the
SEER-Medicare linked datasets.
Objective 1.2: To determine group differences between women who received breast-conserving
surgery plus radiation therapy, mastectomy, or breast-conserving surgery only following an
incident diagnosis of stage I and II breast cancer among fee-for-service Medicare beneficiaries in
the SEER-Medicare linked datasets.
Objective 1.3: To determine factors associated with type of initial loco-regional treatment
received following an incident diagnosis of stage I and II breast cancer among fee-for-service
Medicare beneficiaries in the SEER-Medicare linked datasets.
Specific Aim 2: To determine receipt of guideline-concordant care following an incident
diagnosis of pathologically staged I, II, and III breast cancer among female fee-for-service
Medicare beneficiaries identified in the SEER-Medicare linked dataset.
Objective 2.1: To determine the proportion of women receiving guideline-concordant care
following an incident diagnosis of pathologically staged I, II, and III breast cancer among feefor-service Medicare beneficiaries in the SEER-Medicare linked datasets.
Objective 2.2: To determine group differences between women receiving guideline-concordant
vs. guideline-discordant care following an incident diagnosis of pathologically staged I, II, and
III breast cancer among fee-for-service Medicare beneficiaries in the SEER-Medicare linked
datasets.
Objective 2.3: To determine the factors associated with receipt of guideline-concordant care
following an incident diagnosis of pathologically staged I, II, and III breast cancer among feefor-service Medicare beneficiaries in the SEER-Medicare linked datasets.
Specific Aim 3: To determine overall 5-year survival rates and associated factors following
an incident diagnosis of invasive breast cancer among three different samples of female feefor-service Medicare beneficiaries identified in the SEER-Medicare linked dataset.
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Objective 3.1: To determine overall 5-year survival rates following an incident diagnosis of
breast cancer and by stage among a broad sample of fee-for-service Medicare beneficiaries
diagnosed at stage I, II, and III from 2003 to 2009 in the SEER-Medicare linked datasets.
Objective 3.2: To determine group differences between women who lived and died within 5
years of diagnosis of breast cancer among a broad sample of fee-for-service Medicare
beneficiaries diagnosed at stage I, II, and III from 2003 to 2009 in the SEER-Medicare linked
datasets.
Objective 3.3: To determine factors associated with overall 5-year survival following an incident
diagnosis of breast cancer among a broad sample of fee-for-service Medicare beneficiaries
diagnosed at stage I, II, and III from 2003 to 2009 in the SEER-Medicare linked datasets.
Objective 3.4: To determine overall 5-year survival rates following an incident diagnosis of
breast cancer and by receipt of BCS plus RT, mastectomy, and BCS only among fee-for-service
Medicare beneficiaries diagnosed at stage I and II breast cancer from 2003 to 2009 in the SEERMedicare linked datasets.
Objective 3.5: To determine group differences between women who lived and died within 5
years of diagnosis of breast cancer among fee-for-service Medicare beneficiaries diagnosed at
stage I and II breast cancer from 2003 to 2009 in the SEER-Medicare linked datasets.
Objective 3.6: To determine factors associated with overall 5-year survival following an incident
diagnosis of breast cancer among fee-for-service Medicare beneficiaries diagnosed at stage I and
II breast cancer from 2003 to 2009 in the SEER-Medicare linked datasets.
Objective 3.7: To determine overall 5-year survival rates following an incident diagnosis of
pathologically staged I, II, and III breast cancer and by receipt of GCC among fee-for-service
Medicare beneficiaries diagnosed from 2004 to 2009 in the SEER-Medicare linked datasets.
Objective 3.8: To determine group differences between women who lived and died within 5
years of diagnosis of pathologically staged I, II, and III breast cancer among fee-for-service
Medicare beneficiaries diagnosed from 2004 to 2009 in the SEER-Medicare linked datasets.
Objective 3.9: To determine factors associated with overall 5-year survival following an incident
diagnosis of breast cancer among fee-for-service Medicare beneficiaries diagnosed from 2004 to
2009 in the SEER-Medicare linked datasets.
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Table 1. Definition of "T", "N", and "M" Categories of the TNM Staging System

Breast Cancer Staging Categories
N

T

Tis: non-invasive breast
cancer (DCIS of LCIS)
T0: no evidence of primary
tumor

T1: tumor < 2 cm in
diameter
T2: 2 cm < tumor < 5 cm in
diameter

N0: cancer has not spread to
lymph nodes
N1: cancer has spread to 1 – 3
lymph nodes under the arm on
the same side but are not
attached
N2: cancer has spread to 4 – 9
lymph nodes under the arm on
the same side and are attached
N3: cancer has spread to 10 or
more lymph nodes including
those under the arm and
surrounding areas on the same
side

T3: tumor > 5 cm in
diameter
T4: tumor is any size, but
has spread to the chest wall
or skin
Table 2. TNM Staging System for Breast Cancer

Breast Cancer Stages
Overall Stage
Stage 0
Stage I
Stage IIA

Stage IIB
Stage IIIA

Stage IIIB
Stage IIIC
Stage IV

T Category
Tis
T1
T0
T1
T2
T2
T3
T0
T1
T2
T3
T3
T4
Any T
Any T

N Category
N0
N0
N1
N1
N0
N1
N0
N2
N2
N2
N1
N2
Any N
N3
Any N

M Category
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M1
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M

M0: no distant cancer spread
M1: cancer has spread to
distant organs

Table 3. Breast Cancer Survival, 2001 – 2007

5-Year Breast Cancer Survival
Rates by Stage at Diagnosis
Stage
Rate
0
I
IIA
IIB
IIIA
IIIB
IIIC
IV

93%
88%
81%
74%
67%
41%
49%
15%

Table 4. Breast Cancer Mortality by Age, 2005 – 2009

Average Annual Breast Cancer
Mortality Rate by Age
Age
Rate
< 20 years
20 – 34 years
35 – 44 years
45 – 54 years
55 – 64 years
65 – 74 years
75 – 84 years
> 85 years

0.0%
0.9%
5.6%
14.8%
21.4%
19.9%
22.0%
15.5%

Table 5. Breast Cancer Survival by Race/Ethnicity, 2001 – 2007

5-Year Breast Cancer Survival Rates
by Race/Ethnicity
Race/Ethnicity
Rate
Non-Hispanic White
Black
AI/AN
Asian
Pacific Islander
Hispanic

88.8%
77.5%
85.6%
90.7%
85.4%
83.8%

31

CHAPTER 2

32

CHAPTER 2
"Variations in Initial Loco-Regional Treatment Received for Early-Stage Breast Cancer among
Elderly Women in a SEER-Medicare Population: Associations with Old Age and Vulnerable
Socio-Demographics"

Traci LeMasters 1
S. Suresh Madhavan, M.B.A, Ph.D. Chair 1
Usha Sambamoorthi Ph.D. 1
Kimberly M Kelly Ph.D. 1, 2
Hannah Hazard M.D. 3
Dustin Long Ph.D. 4

1 Department

of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia
University
2 Mary Babb Randolph Cancer Center, West Virginia University
3
Department of Medical Education, School of Medicine, West Virginia University
4
Department of Biostatistics, School of Public Health, West Virginia University

33

Abstract
Background: Breast-conserving surgery (BCS) plus radiation therapy (RT) is an equally
effective loco-regional treatment for long-term early-stage breast cancer survival as mastectomy,
and is often the preferred choice of treatment by the majority of women. While some women
may eventually require mastectomy after treatment failure with BCS plus RT, a considerable
number of elderly women receive mastectomy as their initial loco-regional treatment or do not
receive RT following BCS. Therefore, the purpose of this study was to examine patterns of
initial loco-regional treatment (BCS plus RT, mastectomy, or BCS without RT) among elderly
women with early-stage breast cancer and differences between women who received mastectomy
or BCS without RT, compared to BCS plus RT as initial loco-regional treatment.
Methods: A sample of 45,981 women age > 66 diagnosed with stage I and II breast cancer from
2003 to 2009 were selected from the SEER-Medicare linked dataset. The chi-square statistic was
used to test for group differences between type of treatment and independent variables that
included year of diagnosis, age, health, clinical prognostic factors, oncology care resources, and
socio-demographic characteristics. Multinomial logistic regression was used to identify
predictors of mastectomy or BCS without RT, compared to BCS plus RT for initial loco-regional
treatment.
Results: In all, 55% of elderly women with early-stage breast cancer received BCS plus RT,
23% received mastectomy, and 22% received BCS without RT as their initial type of locoregional treatment. Compared to women who received BCS plus RT, women of older age,
greater comorbidity, with a higher frequency of PCP visits, later stage, and non-white race were
more likely to receive mastectomy or BCS without RT. Whereas women who lived in areas of
higher education, higher income, metro areas, and were treatment by an oncology surgeon or
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both and oncology and general surgeon were less likely to receive mastectomy or BCS without
RT, than BCS plus RT. Additionally, women who resided in areas with a high density of
oncology centers were less likely to receive mastectomy, while women with negative estrogen
and progesterone tumor receptors and less differentiated tumors were more likely to receive
mastectomy, compared to BCS plus RT.
Conclusions: Over half of elderly women have BCS plus RT, while the other half undergo
mastectomy or have BCS without RT, in nearly equal proportions. Yet, many may eventually
undergo mastectomy after initial treatment with BCS. Elderly women who were more likely to
have mastectomy or BCS without RT share similar associations with many of the same sociodemographic characteristics and measures of access to oncology care, indicating they face
additional barriers to receiving preferential and/or optimal treatment. Moreover, positive
associations with increasing age and comorbidity among women who received mastectomy or
BCS without RT may reflect a notion that RT is not well tolerated or will not significantly
increase life-expectancy among some elderly women. Loco-regional treatment of elderly women
with early-stage breast cancer could be improved by ensuring all patients are informed of and
have access to all treatment options, as well as, emphasizing receipt of all recommended
treatments among patients who do not meet specific criteria for exemption.

35

Introduction
Breast conserving surgery (BCS) followed by radiation therapy (RT), has been found to
be an equally effective loco-regional treatment as mastectomy for long-term survival of invasive
early-stage breast cancer.1-5 Since the National Institutes of Health's (NIH) 1991 endorsement of
BCS plus RT as an appropriate alternative to mastectomy for treatment of invasive early-stage
breast cancer, mastectomy rates have decreased while rates of BCS plus RT have steadily
increased.6 In fact, BCS, with or without RT, has become the preferred choice of primary
surgical treatment among women with early-stage breast cancer, with ~ 60% or more receiving
BCS. 7-9 Yet, one in four women who have BCS will undergo additional surgery, and about one
in ten will eventually undergo mastectomy after treatment failure with BCS. 10,11 Whether it is
the initial choice of surgery or not, epidemiological studies have reported an increase in the use
of mastectomy in recent years. 8,9,12 Women who elect for mastectomy when BCS plus RT is an
option tend to be younger, have a desire to avoid RT, fear recurrence, have larger and/or more
aggressive tumors, positive lymph nodes, tumors with negative hormone receptors, and
moderately or poorly differentiated tumors. Additional associations with receipt of mastectomy
are being of lower income, insured by Medicaid or uninsured, residing in a rural location,
increased travel distance for RT, the increased cost of BCS plus RT compared to mastectomy,
and surgeon characteristics that include being male, not trained in the U.S., and less recent
training.8,9, 12-17 In fact, many of these same factors are similarly associated with omission of RT
following BCS. Additional associations with not receiving RT following BCS include being
African American, increased comorbidity, and older age.18-21
Among several issues to consider when choosing local treatment for early-stage breast
cancer, is a willingness to undergo RT when opting to have BCS. Omitting RT following BCS
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may result in short-term treatment failure, and consequently, mastectomy. Moreover, women
who do not received RT following BCS when recommended to do so are at increased risk for
recurrence and poorer survival. 18,22-26 However, guidelines allow for a select group of women to
omit RT following BCS. Following the 2004 publication of the Cancer and Leukemia Group B
(CALGB) C9343 trial study results demonstrating similar 5-year survival between women age >
70 years with specific clinical characteristics who received BCS plus RT or BCS alone, the
National Comprehensive Cancer Network's (NCCN) updated treatment guidelines to allow for
the omission of RT following BCS among women meeting the following requirements: age > 70
years, tumors < 2 cm, node negative, estrogen-receptor positive, and receiving adjuvant hormone
therapy. 27,28 Following this controversial guideline change, rates RT following BCS appeared to
decrease, particularly among women age > 80 years regardless of clinical factors or evidence of
increased breast cancer mortality and recurrence among women receiving BCS only.18, 22-25,29,30
Statement of the Problem
Until now, epidemiological studies of treatment for early-stage breast cancer have
included women of all ages or have limited studies of older women with stage I breast cancer or
who would already meet NCCN guidelines for RT omission. 8,9,12,13,22- 24,31,33 Samples have also
included women with Stage 0, for which surgical guidelines are not clear, or women with Stage
III, a stage where mastectomy is the predominant surgical choice. 12,22,31,33 Moreover, when
reporting surgical patterns, studies have included mastectomy when it may not have been the
initial surgery. 34 Therefore, to gain a better understanding of the intended initial choice of
treatment among elderly women with invasive early-stage breast cancer, this study examine
patterns of initial loco-regional treatment (BCS plus RT, mastectomy, or BCS only) among
women age > 66 years, with stage I and I breast cancer using SEER using a U.S. population-
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based linked SEER-Medicare dataset. Furthermore, this study aims to determine how age, health,
clinical prognostic factors, oncology care resources, and socio-demographic characteristics are
associated with initial choice of loco-regional treatment.
Methods
Data
The SEER-Medicare database was created in a collaborative effort by the National
Cancer Institute (NCI) and Centers for Medicare and Medicaid Services (CMS) to combine
clinical information gathered by the Surveillance Epidemiology and End Results cancer registry
program with Medicare insurance claims. The SEER program collects basic socio-demographic,
clinical, and vital status information on incident cancer cases from multiple reporting sources.
This information is found the Patient Entitlement and Diagnosis Summary File (PEDSF). SEER
data used for this study consisted of 17 population-based registries, representing 26% of the U.S.
population. An algorithm based on name, Social Security number, sex, and date of birth
successfully matched 94% SEER cases to their Medicare claims beginning from the time of
eligibility till death.35 This study used Medicare claims providing information regarding
beneficiary enrollment (Denominator File), hospital inpatient claims (Med-PAR file), hospital
outpatient claim (Outpatient file), physician office visits (NCH file), and durable medical
equipment (DME file).36 Additionally, county and state of diagnosis were used to identify the
area-level density of mammography screening and oncology centers from the U.S. Department
of Health and Human Resource's 2009 Area Resource File (ARF).37
Study Population
This retrospective cohort study selected American Joint Commission on Cancer (AJCC)
staged I and II incident cases of breast cancer recorded in SEER during years 2003 to 2009,
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among female age-eligible Medicare beneficiaries who were continuously enrolled in Medicare
Part A and B fee-for-service programs 1 year before and after diagnosis, and were therefore age
> 66 years at the time of diagnosis. Women were excluded if they were enrolled in a managed
care program at any time during year before or the year after diagnosis, diagnosed at the time of
death or upon autopsy, died within the first year of diagnosis, had end-stage renal disease, did
not have primary surgical treatment, or surgeon specialty was missing. The final sample size was
n = 45,981 elderly women.
Measures
Dependent Variable
The dependent variable of interest was the initial loco-regional treatment received for
early-stage breast cancer (BCS plus RT, mastectomy, or BCS only) identified using surgical and
radiation claims where the claim date was no later than 366 days from the date of diagnosis.
Surgery claims were taken from the MEDPAR, NCH, and Outpatient files using ICD-9
procedure codes 85.20 - 85.29 and CPT/HCPCS 19120, 19125, 19126, 19160, 19162, 19301,
19302 to identify BCS (i.e. lumpectomy, partial mastectomy, segmental mastectomy) and ICD-9
procedure codes 85.33 - 85.48 and CPT/HCPCS 19140, 19180, 19182, 19300, 19303, 19304,
19200, 19220, 19240, 19305, 19306, 19307, 19260, 19271, 19272 to identify mastectomy. When
multiple claims for lumpectomy were present, or when a claim for lumpectomy was followed by
a claim for mastectomy, only the first surgical claim was used, to identify initial choice for
definitive surgical treatment. Receipt of RT was identified from MEDPAR, NCH, Outpatient,
and DME files using ICD-9 diagnosis codes V580,V661,V671, ICD-9 procedure codes 9220 9239, and HCPCS codes 77261 - 77799, G0256, G0261, G0173, G0174, G0243, G0251, G0338G03340. Only the first claim was used to identify the initiation of RT.
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Independent Variables
This study examined the relationship between primary treatment and year of diagnosis,
age, health, clinical prognostic factors, oncology care resources, and socio-demographic
characteristics. Year of diagnosis (2003 thru 2009) was included in analytic models to assess
differences in treatment over time, considering the NCCN's change in recommended treatment
for early-stage breast cancer among elderly women during this time period.
Age & Health
Age at diagnosis (66-69, 70-74, 75-79, > 80) and health were considered together since
declining health associated with increasing age is the reason given by NCCN guidelines for caseby-case use of chemotherapy in women older than 70 years, and are often cited as associations
with undertreatment among elderly women in retrospective studies. Health was measured by
calculating patient comorbidity by applying an algorithm to Medicare claims that identifies a
comorbid condition as the presence of at least one in-patient or two out-patient claims using
ICD-9 diagnoses codes for each co-morbid condition. Overall comorbidity was then classified
using the Klabunde adaption of the Charlson comorbidity index score (0, 1, > 2).38,39 Frequency
of primary care provider (PCP) visits was also used as a proxy for health status, with a higher
number of visits considered an indication of poorer health. An index of PCP visit intensity was
identified by counting of number of unique PCP claim dates the year before diagnosis in the
NCH file. PCP visits were categorized by lower and upper 50th percent median cutoff (low,
high).
Clinical Prognostic Factors
Clinical prognostic factors examined were stage at diagnosis, estrogen receptor (ER)
tumor status (positive, negative, borderline/unknown), progesterone receptor (PR) tumor status
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(positive, negative, borderline/unknown), and tumor grade (well differentiated, moderately
differentiated, poorly differentiated, undifferentiated/unknown). Stage diagnosis was categorized
using the AJCC Stage Group 6th edition (I, II).
Oncology Care Resources
Patient's access to oncology care resources was measured as the area-level density of
mammography screening and oncology treatment centers where they resided and the specialty of
the surgeon that provided their surgical treatment. The density of area-level mammography
screening centers and oncology treatment centers, relative to each women, was measured using
data from the ARF and categorized in similar fashion (low, high). Surgeon specialty was
assessed using provider specialty claims codes 02, 49 (general) and 83, 90, 91, 98 (oncology)
from the NCH file to determine the type of surgeon seen (general only, oncology only, both).
Socio-Demographic Characteristics
Demographic characteristics examined were race (white, other), education (measured by
the 2000 Census tract survey of percent of persons age > 25 with at least 4 years college
education) (< 15%, > 15%), and annual income (measured by the 2000 Census tract survey of
median income by census) (< $35,000, > $35,000). Location of residence was measured as metro
status (non-metro, metro).
Analysis
Descriptive analysis was performed for all study variables. Mantel-Haenszel chi-square
tests of location shift using modified ridit scores or table scores and Mantel-Haenszel chi-square
tests of general association (depending on whether the independent measure was dichotomous,
nominal, or ordinal) were used to compare significant group differences between type of primary
treatment and independent measures, with significance set at P < .05. The probability of
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receiving a type of primary treatment was estimated using multinomial logistic regression
models for each of the independent variables described above. Parameter estimates calculated in
the regression models are presented as adjusted odds ratios (AOR) with their corresponding 95%
confidence intervals (CI). All analysis were conducted using SAS version 9.4 software (SAS
Institute Inc., Cary, NC).
Results
Population Characteristics
In the years of 2003 thru 2009, a total of 45,981 fee-for-service female Medicare
beneficiaries age > 66 years were diagnosed with Stage I (62.9%) and Stage II (37.1%) breast
cancer. The majority were treated with BCS plus RT (54.5%), while the rest received
mastectomy (23.4%) and BCS only (22.1%) in similar proportions, and the majority saw both
general and oncology surgeons (75.6%). In this sample 89.4% of the women were white, 70.5%
lived in an area where greater than 15% of the population was college educated, 76.4% in an area
with an average annual income > $35,000, and 83.3% lived in a metro area (Table 1).
Group Differences by Treatment
All group differences by treatment were significant at the P < .001 level (Table 2). Rates
of BCS plus RT for among elderly women with invasive early-stage breast cancer increased
steadily from 52.8% in 2003 to 56.4% in 2009, while mastectomy rates decreased from 24.8% to
21.9% in 2006 and then increased to 24.3% in 2009. Similar to mastectomy, rates of BCS
without RT increased from 22.3% in 2003 to 24.4% in 2005, and then decreased to 19.3% in
2009.
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Age & Health
Rates of BCS plus RT were the highest among women age 66 - 69 years at 65.0% and
lowest for those age > 80 years (38.3%). In contrast, rates of mastectomy and BCS without RT
were the highest among those age > 80 years (27.7% & 34.0%) and lowest among women age 66
- 69 years (20.0% & 15.0%). Women with a comorbidity score = 0 had the highest rates of BCS
plus RT (57.5%), whereas women with a comorbidity score = 2 had the lowest rates of BCS plus
RT 9 47.8%). Conversely, mastectomy and BCS with RT rates were the highest among women
with a comorbidity score = 2 (25.6% & 26.6%), and the lowest for women with no comorbidity
(22.6% & 19.9%). Possibly reflective of comorbidity, women with a low frequency of PCP visits
had higher rates of BCS plus RT (57.0%), while women with a high frequency of PCP visits had
higher rates of mastectomy and BCS without RT (24.0% & 24.4%).
Clinical Prognostic Factors
Women with favorable prognostic clinical characteristics also had the highest rates of
BCS plus RT. Women who were stage I, had ER and PR positive tumors, and well-differentiated
tumors had the highest rates of BCS plus RT (61.4%, 56.7%, 57.1%, 58.8%), than women who
were stage II, had borderline/unknown ER and PR tumors, and undifferentiated tumors (42.9%,
39.5%, 40.8%, and 46.8%, respectively). In comparison, women with poor prognostic factors
had the highest rates of mastectomy and BCS without RT, and the lowest rates of BCS plus RT.
Oncology Care Resources
Those who resided in area with a high density of mammography screening and oncology
treatment centers had higher rates of BCS plus RT, while those who resided in low density areas
had higher rates of mastectomy and BCS without RT. Women who were treated by a general
surgeon had the lowest rates o BCS plus RT (42.9%), while those treated by a oncology surgeon

43

or both types of surgeons had higher rates of BCS plus RT (59.0% & 56.2%). In contrast, women
treated by a general surgeon had higher rates of BCS without RT (33.8%), and those who saw an
oncology surgeon or both had similarly lower rates (19.0% & 19.4%).
Socio-demographic Characteristics
Treatment differences by socio-demographic characteristics were in the expected
direction with women who were of white race, lived in areas of greater education, higher income,
and of metro status having higher rates of BCS plus RT (55.2%, 57.8%, 57.5%, 56.7%), than did
women of other race, lived in less educated, lower income, and non-metro areas (48.5%, 46.6%,
45.5%, 43.8%, respectively). Comparatively, women of other race, lived in less educated, lower
income, and non-metro areas had the higher rates of mastectomy (28.2%, 28.6%, 28.9%, 29.8%)
and BCS without RT (23.3%, 24.8%, 26.1%, 26.4%).
Associations with Type of Treatment
Age & Health
Compared to women who were age 66-69 years at diagnosis, all other age groups were
more likely to be treated with mastectomy and BCS only, compared to BCS plus RT, with
women age > 80 years being the most likely to have mastectomy vs. BCS plus RT (AOR, 2.32;
95% CI, 2.17, 2.49) and BCS without RT vs. BCS plus RT (AOR, 3.48; 95% CI, 3.25, 3.74).
Women with greater comorbidity were more likely to have mastectomy or BCS without RT vs.
BCS plus RT, compared to women with a comorbidity score of "0". In fact, women with the
highest comorbidity were 38% more likely to receive BCS without RT vs. BCS plus RT (AOR,
1.38, 95% CI, 1.28, 1.47). Correspondingly, women with a high number of PCP visits were more
likely to receive mastectomy (AOR, 1.05; 95% CI, 1.00, 1.08) and BCS only (AOR, 1.13; 95%
CI, 1.06, 1.21) vs. BCS plus RT, compared to women with a low PCP visits (Table 3).
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Clinical Prognostics Factors
Women diagnosed with stage II breast cancer were more than three times as likely to
receive mastectomy (AOR, 3.18; 95% CI, 3.03, 3.34) and 1.29 times more likely (95% CI, 1.22,
1.36) to receive BCS without RT vs. BCS plus RT, compared to women diagnosed with stage I
breast cancer. Those with negative and borderline/unknown ER tumors were more likely to be
treated with mastectomy or BCS without RT vs. BCS plus RT. Women with a negative and
borderline/unknown PR status were also more likely to receive mastectomy vs. BCS plus RT.
Finally, women with moderately, poorly, and undifferentiated/unknown tumors were more likely
to receive mastectomy vs. BCS plus RT, as compared to women with well differentiated tumors.
Women with undifferentiated/unknown tumors were also more likely to receive BCS without RT
vs. BCS plus RT (AOR, 1.47; 95% CI, 1.29, 1.66), compared to women with well differentiated
tumors.
Oncology Care Resources
Women, residing in areas with a high density mammography screening centers were less
likely to be treated with BS without vs. BCS plus RT (AOR, 0.88; 95% CI, 0.79, 0.97), than
women residing in low density screening areas. Similarly, women residing in areas with a high
density of oncology treatment centers (AOR, 0.87; 95% CI, 0.79, 0.96) were less likely to have
mastectomy vs. BCS plus RT, than women residing in low density areas. Compared to women
treated by a general surgeon only, women treated by an oncology surgeon only or treated by both
types of surgeons were 23% (AOR, 0.77; 95% CI, 0.69, 0.86) and 24% less likely (AOR, 0.76;
95% CI, 0.72, 0.82) to receive mastectomy vs. BCS plus RT. Likewise, women treated by an
oncology surgeon only or treated by both types of surgeons were 47% less likely (AOR, 0.53;
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95% CI, 0.47, 0.60) (AOR, 0.53; 95% CI, 0.50, 0.56) to receive BCS without RT vs. BCS plus
RT, than those treated by a general surgeon only.
Socio-Demographic Characteristics
Women of other races were 30% and 27% more likely to have mastectomy (AOR, 1.30;
95% CI, 1.20, 1.40) or BCS without RT vs. BCS plus RT (AOR, 1.24; 95% CI, 1.14, 1.34),
compared to women of white race. In contrast, women living in an area where > 15% of the
population was college educated were less likely to receive mastectomy or BCS without RT vs.
BCS plus RT, than women living in an area that was < 15% college educated. Women residing
in areas with an average annual income > $35,000 were also less likely to receive mastectomy or
BCS without RT vs. BCS plus RT, than women residing in areas with an average annual income
< $35,000. Lastly, women residing in metro areas were 30% and 27% less likely to receive
mastectomy (AOR, 0.70; 95% CI, 0.65, 0.75) or BCS without RT vs. BCS plus RT (AOR, 0.73;
95% CI, 0.68, 0.79), compared to women residing in non-metro areas.
Discussion
Among elderly women diagnosed with invasive early-stage breast cancer in 2003 thru
2009, 55% received BCS plus RT as their initial loco-regional treatment, while 23% had
mastectomy, and 22% had BCS without RT. Somewhat different rates were found by DeSantis
and colleagues (2014) who examined patterns of treatment for early-stage breast cancer among
women of all ages from the National Cancer Data Base. They reported that 50% of women
received BCS plus RT, 36% had mastectomy, and 9% had BCS without RT. 40 An international
comparison of treatment for early-stage breast cancer limited to women age > 65 years, reported
that among US women sampled from 1995 to 2005 SEER-Medicare data, 30% had BCS plus
RT, 41% had mastectomy, and 19% had BCS without RT. 41 While these rates of BCS without
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RT are similar to those found by this study, the rates of BCS with RT are lower and mastectomy
are higher. This discrepancy in findings is likely due to differences in study design. Whereas, this
study looked at initial definitive surgery, Kiderlan and colleagues (2011) classified surgery as
mastectomy if a mastectomy was recorded at any time following BCS. The higher rates of BCS
plus RT and lower rates of mastectomy found by this study suggest that a greater number of
older women with early-stage breast cancer prefer BCS plus RT vs. mastectomy as their first
choice of surgery, but a substantial number eventually require mastectomy. In concurrence with
studies that noted a increase in rates of BCS without RT following the publication of the CALGB
C9343 trial study results and subsequent NCCN guideline update, this study also found that from
2004 to 2006 elderly women with early-stage breast cancer were more likely to have BCS only
than BCS with RT, but after 2006 women were just as likely to receive BCS without RT as they
were to have BCS with RT. 22,24,30 This increase in BCS without RT from 2004 to 2006 mostly
likely reflects a change in oncology practice immediately following the guideline change, but
this increasing trend may have reversed after 2006 amidst the ensuing controversy over omission
of RT for some elderly women.
Age & Health
In accordance with findings of previous studies, this study found that elderly women with
breast cancer had an increased chance of being receiving BCS without RT or mastectomy,
compared to BCS plus RT. Lack of RT following BCS among elderly women has been strongly
linked to increasing age, irrespective of risk factors.22,42 In fact, this study found women who
were age 80 years and older to be more than 3 times likely to not receive RT, as women age 6669 years. Increasing age is commonly cited as the main reason for omission of RT among elderly
women due to greater comorbidity, intolerance to RT toxicity, adverse effects, and shorter life-
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expectancy.42-46 Likewise, elderly women may be more likely to receive mastectomy for the
same reasons RT is omitted following BCS, to avoid any adverse effects of RT or possible
intolerance to toxicity from RT due to greater comorbidity and a general frailty associated with
old age. However, not all experts agree that RT is more toxic or less tolerable among elderly
women, than younger women. In fact, several studies have found RT to be well-tolerated among
elderly women, and determined that it did not increase the risk of myocardial infarction or
cardiovascular disease (CVD).47-50
Declining health is a burden commonly experienced by the elderly population, and
presents additional challenges for tolerating cancer treatments, particularly RT. Accordingly, this
study found that elderly women with 2 or more comorbid conditions were ~ 40% more likely to
not receive RT following BCS and 14% more likely to be treated with mastectomy. The
association between women with greater comorbidity being more likely to have mastectomy or
BCS without RT, may explain why women with a high frequency of PCP visits were more likely
to be treated with mastectomy or BCS without RT. However, over 20% of women with a
comorbidity score = 0 did not receive RT following BCS and 23% were treated with
mastectomy, suggesting that increased comorbidity does not always predict type of treatment.
This may reflect a preference for mastectomy, due to a desire to avoid necessary RT.
Clinical Prognostic Factors
Women diagnosed with stage II breast cancer were 30% more likely to not receive RT,
compared to women with stage I breast cancer, a finding that may also be explained by older
age. Declines in routine mammography screening are commonly observed among elderly
women, particularly the oldest of the old. A decline in mammography screening among elderly
women occurs due to decreased perceived risk of breast cancer, lack of physician
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recommendation, competing health demands, life-expectancy and potential for more harm than
benefit from screening, as indicated by the latest United States Preventive Services Task Force
(USPSTF) recommendation on mammography screening for women age > 74 years. 51-56 This
decrease in screening can, in turn, result in a later stage diagnosis, at which point they are already
less likely to receive RT following BCS due to older age. Similarly, women diagnosed at stage II
vs. I, were over three times more likely to undergo mastectomy. While the likelihood of
mastectomy intuitively increases with increasing stage, it may be that older women are even
more likely to have mastectomy at a later stage when BCS plus RT is an option, in order to avoid
the toxic and adverse effects of RT and the burden of multiple treatments with RT.
Other clinical prognostic factors were associated with receipt of mastectomy in the expected
direction, such that women with negative and borderline/unknown ER and PR tumors statuses,
and less differentiated tumor grades had an increased likelihood for mastectomy.8,31 These
clinical characteristics are associated with poorer prognosis among women with breast cancer
and are often more challenging to treat with BCS plus RT. 18
Oncology Care Resources
Women who were treated by an oncology surgeon or an oncology surgeon and a general
surgeon, opposed to a general surgeon only, were 26% to 47% less likely to be treated with
mastectomy or BCS without RT, compared to BCS with RT. Surgeon characteristics, such as
gender, country of training, year or training, and case-load have be linked to type surgery
received for early-stage breast cancer.19, 33 Evidence suggest that surgeon specialty is also
associated with more advanced methods of breast cancer treatment.57 Being treated by both an
oncology and general surgeon may be an indication of case-load sharing and/or division of
services within high volume treatment centers, which are commonly associated with better
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treatment practices. 58 Moreover, those who have an oncology surgeon as a part of the oncology
treatment care may have shorter travel distances to access specialty care. In fact, women residing
in areas with a high density of mammography screening centers were less likely to have BCS
without RT, while women residing in areas with a high density of oncology treatment centers
were less likely to have mastectomy, compared to BCS plus RT. These finding reflect the benefit
of residing closer to available oncology care resources. Women who have shorter driving
distances to treatment centers may be more likely to choose a treatment such as BCS plus RT,
that required multiple trips for repeated treatments. 59
Socio-Demographic Characteristics
Vulnerable socio-demographic and unfavorable clinical characteristics have long been
established as factors associated with health disparities in general and in breast cancer treatment.
19,20,22,23

Accordingly, findings from this study confirmed these associations. Women of non-

white race, residing in areas that were non-metro, less educated, and low income, were less more
likely to be treated with mastectomy or not have RT following BCS. Women with these
characteristics may not receive RT following BCS or undergo mastectomy for many of the same
reasons. This reasons include a lack of access to specialty care, high quality hospitals, greater
travel distances to oncology care, and fewer financial resources, even after accounting for less
favorable tumor characteristics observed in African American and Hispanic women.59-62 What is
more, increased mastectomy rates among various races and ethnicities of non-white women may
be associated with country of birth, mastery of the English language, navigation of the healthcare
system, and awareness of available treatment options.63
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Limitations & Strengths
Several limitations should be kept in mind when interpreting the results of this study.
First, many women have multiple surgical claims for lumpectomies, mastectomies, or
lumpectomies and mastectomies in various combinations. This study examined only the first
surgical claim for purposes of continuity and capturing the initial intended primary treatment.
This method does not capture the total number of mastectomies and may overestimate the
number of lumpectomies without radiation, due to initial treatment failure. While this study
examined the relationships between type of treatment and a range of covariates, it was unable to
measure how changing attitudes toward mastectomy were associated with type of primary
treatment. Moreover, completion of radiation therapy was not assessed, only the initiation of
therapy. Additionally, several of socio-demographic characteristics examined were aggregate
census level measures, rather than individual level measures. Finally, the SEER individuals
within the SEER database have been found to be of higher income, and higher concentrations of
racial and ethnic minorities, as compared to the U.S. population.64
Despite these limitations, this study holds several strengths that impart credibility to its
findings. To the authors’ best knowledge, this is the first study to examine the initial choice of
loco-regional treatment for early-stage breast cancer among elderly women. This study examined
treatment patterns during times before and after a change in treatment guideline
recommendations, pertaining to necessity of RT among a subset of women in this population.
Concern has been raised whether this guideline change influenced receipt of RT among women
whom RT would have been recommended. A wide range of covariates were examined in relation
to type of treatment that included socio-demographic, access, health, clinical, and physician
characteristics. Despite containing slightly greater proportions of affluent and minority
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individuals, SEER is widely accepted as representative of the U.S. population, making these
results generalizable to the greater population of elderly women with invasive early-stage breast
cancer insured by Medicare.
Significance & Conclusions
In conclusion, more than half of older women with early-stage breast cancer have BCS
plus RT as their initial loco-regional treatment, while fewer than one-fourth have BCS without
RT. However, a substantial number may eventually require mastectomy due to treatment failure.
Women of increasing age, comorbidity, and stage were the most likely to have mastectomy or
BCS without RT, possibly reflecting a reluctance to aggressively treat older women with breast
cancer, thereby increasing their risk of recurrence and mortality. Current study findings also
highlight the importance of access to oncology care resources on receipt of initial type of
treatment. These findings suggest that many elderly women are being undertreated for invasive
early-stage breast cancer, and therefore at increased risk for breast cancer mortality and
recurrence. Aggressive treatment, including adjuvant therapy should be recommended to all
elderly women with early-stage breast who are healthy enough and choose to do so. Some
women may require additional patient support resources such as patient education and navigation
to ensure equity of care.
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Table 1
Characteristics of Elderly Women with Early-Stage Breast Cancer
SEER -Medicare, 2003-2009
N
45,981

All
Treatment
BCS+Radiation
Mastectomy
BCS only
Year of Diagnosis
2003
2004
2005
2006
2007
2008
2009

%
100.0

25067
10768
10146

54.5
23.4
22.1

6667
6527
6418
6494
6564
6629
6682

14.5
14.2
14.0
14.1
14.3
14.4
14.5

10331
11741
10731
13178

22.5
25.5
23.3
28.7

26061
12439
7481

56.7
27.1
16.3

24834
21147

54.0
46.0

28931
17050

62.9
37.1

36364
6301
3316

79.1
13.7
7.2

30504
11766
3711

66.3
25.6
8.1

Age & Health
Age at Diagnosis
66-69
70-74
75-79
> 80
Comorbidity Score
0
1
>2
PCP Visits
Low
High
Clinical Prognostic Factors
Stage at Diagnosis
I
II
ER Status
Positive
Negative
Borderline/Unknown
PR Status
Positive
Negative
Borderline/Unknown
BCS = breast-conserving surgery
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Table 1
Characteristics of Elderly Women with Early-Stage Breast Cancer
SEER -Medicare, 2003-2009
N
45,981

All
Tumor Grade
Well Differentiated
Moderately Differentiated
Poorly Differentiated
Undifferentiated/Unknown

%
100.0

12118
20046
10831
2986

26.4
43.6
23.6
6.5

23789
22192

51.7
48.3

25761
20220

56.0
44.0

8555
2644
34782

18.6
5.8
75.6

23441
4891

89.4
10.6

13557
32424

29.5
70.5

10853
35128

23.6
76.4

7686
38295

16.7
83.3

Oncology Care Resources
Mammography Screening Centers
Low
High
Oncology Treatment Centers
Low
High
Type of Surgeon Seen
General Only
Oncology Only
Both
Socio-Demographic Characteristics
Race
White
Other
Education
< 15% college degree
> 15% college degree
Annual Income
< $35,000
> $35,000
Metro Status
Non-metro
Metro
BCS = breast-conserving surgery
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Table 2
Comparison of Initial Loco-Regional Treatment Among Elderly Women with Early-Stage Breast Cancer
SEER-Medicare, 2003-2009
BCS+Radiation
Mastectomy
BCS Only
N
%
N
%
N
%
p-value
All
25067 54.5
10768 23.4
10146 22.1
Year of Diagnosisb
<0.001***
2003
3523 52.8
1656 24.8
1488 22.3
2004
3503 53.7
1437 22.0
1587 24.3
2005
3389 52.8
1462 22.8
1567 24.4
2006
3572 55.0
1419 21.9
1503 23.1
2007
3637 55.4
1560 23.8
1367 20.8
2008
3676 55.5
1610 24.3
1343 20.3
2009
3767 56.4
1624 24.3
1291 19.3
Age & Health
Age at Diagnosisc
<0.001***
66-69
6714 65.0
2067 20.0
1550 15.0
70-74
7266 61.9
2524 21.5
1951 16.6
75-79
6035 56.2
2525 23.5
2171 20.2
> 80
5052 38.3
3652 27.7
4474 34.0
Comorbidity Scorec
<0.001***
0
14986 57.5
5892 22.6
5183 19.9
1
6504 52.3
2959 23.8
2976 23.9
>2
3577 47.8
1917 25.6
1987 26.6
PCP Visitsa
<0.001***
Low
14157 57.0
5685 22.9
4992 20.1
High
10910 51.6
5083 24.0
5154 24.4
Clinical Prognostic Factors
Stage at Diagnosisa
<0.001***
I
17759 61.4
4517 15.6
6655 23.0
II
7308 42.9
6251 36.7
3491 20.5
ER Statusa
<0.001***
Positive
20599 56.7
7866 21.6
7899 21.7
Negative
3158 50.1
1912 30.3
1231 19.5
Borderline/Unknown
1310 39.5
990 29.9
1016 30.6
a
PR Status
<0.001***
Positive
17405 57.1
6461 21.2
6638 21.8
Negative
6148 52.3
3221 27.4
2397 20.4
Borderline/Unknown
1514 40.8
1086 29.3
1111 29.9
a = cmh chi square test of general association
b = cmh chi square test of location shift using table scores
c = cmh chi square test of location shift using modified ridit scores
BCS = breast conserving surgery
* p < 0.05; ** p < 0.01; *** p < 0.001

Tumor Gradea

<0.001***
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Table 2
Comparison of Initial Loco-Regional Treatment Among Elderly Women with Early-Stage Breast Cancer
SEER-Medicare, 2003-2009
BCS+Radiation
Mastectomy
BCS Only
N
%
N
%
N
%
p-value
All
25067 54.5
10768 23.4
10146 22.1
Well Differentiated
7128 58.8
2197 18.1
2793 23.1
Moderately Differentiated
11129 55.5
4606 23.0
4311 21.5
Poorly Differentiated
5414 50.0
3267 30.2
2150 19.9
Undifferentiated/Unknown
1396 46.8
698 23.4
892 29.9
Oncology Care Resources
Mammography Screening Centersa
<0.001***
Low
12276 51.6
6018 25.3
5495 23.1
High
12791 57.6
4750 21.4
4651 21.0
Oncology Treatment Centersa
<0.001***
Low
13392 52.0
6492 25.2
5877 22.8
High
11675 57.7
4276 21.2
4269 21.1
Type of Surgeon Seena
<0.001***
General Only
3636 42.9
2031 23.7
2888 33.8
Oncology Only
1536 59.0
607 23.0
501 19.0
Both
19895 56.2
8130 23.4
6757 19.4
Socio-Demographic Characteristics
Racea
<0.001***
White
22696 55.2
9389 22.9
9005 21.9
Other
2371 48.5
1379 28.2
1141 23.3
Educationa
<0.001***
< 15% college degree
6318 46.6
3874 28.6
3365 24.8
> 15% college degree
18749 57.8
6894 21.3
6781 20.9
Annual Incomea
<0.001***
< $35,000
4878 45.0
3141 28.9
2834 26.1
> $35,000
20189 57.5
7627 21.7
7312 20.8
Metro Statusa
<0.001***
Non-metro
3367 43.8
2289 29.8
2030 26.4
Metro
21700 56.7
8479 22.1
8116 21.2
a = cmh chi square test of general association
b = cmh chi square test of location shift using table scores
c = cmh chi square test of location shift using modified ridit scores
BCS = breast conserving surgery
* p < 0.05; ** p < 0.01; *** p < 0.001
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Table 3
Associations with Initial Loco-Regional Treatment Among Elderly Women with Early-Stage Breast
Cancer
SEER-Medicare, 2003-2009
Treatment
Mastectomy vs.BCS + RT
BCS Only vs. BCS + RT
AOR
95% CI
Sig.
AOR
95% CI
Sig.
Year of Diagnosis
2003
1.00
1.00
―
―
2004
0.95
[0.87,1.04]
1.16
[1.06,1.26]
**
2005
1.01
[0.92,1.10]
1.22
[1.11,1.33]
***
2006
0.95
[0.87,1.04]
1.13
[1.04,1.24]
**
2007
1.03
[0.95,1.13]
1.01
[0.92,1.11]
2008
1.08
[0.99,1.18]
1.01
[0.92,1.11]
2009
1.08
[0.99,1.18]
0.95
[0.87,1.05]
Age & Health
Age at Diagnosis
66-69
1.00
1.00
―
―
70-74
1.12
[1.05,1.20]
**
1.12
[1.04,1.21]
**
75-79
1.39
[1.30,1.49]
***
1.48
[1.38,1.60]
***
> 80
2.32
[2.17,2.49]
***
3.48
[3.25,3.74]
***
Comorbidity Score
0
1.00
1.00
―
―
1
1.07
[1.01,1.14]
*
1.22
[1.15,1.29]
***
>2
1.14
[1.06,1.22]
***
1.38
[1.28,1.47]
***
PCP Visits
Low
1.00
1.00
―
―
High
1.05
[1.00,1.11]
*
1.11
[1.05,1.16]
***
Clinical Prognostic Factors
Stage at Diagnosis
I
1.00
1.00
―
―
II
3.18
[3.03,3.34]
***
1.29
[1.22,1.36]
***
ER Status
Positive
1.00
1.00
―
―
Negative
1.18
[1.08,1.29]
***
1.02
[0.92,1.12]
Borderline/Unknown
1.57
[1.25,1.97]
***
1.48
[1.18,1.86]
***
PR Status
Positive
1.00
1.00
―
―
Negative
1.13
[1.05,1.21]
***
1.00
[0.93,1.08]
Borderline/Unknown
1.18
[0.95,1.47]
1.18
[0.95,1.47]
Tumor Grade
Well Differentiated
1.00
1.00
―
―
Moderately Differentiated
1.12
[1.05,1.19]
***
0.96
[0.90,1.02]
Poorly Differentiated
1.26
[1.17,1.35]
***
0.95
[0.88,1.02]
Undifferentiated/Unknown
1.21
[1.08,1.35]
***
1.42
[1.29,1.57]
***
BCS = breast-conserving surgery
* p < 0.05; ** p < 0.01; *** p < 0.001
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Table 3
Associations with Initial Loco-Regional Treatment Among Elderly Women with Early-Stage Breast
Cancer
SEER-Medicare, 2003-2009
Treatment
Mastectomy vs.BCS + RT
BCS Only vs. BCS + RT
AOR
95% CI
Sig.
AOR
95% CI
Sig.
Oncology Care Resources
Mammography Screening Centers
Low
1.00
1.00
―
―
High
0.98
[0.89,1.08]
0.88
[0.79,0.97]
**
Oncology Treatment Centers
Low
1.00
1.00
―
―
High
0.87
[0.79,0.96]
**
1.05
[0.95,1.16]
Type of Surgeon Seen
General Only
1.00
1.00
―
―
Oncology Only
0.77
[0.69,0.86]
***
0.53
[0.47,0.60]
***
Both
0.76
[0.72,0.82]
***
0.53
[0.50,0.56]
***
Socio-Demographic Characteristics
Race
White
1.00
1.00
―
―
Other
1.30
[1.20,1.40]
***
1.24
[1.14,1.34]
***
Education
< 15% college degree
1.00
1.00
―
―
> 15% college degree
0.75
[0.70,0.79]
***
0.82
[0.77,0.87]
***
Annual Income
< $35,000
1.00
1.00
―
―
> $35,000
0.87
[0.82,0.93]
***
0.84
[0.78,0.89]
***
Metro Status
Non-metro
1.00
1.00
―
―
Metro
0.70
[0.65,0.75]
***
0.73
[0.68,0.79]
***
BCS = breast-conserving surgery
* p < 0.05; ** p < 0.01; *** p < 0.001
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Abstract
Objectives: Evidenced-based guidelines for the treatment of breast cancer have been put forth
by agencies such as the National Comprehensive Cancer Network (NCCN). Yet, even with
specific guidelines, gaps in the receipt of appropriate care exist, particularly among the aged
population. This study examined factors associated with receipt of guideline-concordant care
(GCC) vs. guideline-discordant care (GDC) and receipt of distinct treatments and testing among
elderly U.S. women with breast cancer.
Methods: A sample of 27,883 women age > 66 with pathologically staged I, II, and III breast
cancer diagnosed from 2004 to 2009 were selected from the SEER-Medicare linked dataset.
Algorithms that considered clinical cancer characteristics and the appropriate course of care as
per guidelines vs. the actual care received, were used to determine receipt of GCC (yes vs. no).
Logistic regression models were used to examine the relationship between GCC and independent
variables that included of age, health, clinical prognostic factors, oncology care resources, and
socio-demographic characteristics. Age was dichotomized to estimate the likelihood for receipt
of specific tests and treatments between younger (age 66-69) and older (age > 70) women.
Results: Less than 34% of elderly women received guideline appropriate care. Women of nonwhite race (AOR, 0.81; 95% CI, 0.73, 0.89), increasing age (> 80 vs. 66-69) (AOR, 0.19; 95%
CI, 0.17, 0.21), increasing comorbidity (> 2 vs. 0) (AOR, 0.71; 95% CI, 0.65, 0.78), and
increasing stage (II vs. I) (AOR, 0.46; 95% CI, 0.40, 0.54) were less likely to receive GCC.
Women with node negative cancer, larger tumors, poorly differentiated tumors, negative and
borderline/unknown tumor receptors were also less likely to receive appropriate care. Yet, the
likelihood of appropriate care was increased for women who were treated by an oncology
surgeon (AOR, 1.84; 95% CI, 1.67, 2.03) or both a general and oncology surgeon vs. general
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surgeon only (AOR, 1.47; 95% CI, 1.26, 1.72). Compared to women age 66-69 years, those age
> 70 years were more likely to have mastectomy (AOR, 1.31; 95% CI, 1.23, 1.39) or have any
definitive surgery (AOR, 2.51; 95% CI, 1.76, 3.58), but less likely to have GCC (AOR, 0.51;
95% CI, 0.48, 0.54), estrogen-receptor status testing (AOR, 0.80; 95% CI, 0.70, 0.92),
progesterone-receptor status testing (AOR, 0.78; 95% CI, 0.68, 0.89), breast-conserving surgery
(AOR, 0.76; 95% CI, 0.71, 0.81), radiation therapy (AOR, 0.63; 95% CI, 0.60, 0.67),
chemotherapy (AOR, 0.30; 95%CI, 0.28, 0.32), and appropriate time to chemotherapy (AOR,
0.78; 95% CI, 0.68, 0.89).
Conclusions: Irrespective of guidelines, younger, less complex patients with greater resources
are more likely to receive GCC. Better efforts should be made for all elderly women with breast
cancer who are healthy enough to receive the aggressive standard of care.
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Introduction
Breast cancer is the most commonly diagnosed and prevalent cancer among women. As
of 2012, over 2.9 million women living with breast cancer in the U.S., and in 2015, an estimated
231,840 incident cases and 40,730 deaths with be attributable to invasive breast cancer (IBC).1,2
However, with early detection from routine screening and appropriate treatment according to
recommended guidelines, prognosis is relatively good with an 89% overall 5-year survival rate.2
Based on the results of clinical trials, evidenced-based recommended guidelines for the treatment
of non-metastatic breast cancer have been put forth by the National Comprehensive Cancer
Network (NCCN) to direct the course of breast cancer care and treatment according to cancer
and patient characteristics.3 Tumor size, spread of cancer to lymph nodes and the number of
nodes affected and tumor hormone receptor status determine the type of primary surgery (breast
conserving surgery or mastectomy) that a patient is eligible for, and if radiation therapy (RT),
chemotherapy, and/or adjuvant hormone therapy (AHT) is recommended. Surgery choice will
also determine recommendation for receipt of adjuvant treatments. Moreover, all women with
IBC should have their lymph nodes tested for spread of disease and biopsies of breast tissue
should be tested to establish whether the tumor is estrogen receptor (ER) positive, progesterone
receptor (PR) positive, and/or HER2/neu positive or negative. Additional quality measures for
breast cancer treatment jointly published by the American Society of Clinical Oncology (ASCO)
and the NCCN suggest that AHT should begin within the first year of diagnosis, RT should
begin within the first year of diagnosis, and chemotherapy should begin within 120 days of
diagnosis.4
Despite the existence of evidence-based treatment guidelines, many women with breast
cancer still do not receive appropriate, or guideline-concordant care (GCC). As with other health
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disparities, access to specialty care and vulnerable socio-demographic characteristics such as
being of non-white race, publicly insured or uninsured, residing in areas of low income, low
education, and/or locations, having greater driving distances to treatment centers, and even
surgeon characteristics have been associated with guideline-discordant care (GDC) for breast
cancer.5-11 In addition to these factors, poor clinical characteristics including unknown receptor
status and tumor grade have also been linked with GDC.6,9,11 The most commonly reported
causes for GDC is the omission of lymph node testing, RT following breast-conserving surgery
(BCS), RT following mastectomy, chemotherapy, and adjuvant hormone therapy.5,6,8-12 An
unknown tumor receptor status may also be an indication that the test for receptor status was not
conducted.13
In addition to these associations, older age and its relationship with increased
comorbidity and frailty, and thereby a possible intolerance and/or toxicity to RT or
chemotherapy have been strongly associated with GDC among elderly women with breast
cancer.5,6,8-11,14-17 However, the belief that RT and/or chemotherapy is less tolerable or more
toxic in older women compared to younger women, is not universal. In fact, many studies have
shown RT and chemotherapy to be well-tolerated and safe among the elderly.18-21 Guidelines do
not make recommendations for or against chemotherapy in women age > 70 years, but suggest
chemotherapy be given on a case-by-case basis, considering comorbidity.22 Moreover, NCCN
treatment guidelines make an exception for the omission of RT following BCS among a specific
group of women meeting the following requirements: age > 70 years, tumors < 2 cm, node
negative, estrogen-receptor positive, and receiving adjuvant hormone therapy.23 This change to
recommended treatment guidelines was made after the 2004 publication of the Cancer and
Leukemia Group B (CALGB) C9343 trial study results that demonstrated similar 5-year survival
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between women with these clinical characteristics who received BCS plus RT or BCS alone.
Since then, rates of RT following BCS have decreased, regardless of clinical factors or the
increased risk for breast cancer mortality and recurrence among elderly women not receiving RT
after BCS.24-26 This trend raises the questions as to what other recommended care are they not
receiving and to how often do elderly women with breast cancer receive GCC?
Statement of the Problem
Few studies have comprehensively studied receipt of GCC among women with breast
cancer. One study by Kimmick and colleagues (2014) comprehensively examined GCC in
relation to comorbidity among women of all ages diagnosed with stage 0 thru stage III, but their
sample was limited to women diagnosed in 2004 from seven cancer registries. 27 Other studies
investigating GCC have done so in piecemeal fashion, either looking at GCC among women
with early-stage breast cancer only, specific racial/ethnic populations, limited loco-regional
treatment, systematic treatment, using small study samples, older data, and/or allowed for the
omission of RT or chemotherapy among women age > 70 years from GCC criteria. 5, 13,27-31 To
address gaps in the literature and build upon existing knowledge of GCC among elderly women,
this study will comprehensively examine receipt of hormone receptor and lymph node status
testing, definitive surgery, RT, chemotherapy, and timeliness of chemotherapy among women
age > 66 years diagnosed with stage I, II, III breast cancer from 2004 to 2009 using a large,
nationally representative database. In order to determine to what degree older populations of
women with breast cancer receive care according to recommended treatment guidelines as they
would otherwise be applied to younger age groups, this study included treatment with RT and
chemotherapy for women age > 70 years with clinical indications in the definition of GCC.

71

Bearing these thoughts in mind, the purpose of this study was to determine to what
degree elderly women with breast cancer receive GCC, factors associated with receipt of GCC,
and how likely women age > 70 vs. age 66-69 years are to receive specific tests and treatments.
Methods
Data
The SEER-Medicare database was created in a collaborative effort by the National
Cancer Institute (NCI) and Centers for Medicare and Medicaid Services (CMS) to combine
clinical information gathered by the Surveillance Epidemiology and End Results cancer registry
program with Medicare insurance claims. The SEER program collects basic socio-demographic,
clinical, and vital status information on incident cancer cases from multiple reporting sources.
This information is found the Patient Entitlement and Diagnosis Summary File (PEDSF). SEER
data used for this study consisted of 17 population-based registries, representing 26% of the U.S.
population. An algorithm based on name, Social Security number, sex, and date of birth
successfully matched 94% SEER cases to their Medicare claims beginning from the time of
eligibility till death.32 This study used Medicare claims providing information regarding
beneficiary enrollment (Denominator File), hospital inpatient claims (Med-PAR file), hospital
outpatient claim (Outpatient file), physician office visits (NCH file), and durable medical
equipment (DME file).33 Additionally, county and state of diagnosis were used to identify the
area-level density of mammography screening and oncology centers from the U.S. Department
of Health and Human Resource's 2009 Area Resource File (ARF).34
Study Population
This retrospective cohort study selected American Joint Commission on Cancer (AJCC)
staged I, II, and III incident cases of breast cancer recorded in SEER during years 2004 to 2009,
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among female age-eligible Medicare beneficiaries who were continuously enrolled in Medicare
Part A and B fee-for-service programs 1 year before and after diagnosis, and were therefore age
> 66 years at the time of diagnosis. Women were excluded if they were enrolled in a managed
care program at any time during year before to the year after diagnosis, diagnosed at the time of
death or upon autopsy, died within the first year of diagnosis, had end-stage renal disease, did
not have primary surgical treatment, or if surgeon specialty or tumor size was missing. The final
sample size was n = 27,883 elderly women.
Measures
Dependent Variables
The primary outcome of interest was receipt of GCC vs. GDC. This was determined by
comparing the correct course of care according to tumor size and nodal status of each women as
per NCCN evidence-based clinical practice guidelines, to the actual care received (Table 1.) Care
was also determined to be guideline-concordant if chemotherapy was initiated within 120 days of
diagnosis, when chemotherapy was indicated, as per ASCO/NCCN quality measures, and if
lymph node invasion, and hormone receptor statuses were tested. Although ASCO/NCCN
quality measures indicate RT should be initiated within 1 year of diagnosis, this was not
considered in the determination of GCC, as all claims used for this study were made within 1
year after diagnosis. For this study purpose, being of age > 70 years was not considered a
determining factor for GCC vs. GDC when RT or chemotherapy was indicated, in order to
determine the extent that younger and older women receive differential care.
The secondary outcome of interest was the receipt of individual treatments and tests.
These included lymph node testing (yes or no), ER status testing (yes or no), PR status testing
(yes or no), had any primary surgery (BCS or mastectomy) (yes or no), had BCS (yes or no), had
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mastectomy (yes or no), had RT (yes or no), had chemotherapy (yes or no), and chemotherapy
was initiated within 120 day of diagnosis (yes, no, or not applicable). For women who had BCS
and mastectomy, both types of surgery were included in analysis, with totals from both category
adding to greater than 100%. Hormone receptor status testing was assessed using the status given
by the ER status and PR status variable in the Patient Entitlement and Diagnosis Summary File
(PEDSF) file. If the status was listed as "positive", "negative", or "borderline", then the receptor
status was determined to have been tested. If the status was listed as "unknown", then it was
considered as not having been tested. Lymph node testing was defined by the claims codes for
axillary lymph node dissection (ALND) or sentinel lymph node (SNB) biopsy. Surgical, RT, and
chemotherapy treatments were determined using International Classification of Diseases, 9th
Revision (ICD-9) diagnostic and procedure, Healthcare Common Procedure Coding System
(HCPCS) and Current Procedural Terminology (CPT) codes found in Medicare Provider and
Analysis Review (MEDPAR), Outpatient, and Physician/Supplier Data File data files. See
Appendix 1.
Independent Variables
Independent variables examined in this study encompassed year of diagnosis, age, health,
clinical prognostic factors, specific tests and treatments, oncology care resources, and sociodemographic characteristics. Age at diagnosis (66-69, 70-74, 75-79, > 80) and health were
considered together since declining health associated with increasing age is the reason given by
NCCN guidelines for case-by-case use of chemotherapy in women older than 70 years, and are
often cited as associations with undertreatment among elderly women in retrospective studies.
Age was also dichotomized (66-69 or > 70) to test for differences between younger and older
elderly women. Health was measured by calculating patient comorbidity by applying an
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algorithm to Medicare claims that identifies a comorbid condition as the presence of at least one
in-patient or two out-patient claims using ICD-9 diagnoses codes for each co-morbid condition.
Overall comorbidity was then classified using the Klabunde adaption of the Charlson
comorbidity index score (0, 1, > 2). 35,36 Frequency of primary care provider (PCP) visits was
also used as a proxy for health status, with a higher number of visits considered an indication of
poorer health. An index of PCP visit intensity was identified by counting of number of unique
PCP claim dates the year before diagnosis in the NCH file. PCP visits were categorized by lower
and upper 50th percent median cutoff (low, high). Clinical prognostic factors examined were
stage at diagnosis, tumor size (< 1cm, < 2 cm, 2 - 5 cm, > 5 cm), lymph node status (positive or
negative), ER tumor status (positive, negative, borderline/unknown), PR tumor status (positive,
negative, borderline/unknown), and tumor grade (well differentiated, moderately differentiated,
poorly differentiated, undifferentiated/unknown). Stage diagnosis was categorized using the
pathologically staged AJCC Stage Group 6th edition (I, II, III). Individual tests and treatments
examined were ER tumor status testing (yes or no), PR tumor status testing (yes or no), lymph
node status testing (yes or no), receipt of any definitive surgery (yes or no), mastectomy (yes or
no), BCS (yes or no), RT (yes or no), chemotherapy (yes or no), and initiation of chemotherapy
within 120 days of diagnosis (yes or no). Measures of oncology care resources were the density
of area-level mammography screening centers and oncology treatment centers relative to each
woman's location of residence. This area-level density was measured using data from the ARF
and was categorized by lower and upper 50th percent median cutoff (low, high). Surgeon
specialty was assessed using provider specialty claims codes 02, 49 (general) and 83, 90, 91, 98
(oncology) from the NCH file to determine the type of surgeon seen (general only, oncology
only, both). Socio-demographic characteristics examined were race (white, other), education
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(measured by the 2000 Census tract survey of percent of persons age > 25 with at least 4 years
college education) (< 15%, > 15%), annual income (measured by the 2000 Census tract survey of
median income by census) (< $35,000, > $35,000), and metro status (non-metro, metro).
Analysis
Descriptive analysis was conducted for all study variables. Mantel-Haenszel chi-square
tests of location shift using modified ridit scores or table scores and Mantel-Haenszel chi-square
tests of general association (depending on whether the independent measure was dichotomous,
nominal, or ordinal) were used to test for significant group differences between GCC vs. GDC
and independent measures, with significance set at P < .05. Binomial logistic regression models
were used to estimate the adjusted odds of receiving GCC vs. GDC for each of the independent
variables described above and for receipt of specific tests and treatments for women age > 70
years vs. age 66-69 years old, controlling for the independent measures. Parameter estimates
calculated in the regression models are presented as adjusted odds ratios (AOR) with their
corresponding 95% confidence intervals (CI). All analysis were conducted using SAS version
9.4 software (SAS Institute Inc., Cary, NC).
Results
Population Characteristics
Among this sample of elderly female fee-for-service Medicare beneficiaries diagnosed
with pathologically staged breast cancer in 2004 thru 2009, the majority were age 70-74 years at
diagnosis (27.1%), of white race (88.2%), lived in metro areas (83.3%), areas where the
population was > 15% college educated (69.5%) and had an annual income > $35,000 (75.6%).
The majority had a comorbidity score = 0 (55.7%), were diagnosed at Stage I (56.4%), had their
were lymph node negative (73.1%), had BCS (74.8%), had RT (61.1%), did not have
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chemotherapy (74.9%), saw both a general and oncology surgeon (79.6%), and did not receive
GCC (66.5%).
Group Differences by Receipt of GCC
All group differences were significant at the P < .001 level, with the exception of density
of mammography screening centers (P = .219) and density of oncology centers (P = .083).
Receipt of GCC increased from 31.9% in 2004 to 35.2% in 2009. Yet, receipt of GCC decreased
with increasing age (45.8% for those age 66-69 years vs. 17.2% for those age > 80 years) and
increasing comorbidity (35.3% for those with comorbidity score = 0 vs. 27.9% with comorbidity
score > 2). Women diagnosed as Stage I had the highest rates of GCC (39.7%), whereas those
diagnosed at II had the lowest rates of GCC (22.6%). Additional clinical prognostic factors with
lower rates of GCC were positive lymph nodes, larger tumor size, positive and
borderline/unknown ER status, positive and borderline/unknown PR status, and
undifferentiated/unknown tumor grades. Women who were treated by an oncology surgeon or
both an oncology and general surgeon had higher rates of GCC (32.8% & 35.1%, respectively)
than women treated by a general surgeon only (25.2%). In regards to socio-demographic
characteristics women of white race vs. non-white, lived in metro areas vs. non-metro, areas
where > 15% of the population was college educated vs. < 15%, or average annual income was >
$35,000 vs. < $35,000 had higher rates of GCC.
Associations with Receipt of GCC
Receipt of GCC became less likely with increasing age, such that women age > 80 years
(AOR, 0.19; 95% CI, 0.17, 0.21) were the least likely to receive GCC, compared to women age
66-69 years. Women with a comorbidity score > 2 were about 30% less likely (AOR, 0.71; 95%
CI, 0.65, 0.78) to receive GCC, than women with a score = zero. Compared to women diagnosed
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at Stage I, those diagnosed at Stage II were less than half as likely to receive GCC (AOR, 0.46;
95% CI, 0.40, 0.54). Likewise, women with larger tumors were less likely to have had GCC,
than women with tumors < 1 cm. Elderly women with lymph node negative breast cancer were
less than half as likely to have had GCC (AOR, 0.49; 95% CI, 0.44, 0.56), than women who
were lymph node positive. However, women who had tumors that were ER and PR negative vs.
positive were more likely to receive GCC (AOR, 1.89; 95% CI, 1.69, 2.11) and (AOR, 1.20;
95% CI, 1.10, 1.32), respectively. Whereas, those whose tumors were ER and PR
borderline/unknown were 96% and 68% less likely to receive GCC (AOR, 0.04; 95% CI, 0.02,
0.07) and PR statuses (AOR, 0.32; 95% CI, 0.22, 0.47), respectively. In contrast, women with
moderately and poorly differentiated tumors vs. well-differentiated, were more likely to have had
GCC. Women treated by an oncology surgeon or both a general and oncology surgeon were 47%
(AOR, 1.47; 95% CI, 1.26, 1.72) and 84% (AOR, 1.84; 95% CI, 1.67, 2.03), more likely to
receive GCC, respectively, than women treated by a general surgeon only. Women of non-white
race vs. white were less likely to receive GCC (AOR, 0.81; 95% CI, 0.73, 0.89), whereas women
who resided in areas where > 15% was college educated vs. < 15% were more likely to receive
GCC.
Associations with Tests & Treatments among Women Age > 70 vs. 66-69 years
Women age > 70 years were half as likely (AOR, 0.51; 95% CI, 0.48, 0.54) to receive
GCC, than women age 66-69 years. Compared to younger women, older women were less likely
to have ER status testing (AOR, 0.80; 95% CI, 0.70, 0.92) and PR status testing (AOR, 0.78;
95% CI, 0.68, 0.89). However, older women were 2.5 times more likely than younger women to
have had any definitive surgery (AOR, 2.51; 95% CI, 1.76, 3.58). In regards to type of surgery,
older women were less likely to have BCS (AOR, 0.76; 95% CI, 0.71, 0.81), but more likely to
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have mastectomy (AOR, 1.31; 95% CI, 1.23, 1.39), than younger women. Finally, older women
were older women were less likely to have RT (AOR, 0.63; 95% CI, 0.60, 0.67), chemotherapy
(AOR, 0.30; 95% CI, 0.28, 0.32), or appropriate time to chemotherapy (AOR, 0.78; 95% CI,
0.68, 0.89), compared to younger women.
Discussion
To these authors knowledge, this is the first study to comprehensively examine GCC as
treatment guidelines are applied to all women with breast cancer among a large nationally
representative sample of elderly women diagnosed at stage I, II, and III, stages for which
guidelines are clearly defined. Applying to a strict definition of GCC, this study found that fewer
than 34% of elderly women diagnosed with breast cancer in 2004 thru 2009 received care
concordant with NCCN and ASCO recommended treatment guidelines.
Age & Health
In regards to age, the highest rates of GCC were observed among women age 66-69
years, at 46% and lowest rates among women age > 80 years, at 17%. In fact, women age > 70
years were less than half as likely to receive GCC, than women age 66-69 years. Previous studies
have reported receipt of GCC to range from 35% - 88% among women with breast cancer. 5, 2729,37

The variation in these rates of GCC are likely attributable to differences in study design and

sample selection, that include varying definitions of GCC (local and systematic treatment, local
treatment only, or systematic therapy only), exempting women age > 70 years from
recommended RT or chemotherapy, the inclusion of women age < 65 years in their study
sample, data collected from different years, samples that were limited to earlier stages or
included Stage 0, sampled from smaller registries, and/or fewer number of registries. Despite
their differences, all studies reported a strong inverse relationship between receipt of GCC and
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age. Increasing age, along with increasing comorbidity and declining functional performance, is
commonly cited by oncologists as a primary reason for less aggressive breast cancer treatment.
38,39

Among elderly women, those age > 70 are particularly less likely to receive RT after BCS or

chemotherapy when indicated, than younger women. In fact, a greater number of women than
those meeting guideline exemption from RT, and many women who could benefit from
chemotherapy, do not receive these treatments. 40-42 This study found women age > 70 years to
be as much as 45%, 73%, and 34% less likely to have RT, chemotherapy, or receive
chemotherapy within an appropriate time period, respectively, than those 66-69 years of age.
Undertreatment of the elderly is a phenomenon observed across different cancers and countries.
43-46

Although the disparity in aggressive treatment between younger and older elderly breast

cancer patients is widely acknowledged, the application of aggressive treatment among older
patients continues to be debated. Conflicting findings have been reported regarding the benefits
of adjuvant treatments. Ten-year results of the CALGB 9343 trial comparing BCS only vs. BCS
plus RT among women age > 70 years with Stage I, ER positive breast cancer taking tamoxifen
showed no differences in breast cancer specific and overall survival, and minimal difference in
recurrence (2% vs. 10%). 47 Similar findings were reported by the more recent PRIME II
randomized controlled trial, but with no difference in 5-year overall survival, and little difference
in recurrence (1% vs. 4%). 48 However, the National Surgical Adjuvant Breast and Bowel Project
(NSABP) B-17 randomized trial demonstrated that women treated with BCS only had
significantly higher rates of recurrence after 15 years (19% vs. 9%), than women treated with
BCS plus RT. 49 Multiple retrospective database studies support these findings. A recently
published study using SEER-Medicare data to compare treatment outcomes among women age
70-79 years with Stage I, ER positive breast cancer treated with BCS only vs. BCS plus RT,
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found that after 10 years, women treated with BCS only ended up having a mastectomy twice as
often, as women treated with BCS plus RT. 50 Further studies comparing these treatment groups
using SEER-Medicare and cancer registry data from the British Columbia Cancer Agency also
reported an increased risk for breast cancer recurrence and mortality among women treated with
BCS only, compared to BCS plus RT. 51-54 In contrast to study findings of RT outcomes, the
survival and disease-free benefits of chemotherapy for women with breast cancer of all ages is
generally agreed upon. 55-57 Despite the demonstrated benefits of chemotherapy and RT, whether
these adjuvant therapies should be administered to elderly women as often as younger women
with breast cancer when indicated, remains a topic of debate due to their possible harm. Toxic
effects and treatment burden from RT and chemotherapy have the potential for adverse effects on
health and quality of life. 58-61 Often, these effects may be amplified in the elderly due to
increased comorbidity, impaired organ function, declining functional status, lack of reliable
transportation for repeated treatments, or are unjustifiable depending on projected life
expectancy. 62,63 Yet, among elderly women with low comorbidity and good functional status,
adjuvant therapy may be well tolerated just and no more toxic, than among younger women. 64,65
Moreover, many maintain that the harm of potential toxic and adverse side effects of adjuvant
therapy, outweigh the potential benefits. 60,61 Nevertheless, chemotherapy should be initiated
within a timely manner as to not compromise survival. 66,67
In conjunction with increasing age, increasing comorbidity has been strongly associated
with less aggressive treatment and GDC among elderly breast cancer patients. 37,39,40 Patients
with increased comorbidity may be less likely to receive GCC for reasons similarly associated
with increasing age, that include competing health demands, decreased functional status, and
decreased overall survival because of their comorbidity. 68,69 Despite these concerns, comorbidity
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itself has not been linked with increased toxicity to adjuvant treatment or time to recurrence, and
thus, should not prevent GCC when patients are strong and functional enough to endure the
demands of adjuvant treatments. 70
Clinical Prognostic Factors
Aside from age and health, clinical characteristics were strongly associated with GCC.
Women who were diagnosed at later stages, had larger tumors, moderately and poorly tumor
grades, borderline/unknown tumors hormone receptors, and were lymph node negative were less
likely to receive GCC. This most likely reflects the reluctance of providers to use aggressive
treatment in elderly women that would otherwise be recommended for more advanced cancers. It
is possible that while women who were lymph node negative did not require chemotherapy, they
may have been indicated for RT following BCS, but were less likely to receive it due to older
age. In contrast to these associations, women with ER and PR negative tumors were 90% to 20%
more likely to receive GCC, respectively. A plausible explanation for these findings may lie with
the poorer survival outcomes observed among women negative hormone receptors. 71,72
Therefore, they may be more likely to be aggressively treated with RT and chemotherapy,
women with positive hormone receptors, thus making them likely to receive GCC
Oncology Care Resources
Women who were treated by an oncology surgeon only or both a general and oncology
surgeon, compared to a general surgeon only, were more likely to receive GCC. This sharing of
care may be a sign of high patient volume, a factor that has been associated with increased GCC.
Also, the involvement of an oncology surgeon in coordination of care may ensure that lymph
node surgery is performed. 29
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Socio-Demographic Characteristics
Additional factors associated with receipt of GCC were race and education. Women of
non-white race, and those residing in areas of lower education were less likely to receive GCC.
The association between vulnerable socio-demographic characteristics and disparities in breast
cancer care have been well documented. 13,27 While the relationship between health disparities
and residents of low education areas may be explained by limited resources and access to
specialty services, the relationship between race and receipt of GCC is not well understood,
especially in the context of uniform Medicare coverage. A recently published study by Freedman
and colleagues (2015) may shed light on this subject. 73 Compared to white women, black and
Hispanic women were less likely to be knowledgeable about their breast cancer characteristics, a
factor that may prevent them from taking part in the treatment decision process. Similarly,
increasing age was also associated with decreased breast cancer knowledge. While it is not
realistic to recommend aggressive breast cancer treatment to all elderly patients due to variation
in health and functional status, treatment patterns among this population could be improved if
emphasis was placed upon dissemination of GCC, unless patients are otherwise unable to do so.
In the meantime, patient navigation programs have shown to help direct patients to receipt of
GCC and adhere to the course of treatment. 74,75 Vulnerable populations, including the elderly,
may benefit from such patient navigation and education programs to aid in their understanding,
decision making process, and ultimately receipt of GCC.
Limitations & Strengths
Several limitations should be kept in mind when interpreting the results of this study.
This study did not exempt women age > 70 with tumors < 2 cm, node negative, estrogenreceptor positive, and receiving adjuvant hormone therapy from radiation or women age > 70
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years from chemotherapy in determining GCC, and instead examined the application of GCC to
all ages to compare treatment differences. This method may have underestimated the number of
women receiving GCC due to poor health or functional status. This study did not assess the
completion of radiation or chemotherapy, only the initiation of therapy, nor did this study
distinguish between the receipt of neoadjuvant or adjuvant chemotherapy. Neoadjuvant
chemotherapy is received by some women to shrink larger tumors and provide an opportunity for
BCS, after clinical staging, but before pathological staging has been conducted. Thus, this study
did not capture how the use of neoadjuvant chemotherapy, and resulting differences in clinical
and pathological staging were associated with receipt of GCC or individual tests and treatments.
Furthermore, this study did not examine how genetic testing for specific genetic mutations
related to breast cancer and subsequent findings were associated with treatment. Also, tumor
receptor status was used as a proxy measure of for tumor receptor testing and does not provide
any information regarding the initiation of adjuvant hormone therapy when indicated. Moreover,
this study was unable to examine receipt of adjuvant hormone therapy. Additionally, several of
socio-demographic characteristics examined were aggregate census level measures, rather than
individual level measures. Finally, the SEER individuals within the SEER database have been
found to be of higher income, and higher concentrations of racial and ethnic minorities, as
compared to the U.S. population.76
Despite these limitations, this study holds several strengths that impart confidence in its
findings. This is one of few studies to investigate GCC among women with breast cancer and
possibly the first to do so comprehensively among elderly women using a large, nationally
representative database. Pathological staging was used to determine the cancer characteristics of
the study sample and algorithms were used to identify receipt of GCC based on the
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recommended course of treatment according to cancer characteristics put forth by the NCCN and
ACSO. A variety of tests and treatments were included in this study and examined in relation to
younger and older elderly women. Additionally, a wide range of covariates were controlled for
that included age, health, clinical prognostic factors, access to oncology care resources, and
socio-demographic characteristics. Despite containing slightly greater proportions of affluent and
minority individuals, SEER is widely accepted as representative of the U.S. population, making
these results generalizable to the greater population of elderly women with invasive early-stage
breast cancer insured by Medicare.
Significance & Conclusions
In conclusion, rates of GCC among elderly women as determined the current study are
much lower than those observed by other studies that were heavily populated by younger
women. These findings indicate that older women with breast cancer receive considerably less
aggressive treatment than younger women, although they have the highest incidence of breast
cancer. Among elderly women, receipt of GCC decreases with increasing age and comorbidity.
Yet, about 2/3s of women with no comorbidity still do not receive GCC, suggesting that age
alone or other factors not related to strength and vitality are affecting receipt of GCC. Receipt of
GCC also decreases with later stage at diagnosis and worse prognostic clinical factors,
circumstances that necessitate more aggressive treatment, but perhaps reflect a reluctance to do
so. Women older than 70 years are especially less likely to receive RT and/or chemotherapy. A
greater number of elderly women may benefit from receiving GCC than those that actually
receive it. In order to maximize the probability of disease-free survival and life-expectancy,
patients, family members, and oncology care providers should be encouraged to accept the same
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standard of aggressive breast cancer treatment to older women, as would be applied to younger
women.
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Table 1
Characteristics of Elderly Women with Stages I, II, and III Breast Cancer
SEER-Medicare, 2004-2009
N
%
All
27,883
Year of Diagnosis
2004
3885
2005
3726
2006
3873
2007
4025
2008
6151
2009
6223
Age & Health
Age at Diagnosis
66-69
6694
70-74
7551
75-79
6704
> 80
6934
Comorbidity Score
0
15520
1
7559
>2
4804
PCP Visits
Low
15354
High
12529
Clinical Prognostic Factors
Stage at Diagnosis
I
15731
II
9514
III
2638
Tumor Size
< 1 cm
8201
< 2 cm
10701
2 - 5 cm
7834
> 5 cm
1147
Lymph Nodes
Positive
7505
Negative
20378
ER Status
Positive
22298
Negative
4136
Borderline/Unknown
1449
PR Status
Positive
18762
Negative
7463
Borderline/Unknown
1658
BCS = breast-conserving surgery
GCC = Guideline-Concordant Care
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100.0
13.9
13.4
13.9
14.4
22.1
22.3

24.0
27.1
24.0
24.9
55.7
27.1
17.2
55.1
44.9

56.4
34.1
9.5
29.4
38.4
28.1
4.1
26.9
73.1
80.0
14.8
5.2
67.3
26.8
6.0

Table 1
Characteristics of Elderly Women with Stages I, II, and III Breast Cancer
SEER-Medicare, 2004-2009
N
%
27,883

All
Tumor Grade
Well Differentiated
Moderately Differentiated
Poorly Differentiated
Undifferentiated/Unknown

100.0

6741
12287
7302
1553

24.2
44.1
26.2
5.6

26482
1401

95.0
5.0

26435
1448

94.8
5.2

25685
2198

92.1
7.9

27754
129

99.5
0.5

20865
7018

74.8
25.2

11636
16247

41.7
58.3

17023
10860

61.1
39.0

6992
20891

25.1
74.9

5796
1196
20891

20.8
4.3
74.9

9336
18547

33.5
66.5

15665
12218

56.2
43.8

Tests & Treatments
ER Status Tested
Yes
No
PR Status Tested
Yes
No
Lymph Nodes Tested
Yes
No
Had any Surgery
Yes
No
Had BCS
Yes
No
Had Mastectomy
Yes
No
Had Radiation
Yes
No
Had Chemotherapy
Yes
No
Time to Chemotherapy
Appropriate
Not Appropriate
No Chemotherapy
Received GCC
Yes
No
Oncology Care Resources
Mammography Screening Centers
Low
High
BCS = breast-conserving surgery
GCC = Guideline-Concordant Care
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Table 1
Characteristics of Elderly Women with Stages I, II, and III Breast Cancer
SEER-Medicare, 2004-2009
N
%
All
27,883
Oncology Treatment Centers
Low
12541
High
15342
Type of Surgeon Seen
General Only
4045
Oncology Only
1638
Both
22200
Socio-Demographic Characteristics
Race
White
24594
Other
3289
Education
< 15% college degree
8493
> 15% college degree
19390
Annual Income
< $35,000
6806
> $35,000
21077
Metro Status
Non-metro
4660
Metro
23223
BCS = breast-conserving surgery
GCC = Guideline-Concordant Care
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100.0
45.0
55.0
14.5
5.9
79.6

88.2
11.8
30.5
69.5
24.4
75.6
16.7
83.3

Table 2
Comparison of Guideline-Concordant Care among Elderly Women with Stages I, II, and III Breast
Cancer
SEER-Medicare, 2004-2009
Concordant
Discordant
N
%
N
%
p-value
All
9,336 33.5
18,547
66.5
Year of Diagnosisb
< 0.001***
2004
1240 31.9
2645
68.1
2005
1166 31.3
2560
68.7
2006
1234 31.9
2639
68.1
2007
1334 33.1
2691
66.9
2008
2170 35.3
3981
64.7
2009
2192 35.2
4031
64.8
Age & Health
Age at Diagnosisc
< 0.001***
66-69
3066 45.8
3628
54.2
70-74
2966 39.3
4585
60.7
75-79
2114 31.5
4590
68.5
> 80
1190 17.2
5744
82.8
Comorbidity Scorec
< 0.001***
0
5484 35.3
10036
64.7
1
2513 33.3
5046
66.8
>2
1339 27.9
3465
72.1
PCP Visitse
< 0.001***
Low
5300 34.5
10054
65.5
High
4036 32.2
8493
67.8
Clinical Prognostic Factors
Stage at Diagnosisc
< 0.001***
I
6250 39.7
9481
60.3
II
2152 22.6
7362
77.4
III
934 35.4
1704
64.6
c
Tumor Size
< 0.001***
< 1 cm
5613 68.4
2588
31.6
< 2 cm
1564 14.6
9137
85.4
2 - 5 cm
1932 24.7
5902
75.3
> 5 cm
227 19.8
920
80.2
e
Lymph Nodes
< 0.001***
Positive
2307 30.7
5198
69.3
Negative
7029 34.5
13349
65.5
a = cmh chi square test of general association
b = cmh chi square test of location shift using table scores
c = cmh chi square test of location shift using modified ridit scores
d = Fisher's exact chi square test
e = Pearson's chi square test of association
BCS = breast-conserving surgery
* p < 0.05; ** p < 0.01; *** p < 0.001
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Table 2
Comparison of Guideline-Concordant Care among Elderly Women with Stages I, II, and III Breast
Cancer
SEER-Medicare, 2004-2009
Concordant
Discordant
N
%
N
%
p-value
All
9,336 33.5
18,547
66.5
ER Statusa
< 0.001***
Positive
7437 33.4
14861
66.7
Negative
1880 45.5
2256
54.6
Borderline/Unknown
19
1.3
1430
98.7
PR Statusa
< 0.001***
Positive
6248 33.3
12514
66.7
Negative
3025 40.5
4438
59.5
Borderline/Unknown
63
3.8
1595
96.2
a
Tumor Grade
< 0.001***
Well Differentiated
2456 36.4
4285
63.6
Moderately Differentiated
3810 31.0
8477
69.0
Poorly Differentiated
2595 35.5
4707
64.5
Undifferentiated/Unknown
475 30.6
1078
69.4
Tests & Treatments
ER Status Testedd
< 0.001***
Yes
9336 35.3
17146
64.8
No
0
0.0
1401 100.0
PR Status Testedd
< 0.001***
Yes
9336 35.3
17099
64.7
No
0
0.0
1448 100.0
Lymph Nodes Testedd
< 0.001***
Yes
9336 36.4
16349
63.7
No
0
0.0
2198 100.0
Had any Surgeryd
< 0.001***
Yes
9336 33.6
18418
66.4
No
0
0.0
129 100.0
Had BCSe
< 0.001***
Yes
7152 34.3
13713
65.7
No
2184 31.1
4834
68.9
Had Mastectomye
< 0.001***
Yes
2651 22.8
8985
77.2
No
6685 41.2
9562
58.9
a = cmh chi square test of general association
b = cmh chi square test of location shift using table scores
c = cmh chi square test of location shift using modified ridit scores
d = Fisher's exact chi square test
e = Pearson's chi square test of association
BCS = breast-conserving surgery
* p < 0.05; ** p < 0.01; *** p < 0.001
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Table 2
Comparison of Guideline-Concordant Care among Elderly Women with Stages I, II, and III Breast
Cancer
SEER-Medicare, 2004-2009
Concordant
Discordant
N
%
N
%
p-value
All
9,336 33.5
18,547
66.5
Had Radiatione
< 0.001***
Yes
7836 46.0
9187
54.0
No
1500 13.8
9360
86.2
Had Chemotherapye
< 0.001***
Yes
4218 60.3
2774
39.7
No
5118 24.5
15773
75.5
Time to Chemotherapya
< 0.001***
Appropriate
4218 72.8
1578
27.2
Not Appropriate
0
0.0
1196 100.0
No Chemotherapy
5118 24.5
15773
75.5
Oncology Care Resources
Mammography Screening Centerse
0.219
Low
5197 33.2
10468
66.8
High
4139 33.9
8079
66.1
e
Oncology Treatment Centers
0.083
Low
4131 32.9
8410
67.1
High
5205 33.9
10137
66.1
Type of Surgeon Seena
< 0.001***
General Only
1019 25.2
3026
74.8
Oncology Only
537 32.8
1101
67.2
Both
7780 35.1
14420
65.0
Socio-Demographic Characteristics
Racee
< 0.001***
White
8335 33.9
16259
66.1
Other
1001 30.4
2288
69.6
e
Education
< 0.001***
< 15% college degree
2567 30.2
5926
69.8
> 15% college degree
6769 34.9
12621
65.1
e
Annual Income
< 0.001***
< $35,000
1930 28.4
4876
71.6
> $35,000
7406 35.1
13671
64.9
Metro Statuse
< 0.001***
Non-metro
1432 30.7
3228
69.3
Metro
7904 34.0
15319
66.0
a = cmh chi square test of general association
b = cmh chi square test of location shift using table scores
c = cmh chi square test of location shift using modified ridit scores
d = Fisher's exact chi square test
e = Pearson's chi square test of association
BCS = breast-conserving surgery
* p < 0.05; ** p < 0.01; *** p < 0.001
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Table 3
Associations with Guideline-Concordant Care among Elderly Women with Stages I, II, and III Breast
Cancer
SEER-Medicare, 2004-2009
Concordant vs. Discordant
All
AOR
95% CI
Sig.
Year of Diagnosis
2004
2005
2006
2007
2008
2009

1.00
0.93
0.95
1.01
1.09
1.07

[0.82,1.05]
[0.84,1.07]
[0.90,1.14]
[0.98,1.21]
[0.97,1.20]

1.00
0.71
0.44
0.19

[0.65,0.77]
[0.40,0.48]
[0.17,0.21]

―

Age & Health
Age at Diagnosis
66-69
70-74
75-79
> 80
Comorbidity Score
0
1
>2
PCP Visits
Low
High

―

1.00
0.91
0.71

[0.84,0.97]
[0.65,0.78]

1.00
1.04

[0.97,1.11]

1.00
0.46
0.93

[0.40,0.54]
[0.75,1.16]

1.00
0.05
0.13
0.06

[0.04,0.05]
[0.11,0.15]
[0.05,0.07]

1.00
0.49

[0.44,0.56]

1.00
1.89
0.04

[1.69,2.11]
[0.02,0.07]

***
***
***

―

**
***

―

Clinical Prognostic Factors
Stage at Diagnosis
I
II
III
Tumor Size
< 1 cm
< 2 cm
2 - 5 cm
> 5 cm
Lymph Nodes
Positive
Negative
ER Status
Positive
Negative
Borderline/Unknown
* p < 0.05; ** p < 0.01; *** p < 0.001
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―

***

―

***
***
***

―

***

―

***
***

Table 3
Associations with Guideline-Concordant Care among Elderly Women with Stages I, II, and III Breast
Cancer
SEER-Medicare, 2004-2009
Concordant vs. Discordant
All
AOR
95% CI
Sig.
PR Status
Positive
1.00
―
Negative
1.20
[1.10,1.32]
***
Borderline/Unknown
0.32
[0.22,0.47]
***
Tumor Grade
Well Differentiated
1.00
―
Moderately Differentiated
1.15
[1.06,1.25]
***
Poorly Differentiated
1.63
[1.48,1.80]
***
Undifferentiated/Unknown
1.02
[0.87,1.19]
Oncology Care Resources
Mammography Screening Centers
Low
1.00
―
High
0.99
[0.90,1.09]
Oncology Treatment Centers
Low
1.00
―
High
1.01
[0.91,1.12]
Type of Surgeon Seen
General Only
1.00
―
Oncology Only
1.47
[1.26,1.72]
***
Both
1.84
[1.67,2.03]
***
Socio-Demographic Characteristics
Race
White
1.00
―
Other
0.81
[0.73,0.89]
***
Education
< 15% college degree
1.00
―
> 15% college degree
1.09
[1.00,1.18]
*
Annual Income
< $35,000
1.00
―
> $35,000
1.07
[0.97,1.20]
Metro Status
Non-metro
1.00
―
Metro
1.00
[0.90,1.10]
* p < 0.05; ** p < 0.01; *** p < 0.001
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Table 4
Associations with Tests & Treatment among Elderly Women with Stages I, II, and III Breast Cancer
SEER-Medicare, 2004-2009
Age > 70 vs. Age 66-69 years
All
AOR
95% CI
Sig.
Guideline-Concordant Care
Yes
0.51
[0.48,0.54]
***
No
1.00
―
ER Status Tested
Yes
0.80
[0.70,0.92]
**
No
1.00
―
PR Status Tested
Yes
0.78
[0.68,0.89]
***
No
1.00
―
Lymph Nodes Tested
Yes
0.91
[0.82,1.01]
No
1.00
―
Had any Surgery
Yes
2.51
[1.76,3.58]
***
No
1.00
―
Had BCS
Yes
0.76
[0.71,0.81]
***
No
1.00
―
Had Mastectomy
Yes
1.31
[1.23,1.39]
***
No
1.00
―
Had Radiation
Yes
0.63
[0.60,0.67]
***
No
1.00
―
Had Chemotherapy
Yes
0.30
[0.28,0.32]
***
No
1.00
―
Time to Chemotherapy
Appropriate
0.78
[0.68,0.89]
***
Not Appropriate
1.00
―
No Chemotherapy
2.71
[2.38,3.09]
***
BCS = breast-conserving surgery
* p < 0.05; ** p < 0.01; *** p < 0.001
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Appendix 1. Claims Codes Used for Identifying Types of Treatment
Type of Treatment
Lymph Node Surgery

ICD-9 Diagnostic

ICD-9 Procedure
40.3, 40.41-40.42, 40.5040.54, 40.59, 85.43,
85.48

Lumpectomy

85.20-85.29

Mastectomy

85.33-85.36, 85.40-85.48

Radiation Therapy

V58.0, V66.1, V67.1

92.20-92.39

Chemotherapy

V58.1, V66.2, V67.2,

99.25, 99.28
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HCPCS/CPT
38500, 38510, 38520,
38525, 38530, 39542,
38720, 38740, 38745,
38792, 78195, 7880078801
19120, 19125-19126,
19160, 19162, 1930119302
19140, 19180, 19182,
19300, 19303-19307,
19200, 19220, 19240,
19260, 19271-19272
77261-77799, G0256,
G0261, G0173-G0174,
G0243, G0251, G0338G03340
96400-96599, C8953C8955, G0355-G0363,
G902-G9032, J0640,
J8510, J8520-J8521,
J8530-J8999, J9000J9999, Q0083-Q0085,
S9329-S9331,

Revenue Center

0330, 0333

0331, 0332, 0335

Appendix 1. Guideline-Concordant Treatment Options by Tumor Size and Lymph Node
Status
Stage

Treatment Option A

Treatment Option B

 Mastectomy
 BCS
• ERST & PRST

LNT
 RT

ERST & PRST
 LNT
Stage I:
 BCS
• CT
 Mastectomy
• CT < 120days
1 cm < T < 2 cm, N-  RT
• CT < 120days
 LNT
• ERST & PRST
 LNT
• ERST & PRST  CT
Stage IIA:
 BCS
• CT
 Mastectomy
• CT < 120days
0 cm < T < 2 cm, N+  RT
• CT < 120days
 LNT
• ERST & PRST
 LNT
• ERST & PRST  CT
Stage IIA:
 BCS
• CT
 Mastectomy
• CT < 120days
2 cm < T < 5 cm, N-  RT
• CT < 120days
 LNT
• ERST & PRST
 LNT
• ERST & PRST  CT
Stage IIB:
 BCS
• CT
 Mastectomy
• CT < 120days
2 cm < T < 5 cm, N+  RT
• CT < 120days
 LNT
• ERST & PRST
 CT
 LNT
• ERST
Stage IIB:
 Mastectomy
• CT < 120days
T > 5 cm, N LNT
• ERST & PRST
 CT
Stage IIIA:
 BCS
• CT
 Mastectomy
• CT < 120days
0 cm < T < 5 cm, N+  RT
• CT < 120days
 LNT
• ERST & PRST
 CT
 LNT
• ERST
Stage IIIA:
 Mastectomy
• CT < 120days
T > 5 cm, N+
 LNT
• ERST & PRST
 CT
Stage IIIB & IIIC
 Mastectomy
• CT < 120days
 LNT
• ERST & PRST
 CT
T = tumor size; N = nodal status; BCS = breast-conserving surgery; RT = radiation therapy; LNT = lymph node
testing; ERST = estrogen receptor status testing; PRST = progesterone receptor status testing; CT = chemotherapy;
Stage I:
T < 1 cm, N-
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Abstract
Objectives: Overall breast cancer survival has improvement dramatically over the past 20 years
and survival rates are relatively high, especially when detected at an early stage. Still, several
factors remain formidable influences on breast cancer survival. This study examined factors
associated with overall 5-year breast cancer survival among three different large groups of
elderly US women with non-metastatic invasive breast cancer.
Methods: The linked SEER-Medicare data set was used to identify 1) a broadly inclusive group
of women age > 66 years diagnosed with stage I, II, and II breast cancer in 2003 to 2009 (N =
53,830), 2) women age > 66 years diagnosed with early-stage invasive breast cancer in 2003 to
2009 (N = 45,981) by initial loco-regional treatment patterns (breast-conserving surgery (BCS)
plus radiation therapy (RT), mastectomy or BCS without RT), and 3) women age > 66 years with
pathologically staged I, II, and III breast cancer in 2004 to 2009 (N = 27,883) by individual tests
and treatments receipt of guideline-concordant care (GCC), among fee-for-service beneficiaries
continuously enrolled in Part A and B services. Five-year survival rates, adjusted hazard ratios,
and Kaplan Meier survival curves were computed for each sample according to study covariates.
Results: Among elderly women in cohort 1, the average time till death was 1,247.2 days (SD = +
722.3) with an 82% 5-year survival rate. Groups with the highest 5-year survival rates were age
66-69 years (91%) (P < 0.001), with a comorbidity score = 0 (86%) (P < 0.001), and diagnosed
at stage I (88%) (P < 0.001). Groups with the greatest mortality risk within 5 years of diagnosis
were those age > 80 years (AHR, 4.01; 95% CI, 3.74, 4.29), with a comorbidity score > 2 (AHR,
2.17; 95% CI, 2.06, 2.28), and diagnosed at stage III (AHR, 3.95; 95% CI, 3.74, 4.18). In cohort
2, the average time till death was 1,410.6 days (SD = + 696.9) with 86% 5-year survival rate.
Groups with highest 5-year survival rates were those who were age 66-69 years (94%) (P <
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0.001), with a comorbidity score = 0 (90%) (P < 0.001), diagnosed at stage I (90%) (P < 0.001),
treated by both an oncology surgeon (87%) (P < 0.001) or both an oncology and general surgeon
(88%) (P < 0.001), and received BCS plus RT (92%) (P < 0.001). Groups of women with the
greatest mortality risk within 5 years of diagnosis were those age > 80 years (AHR, 3.76; 95%
CI, 3.45, 4.10), a comorbidity score > 2 (AHR, 2.39; 95% CI, 2.25, 2.55), and had BCS without
RT (AHR, 1.94; 95% CI, 1.82, 2.06). In cohort 3 the average time till death was 1,246.7 days
(SD = + 600.8) with a 88% 5-year survival rate. Groups with the highest 5-year survival rates
were those age 66-69 years (94%) (P < 0.001), with a comorbidity score = 0 (91%) (P < 0.001),
a low frequency of primary care visits (90%) (P < 0.001), diagnosed at stage I (93%) (P <
0.001), lymph node negative (91%) (P < 0.001), ER positive (89%) (P < 0.001), PR positive
(90%) (P < 0.001), treated by an oncology surgeon (90%) (P < 0.001) or both an oncology and
general surgeon (88%) (P < 0.001), received GCC (93%) (P < 0.001), and had RT (91%) (P <
0.001). Groups of women with the greatest risk within 5 years of diagnosis were those age > 80
years (AHR, 2.85; 95% CI, 2.54, 3.20), a comorbidity score > 2 (AHR, 2.09; 95% CI, 1.92,
2.27), diagnosed at stage III (AHR, 1.81; 95% CI, 1.48, 2.21), received GCC (AHR, 1.18; 95%
CI, 1.04, 1.35), and did not have RT (AHR, 1.53; 95% CI, 1.39, 1.68).
Conclusions: Across all three study samples, age, health, stage at diagnosis, and type of
treatment, were strong and consistent factors associated with overall 5-year breast cancer
survival. Undertreatment among elderly women with breast cancer was associated with a greater
risk of death within 5 years of diagnosis, particularly for women who did not receive RT
following BCS for early-stage breast cancer or receive GCC for all invasive non-metastatic. In
order to increase survival, older women with breast cancer should receive aggressive treatment in
accordance with recommended guidelines as long as they are healthy enough to do so.
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Modifiable factors such as stage at diagnosis should continue to be targeted by encouraging
persistent mammography screening among elderly women. Reducing comorbidity burden among
US women would be an effective means for improving overall breast cancer survival among all
groups of women, and especially among older women whose vitality and functional status is
already at risk for decline.
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Introduction
While breast cancer is the most frequently diagnosed type of cancer among women in the
United States (US), it also has among the highest survival rates, relative to other types of cancer.
Relative to women who have never been diagnosed with breast cancer, breast cancer survivors
have 89% 5-year and 83% 10-year survival rates. 1,2 Moreover, earlier stage diagnosis is
associated with greater survival, such that women diagnosed at Stage I, II, and III have 100%,
93%, and 72% 5-year survival rates, respectively. 3 Decreasing mortality and increasing survival
rates throughout the years are attributed to improvements in understanding of the disease and its
treatment, alongside earlier detection due to increased routine breast cancer screening. 4 Yet,
despite these advancements, several factors still affect survival outcomes. These factors
encompass clinical characteristics of the cancer, receiving the standard of oncology care, such
that treatment is in concordance with evidence based recommended treatment guidelines without
the omission of necessary tests and treatments, otherwise referred to as guideline-concordant
care (GCC), age, health, access to specialty care, and socio-demographic characteristics. Clinical
characteristics associated with greater survival are earlier stage at diagnosis, smaller tumor size,
less or no lymph node invasion, well differentiated tumor grade, and estrogen and progesterone
positive tumors. 3,5-7 Receiving GCC is associated with greater breast cancer survival, while
guideline-discordant care (GDC), particularly the omission of recommended treatments and
testing, is associated with poorer survival. 8-11 The most commonly omitted treatments are
radiation therapy (RT) following breast-conserving surgery (BCS) or mastectomy when
indicated, chemotherapy, adjuvant hormone therapy, and lymph node sampling. The appropriate
course of treatment for each women is determined by tumor size, lymph node invasion, and
hormone receptor status. When diagnosed at an early-stage, women often have an option for the
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type of local treatment received. Women with tumors < 5 cm have the option of mastectomy or
BCS followed by RT. Multiple randomized clinical studies have shown BCS followed by RT to
be as equally effective as mastectomy for long-term survival of invasive early-stage breast
cancer.12-15 Since the National Institutes of Health's (NIH) 1991 endorsement of BCS plus RT as
an appropriate alternative to mastectomy for treatment of invasive early-stage breast cancer,
mastectomy rates have decreased while rates of BCS plus RT have steadily increased.16 In fact,
BCS, with or without RT, has become the preferred choice of primary surgical treatment among
women with early-stage breast cancer, with ~ 60% or more receiving BCS. 17-19 Yet, in recent
years, rates of mastectomy have started to slowly increase.18-20 Associations with receipt of
mastectomy when BCS is an option, include a desire to avoid radiation therapy due to side
effects, fear of recurrence, larger tumor size, positive lymph nodes, tumors with negative
hormone receptors, moderately or poorly differentiated tumors, lower income, being insured by
Medicaid or uninsured, residing in a rural location, increased travel distance for RT, the
increased cost of BCS plus RT, compared to mastectomy, and surgeon characteristics that
include being male, not trained in the U.S., and less recent training.18,19,21-25
Regardless of stage or treatment options, there are several factors that are indirectly
associated with survival via their association with receipt of GCC. Age and comorbidity are two
related and strongly associated predictors of GCC. While increasing age has its own associated
frailty, it is also associated with increasing comorbidity, that together, may make some
treatments with adverse and toxic effects intolerable for some women, to the point that the harms
of such treatments outweigh the benefits. 26-31 In fact, clinical evidence-based treatment
guidelines put forth by the National Comprehensive Cancer Network (NCCN) do not make
recommendations for or against chemotherapy in women age > 70 years, but suggest
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chemotherapy be given on a case-by-case basis, depending on the patient's health.32 Additionally,
guidelines specify that RT following BCS may be omitted among women meeting the following
requirements: age > 70 years, tumors < 2 cm, node negative, estrogen-receptor positive, and
receiving adjuvant hormone therapy.33 This change to recommended treatment guidelines that
had previously recommended RT following BCS for all age groups, was made after the 2004
publication of the Cancer and Leukemia Group B (CALGB) C9343 trial study results
demonstrated similar 5-year survival between women with these clinical characteristics who
received BCS plus RT or BCS alone. However, since this change in treatment recommendations,
evidence suggests that a greater number of elderly women do not receive RT or chemotherapy,
than those that meet exemption requirements from RT or who are in too poor of health to
undergo chemotherapy. 34-36 Women's receipt of GCC is often affected by their access to
oncology services due to their location of residence and socio-demographic characteristics.
Women residing in rural vs. urban areas, in areas with a lower density of oncology service
providers, and that have greater distances to travel for care are more likely to not receive
adjuvant treatments such as RT and chemotherapy, or delay the initiation of treatment. 26,36-38
Women who are of black or non-white Hispanic race, lower income, lower education, publically
insured or uninsured are less likely to receive GCC. 27,39,40 Race is also directly associated with
survival outcomes. Black women have markedly worse survival outcomes, as compared to white
women, such that 5-year survival for white and black women is 90% and 79%, respectively.
1,41,42

In addition to vulnerable socio-demographic factors that decrease the likelihood of

receiving GCC, black women diagnosed with breast cancer are more to have tumors with less
favorable characteristics and aggressive cancers. 43,44
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Statement of the Problem
While one can see from this review of the literature that numerous studies on breast
cancer survival have been conducted throughout the years, the data sources, subsets of
populations, stage at diagnosis, year of diagnosis, treatment patterns, and covariates, have also
been numerous and of wide ranging. In contrast, this study seeks to provide a comprehensive
understanding of overall breast cancer survival by examining all of the previously discussed
factors associated with survival using large, nationally representative data set with recent
survival data. Moreover, this study will focus on the survival of elderly women with breast
cancer, who are uniquely vulnerable to worse survival outcomes due to increasing age and
comorbidity.
Keeping these thoughts in mind, this study aims to examine overall 5-year survival and
age, health, clinical prognostic factors, access to oncology care resources, socio-demographic
characteristics, and treatment patterns among three different cohorts of elderly women with
breast cancer sampled from the SEER-Medicare linked dataset. Survival analysis of the first
cohort, a broadly inclusive group of women with stage I, II, and III breast cancer, will examine
how age, health, clinical prognostic factors, and socio-demographic characteristics are associated
with overall 5-year survival and provide a baseline understanding of survival as a cohort and by
stage. The second cohort analyses will examine survival among women with early-stage (stage I
and II) breast cancer according to the factors listed in cohort 1, and by type of loco-regional
treatment (BCS plus RT, mastectomy, and BCS without RT). Building upon the first two
analysis, the third cohort analysis will additionally determine how receipt of individual tests,
treatments, and GCC vs. GDC are differentially associated with overall 5-year survival among
elderly women with pathologically staged I, II, and III breast cancer.
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Methods
Data & Study Design
This retrospective cohort study was conducted using the linked SEER-Medicare dataset.
The SEER-Medicare database was created in a collaborative effort by the National Cancer
Institute (NCI) and Centers for Medicare and Medicaid Services (CMS) to combine clinical
information gathered by the Surveillance Epidemiology and End Results cancer registry program
with Medicare insurance claims. The SEER program collects basic socio-demographic, clinical,
and vital status information on incident cancer cases from multiple reporting sources. This
information is found the Patient Entitlement and Diagnosis Summary File (PEDSF). SEER data
used for this study consisted of 17 population-based registries, representing 26% of the U.S.
population. An algorithm based on name, Social Security number, sex, and date of birth
successfully matched 94% SEER cases to their Medicare claims beginning from the time of
eligibility till death.45 This study used Medicare claims providing information regarding
beneficiary enrollment (Denominator File), hospital inpatient claims (MedPAR file), hospital
outpatient claim (Outpatient file), physician office visits (NCH file), and durable medical
equipment (DME file).46 Additionally, county and state of diagnosis were used to identify the
area-level density of mammography screening and oncology centers from the U.S. Department
of Health and Human Resource's 2009 Area Resource File (ARF).47
Study Populations
Cohort 1: All Women with Stage I, II, & III Breast Cancer
This study sample consisted of American Joint Commission on Cancer (AJCC) clinically
and/or pathologically staged I, II, and III incident cases of breast cancer recorded in SEER
during years 2003 to 2009, among female age-eligible Medicare beneficiaries who were
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continuously enrolled in Medicare Part A and B fee-for-service programs 1 year before and after
diagnosis, and were therefore age > 66 years at the time of diagnosis. Women were excluded if
they were enrolled in a managed care program at any time during year before to the year after
diagnosis, diagnosed at the time of death or upon autopsy, had end-stage renal disease, did not
have primary surgical treatment, or surgeon specialty was missing. The final sample size was n =
53,830 elderly women.
Cohort 2: Local Treatment among Women with Stage I & II Breast Cancer
This study sample consisted of American Joint Commission on Cancer (AJCC) clinically
and/or pathologically staged I and II incident cases of breast cancer recorded in SEER during
years 2003 to 2009, among female age-eligible Medicare beneficiaries who were continuously
enrolled in Medicare Part A and B fee-for-service programs 1 year before and after diagnosis,
and were therefore age > 66 years at the time of diagnosis. Women were excluded if they were
enrolled in a managed care program at any time during year before to the year after diagnosis,
diagnosed at the time of death or upon autopsy, had end-stage renal disease, did not have primary
surgical treatment, or surgeon specialty was missing. The final sample size was n = 45,981
elderly women.
Cohort 3: Guideline-Concordant Care among Women with Stage I, II, & III Breast Cancer
This study sample consisted of American Joint Commission on Cancer (AJCC)
pathologically staged I, II, and III incident cases of breast cancer recorded in SEER during years
2004 to 2009, among female age-eligible Medicare beneficiaries who were continuously enrolled
in Medicare Part A and B fee-for-service programs 1 year before and after diagnosis, and were
therefore age > 66 years at the time of diagnosis. Women were excluded if they were enrolled in
a managed care program at any time during year before to the year after diagnosis, diagnosed at
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the time of death or upon autopsy, died within the first year of diagnosis, had end-stage renal
disease, did not have primary surgical treatment, or surgeon specialty was missing. The final
sample size was n = 27,883 elderly women.
Measures
Dependent Variable
Overall survival is measured by examining all-cause mortality (breast cancer specific and
all other causes of death). Survival outcomes measured were average time-to-death in days and
5-year survival as calculated by subtracting the date of diagnosis from the Medicare date of death
(DOD) or end of follow-up. Medicare DOD is captured from CMS's Master Enrollment (EDB)
and MedPAR data files. The EDB obtains information regarding DOD from the Social Security
Administration (SSA). The DOD is flagged as a "valid" date if it has been validated by a death
certificate. If the DOD has not been validated then the DOD is set the last day of the month in
which the beneficiary died. MedPAR records the DOD for those who died in a hospital. SEER
registries also collect information regarding DOD from state death certificates and other sources.
SEER and Medicare DOD information are in 99.5% level of agreement with one another.
Observations were censored for women who were alive as of February 29, 2012.
Independent Variables
Specific to cohort 2, initial loco-regional treatment received for early-stage breast cancer
(BCS plus RT, mastectomy, or BCS only) was identified using surgical and radiation claims
where the claim date was no later than 366 days from the date of diagnosis. Surgery claims were
identified using the Medicare Provider and Analysis Review (MEDPAR), Physician/Supplier
(NCH), and Outpatient files using International Classification of Diseases, 9th Revision (ICD-9)
procedure codes, Healthcare Common Procedure Coding System (HCPCS), and Current
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Procedural Terminology (CPT) to identify BCS (i.e. lumpectomy, partial mastectomy, segmental
mastectomy) and mastectomy. When multiple claims for lumpectomy were present, or when a
claim for lumpectomy was followed by a claim for mastectomy, only the first surgical claim was
used, to identify initial choice for primary surgical treatment. Receipt of RT was identified from
MEDPAR, NCH, Outpatient, and DME files using ICD-9 diagnosis codes, ICD-9 procedure
codes, and HCPCS/CPT codes. Only the first claim was used to identify the initiation of RT.
Specific to cohort 3, GCC vs. guideline-discordant care (GDC) was determined by
comparing the correct course of care according to tumor size and nodal status of each women as
per NCCN evidence-based clinical practice guidelines, to the actual care received (Table 1). Care
was also determined to be guideline-concordant if chemotherapy was initiated within 120 days of
diagnosis, when chemotherapy was indicated, as per ASCO/NCCN quality measures, and if
lymph node invasion, and hormone receptor statuses were tested. Although ASCO/NCCN
quality measures indicate RT should be initiated within 1 year of diagnosis, this was not
considered in the determination of GCC, as all claims used for this study were made within 1
year after diagnosis. For this study purpose, being of age > 70 years was not considered a
determining factor for GCC vs. GDC when RT or chemotherapy was indicated, in order to
determine the extent that younger and older women receive differential care.
Within cohort 3, receipt of individual treatments and tests were also examined and
included lymph node testing (yes or no), ER status testing (yes or no), PR status testing (yes or
no), had any primary surgery (BCS or mastectomy) (yes or no), had BCS (yes or no), had
mastectomy (yes or no), had RT (yes or no), had chemotherapy (yes or no), and chemotherapy
was initiated within 120 day of diagnosis (yes, no, or not applicable). Hormone receptor status
testing was assessed using the status given by the ER status and PR status variable in the Patient

118

Entitlement and Diagnosis Summary File (PEDSF) file. If the status was listed as "positive",
"negative", or "borderline", then the receptor status was determined to have been tested. If the
status was listed as "unknown", then it was considered as not having been tested. Lymph node
testing was defined by the claims codes for axillary lymph node dissection (ALND) or sentinel
lymph node (SNB) biopsy. Surgical, RT, and chemotherapy treatments were determined using
ICD-9 diagnostic and procedure, HCPCS/CPT codes found in the MEDPAR, Outpatient, and
NCH data files. All claims codes are shown in Appendix 1.
Others measures examined in relation to survival were year of diagnosis, age at diagnosis
(66-69, 70-74, 75-79, > 80), health, clinical prognostic factors, oncology care resources, and
socio-demographic characteristics. Age was also dichotomized (66-69 or > 70) to estimate the
probability of receipt of individual tests and treatments between younger and older elderly
women in the third cohort. Health was measured examining patient comorbidity and frequency
of primary care provider (PCP) visits. Patient comorbidity was calculated by applying an
algorithm to Medicare claims that identifies a comorbid condition as the presence of at least one
in-patient or two out-patient claims using ICD-9 diagnoses codes for each co-morbid condition.
Overall comorbidity was then classified using the Klabunde adaption of the Charlson
comorbidity index score (0, 1, > 2).48,49 An index of PCP visit intensity was identified by
counting of number of unique PCP claim dates the year before diagnosis in the NCH file. PCP
visits were categorized by lower and upper 50th percent median cutoff (low, high). Clinical
prognostic factors examined were stage diagnosis (I, II, III) using the AJCC Stage Group 6th
edition. Women in the cohort 3, were limited to those who were pathologically staged. Other
clinical measures included tumor size (< 1cm, < 2 cm, 2 - 5 cm, > 5 cm), lymph node status
(positive or negative), estrogen-receptor (ER) status, progesterone-receptor (PR) status (positive,
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negative, borderline/unknown) and tumor grade (well differentiated, moderately differentiated,
poorly differentiated, undifferentiated/unknown). Access to oncology care resources was
examined using the density of area-level mammography screening and oncology treatment
centers, and surgeon specialty. The density of area-level mammography screening centers and
oncology treatment centers, relative to each women, was measured using data from the ARF and
categorized lower and upper 50th percent median cutoff (low, high). Surgeon specialty was
assessed using provider specialty claims codes 02, 49 (general) and 83, 90, 91, 98 (oncology)
from the NCH file to determine the type of surgeon seen (general only, oncology only, both).
Socio-demographic characteristics examined were race (white or other), education (measured by
the 2000 Census tract survey of percent of persons age > 25 with at least 4 years college
education) (< 15%, > 15%), annual income (measured by the 2000 Census tract survey of
median income by census) (< $35,000, > $35,000), and metro status (non-metro, metro).
Analysis
Descriptive analysis was performed for all study variables. Mantel-Haenszel chi-square
tests of location shift using modified ridit scores or table scores and Mantel-Haenszel chi-square
tests of general association (depending on whether the independent measure was dichotomous,
nominal, or ordinal) were used to test for significant group differences between independent
measures and women who were dead or alive 5 years after diagnosis, with significance set at P <
.05. Cox proportional hazards regression models were used to estimate the hazard, or risk, of
death at any time within 5 years of diagnosis, adjusting for independent variables. Parameter
estimates calculated in the regression models are presented as adjusted hazard ratios (AHR) with
their corresponding 95% confidence intervals (CI). The probability of death from time of
diagnosis till end of follow-up was also estimated via survival functions for each study cohort
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and stratified by stage at diagnosis, type of loco-regional treatment, and receipt of GCC using the
Kaplan Meier method. All analysis were conducted using SAS version 9.4 software (SAS
Institute Inc., Cary, NC).
Results
Cohort 1: All Women with Stage I, II, & III Breast Cancer
Cohort Characteristics
Among elderly women diagnosed with stage I, II, and III breast cancer in 2003 to 2009,
the average time-to-death was 1,247.2 (SD = + 722.3) days. The majority were > 80 years old
(30.0%), had a comorbidity score = 0 (56.3%), had a low frequency of PCP visits (54.6%),
diagnosed at stage I (56.0%), had ER positive (77.7%) and PR positive (64.8%) tumors,
moderately differentiated tumor grades (42.7%), lived in areas with a low density of
mammography screening centers (51.6%) and oncology treatment centers (56.0%), were treated
by both a general and oncology surgeon (75.7%), white (88.6%), lived in metro areas (83.4%),
areas where 15% or more of the population was college educated (69.9%) or where the average
annual income was greater than $35,000 (75.7%).
Group Differences in 5-Year Survival
All group comparisons (shown in Table 3) were significant at the P < 0.001 level. The
average time-to-death between women who were alive and dead 5 years after diagnosis was
2,327.2 days (SD = + 357.6) vs. 938.9 days (SD = + 454.1) (P < 0.001).
Age & Health
As age at diagnosis increased, 5-year survival rates decreased, with 91.3% of women
diagnosed at 66-69 years vs. 66.5% of women diagnosed at age > 80 years still living. Five-year
survival rates decreased with increasing comorbidity, such that 86.2% of women with a
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comorbidity score = 0 vs. 69.6% of women with a comorbidity score > 2 were still alive 5 years
after diagnosis. Women with a lower frequency of PCP visits (84.5%) had higher 5-year survival
rates than women with a higher frequency of visits (78.1%).
Clinical Prognostic Factors
Women diagnosed at stage I (88.3%) had higher 5-year survival rates than those
diagnosed at stage II (77.4%) and III (58.1%). Women whose tumors were ER and PR positive
(84.1% & 84.9%) had higher 5-year survival rates, than those that were ER and PR negative
(72.0% & 75.8%). Women with well differentiated tumors also had higher 5-year survival rates
(88.1%), than those who were moderately (83.8%), poorly (73.3%) differentiated, or
undifferentiated/unknown (75.9%).
Oncology Care Resources
Women who resided in areas with higher densities of mammography screening centers
(82.1%) and oncology treatment centers (82.4%) had slightly higher 5-year survival rates, than
those living in lower density areas (81.0% & 80.9%, respectively). Higher 5-year survival rates
were observed among women treated by and oncology surgeon (82.4%) or both a general and
oncology surgeon (83.6%), as compared to women treated by a general surgeon only (73.5%).
Socio-Demographic Characteristics
In regards to race, 81.8% of white women vs. 79.4% of women of other race were still
alive 5 years after diagnosis. Women residing in areas where the population was > 15% college
educated (82.8%) and had average income > $35,000 (82.9%) had higher 5-year survival rates
than those living in areas where < 15% was college educated (78.6%) and the average income
was < $35,000 (77.2%). Similarly, women residing in metro areas (82.0%) had higher survival
rates, than those living in non-metro areas (79.6%).
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Risk of Death within 5 Years of Diagnosis
Age & Health
Adjusted hazard ratios estimating the risk of death 5 years after diagnosis according to
study covariates are presented in Table 4. The risk of death at any time within 5 years of
diagnosis increased substantially as age at diagnosis increased, with women diagnosed at 70-74
years, 75-79 years, and > 80 years being 24% (AHR, 1.24; 95% CI, 1.15, 1.35), 86% (AHR,
1.86; 95% CI, 1.73, 2.01), and over 400% (AHR, 4.01; 95% CI, 3.74, 4.29) more likely to die
than women diagnosed at age 66-69 years. Compared to women with a comorbidity score = 0,
those with a score = 1 or score > 2 were 1.44 (95% CI, 1.37, 1.51) and 2.17 (95% CI, 2.06, 2.28)
times more likely to die within 5 years of diagnosis. Similarly, women with a high frequency of
PCP visits were 1.14 times more likely to die (95% CI, 1.10, 1.19), than women with a low
frequency of visits, adjusting for all other variables.
Clinical Prognostic Factors
Later stage at diagnosis was strongly associated with 5-year survival, such that women
diagnosed at stage II and stage III had an 82% (AOR, 1.82; 95% CI, 1.74, 1.91) and 395%
(AOR, 3.95; 95% CI, 3.74, 4.18) greater risk of death at any time within 5 years of diagnosis,
compared to women diagnosed at stage I. Women with tumors that were ER and PR negative
were 1.36 (95%CI, 1.27, 1.45) and 1.19 (95% CI, 1.12, 1.26) times more likely to die within 5
years of diagnosis, than women with ER and PR positive tumors. Compared to women with well
differentiated tumors, those with moderately, poorly, and undifferentiated/unknown tumors were
1.14 (95% CI, 1.07, 1.21), 1.54 (95% CI, 1.44, 1.65), and 1.38 (95% CI, 1.27, 1.50) times more
likely to die within 5 years of diagnosis.
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Oncology Care Resources
Compared to women treated by a general surgeon, those who were treated by an
oncology surgeon or both an oncology and general surgeon had a 22% (AOR, 0.78; 95%, 0.72,
0.86) and 32% (AOR, 0.68; 95%, 0.65, 0.71) decreased risk of death within 5 years of diagnosis,
adjusting for all other independent variables.
Socio-Demographic Characteristics
Women residing in areas where > 15% of the population was college educated were 0.92
times less likely (95% CI, 0.88, 0.99) to die within 5 years of diagnosis, than women living in
less college educated areas. Similarly, women residing in areas with an average income >
$35,000 were also less likely to die within 5 years of diagnosis.
Kaplan Meier Estimates
Five-year overall survival rates for all women in cohort 1and stratified by stage at
diagnosis are shown in Figures 1 and 2, with the number at risk for death given in 366 day
intervals. Figure 2 shows that women with earlier stage at diagnosis have significantly greater
probability of overall 5-year survival at all time points, than those with later stage at diagnosis (P
< 0.001).
Cohort 2: Local Treatment among Women with Stage I & II Breast Cancer
Cohort Characteristics
The average time to death was 1,410.6 days (SD = + 696.9) among women diagnosed
with early-stage breast cancer in 2003 to 2009. The majority of elderly women were age > 80
years at diagnosis (28.7%), had a comorbidity score = 0 (56.7%), and a low frequency of PCP
visits (54.0%). About 63% of women were diagnosed at stage I, most had ER (79.1%) and PR
(66.3%) positive tumors, and moderately differentiated (43.6%) tumors. A little over half of

124

women lived in areas with a low density of mammography screening centers (51.7%), and low
density of oncology treatment centers (56.0%). The majority of women were treated by both a
general and oncology surgeon (75.6%). In regards to socio-demographics, most women were
white (89.4%), lived in metro areas (83.3%), areas where the population was > 15% college
educated (70.5%), and had an annual income > $35,000 (76.4%). More than half of the women
received BCS plus RT (54.5%) as their initial loco-regional treatment, while 23.4% had
mastectomy and 22.1% had lumpectomy without RT.
Group Differences in 5-Year Survival
All group comparisons between women who were alive or dead 5 years after diagnosis
were significant at the P < 0.001, except race (P = 0.092). Women still living 5 years after
diagnosis had a significantly greater time-to-death (M = 2,338.7 days, SD = + 361.6), than those
who died (M = 1055.1 days, SD = + 406.5) (P < 0.001).
Age & Health
Survival rates decreased with increasing age. About 94% of women age 66-69 years vs.
73.3% of women age > 80 years were still living 5 years after diagnosis. Those with a
comorbidity score = 0 had higher 5-year survival rates (89.9%), than women with a score = 1
(79.8%) and score > 2 (75.2%). Compared to women with a high frequency of PCP visits
(82.8%), women with a low frequency of PCP visits had higher 5-year survival rates (88.6%).
Clinical Prognostic Factors
Elderly women diagnosed at stage I had an 89.5% 5-year survival rate, whereas women
diagnosed at stage II had a 79.9% 5-year survival rate. Similar differences were observed
between positive and negative tumor receptors. Those with ER and PR positive tumors had
87.6% and 88.1% 5-year survival rates, in contrast to 79.1% and 81.9% survival rates among
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those with ER and PR negative tumors. Women with well-differentiated tumor grades had the
highest 5-year survival rates (89.9%), compared to women with moderately (86.9%), poorly
(80.2%), and undifferentiated/unknown tumor grades (85.0%).
Oncology Care Resources
Women residing in areas with a high density of mammography screening centers and
oncology treatment centers had slightly higher 5-year survival rates (86.5% & 86.7%), than those
residing in lower density areas (85.4% & 85.4%, respectively). Whereas women who were
treated by an oncology surgeon (87.3%) or both an oncology and general surgeon had higher 5year survival rates (87.8%), than those treated by a general surgeon (78.0%).
Socio-Demographic Characteristics
Women who resided in metro vs. non-metro areas (86.3% vs. 84.3%), areas where > 15%
of the population was college educated vs. < 15% college educated (87.0% vs. 83.5%) or annual
income > $35,000 vs. < $35,000 (87.0% vs. 82.6%) had higher 5-year survival rates.
Treatment
Women who were received BCS plus RT as their initial loco-regional treatment had
higher 5-year survival rates at almost 92%, compared to women who were treated with
mastectomy (79.3%) or BCS only (78.2%).
Risk of Death within 5 Years of Diagnosis
Age & Health
Women who age 70-74, 75-79, and > 80 years had a 21% (AHR, 1.21; 95% CI 1.10,
1.34), 90% (AHR, 1.90; 95% CI, 1.73, 2.09), and 376% (AHR, 3.76; 95% CI, 3.45, 4.10)
increased risk of death within 5 years of diagnosis, adjusting for all other independent variables,
than women age 66-69 years at diagnosis. Compared to women with a comorbidity score = 0,
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those with a score = 1 or score > 2 were 1.49 (95% CI, 1.41, 1.58) and 2.39 (95% CI, 2.25, 2.55)
times more likely to die within 5 years of diagnosis.
Clinical Prognostic Factors
Women diagnosed at stage II had a 65% increased risk of death within 5 years of
diagnosis (AHR, 1.66; 95% CI, 1.57, 1.74), compared to women diagnosed at stage I. Women
with ER and PR negative tumors were 33% (AHR, 1.33; 95% CI, 1.23, 1.45) and 17% (AHR,
1.17; 95% CI, 1.09, 1.26) more likely to die within 5 years of diagnosis. Having poorly
differentiated tumors increased the hazard of death by 49% (AHR, 1.49; 95% CI, 1.38, 1.61),
while having moderately tumors increased the hazard of death by 15% (AHR, 1.15; 95% CI,
1.08, 1.24), compared well differentiated tumors.
Oncology Care Resources
Women treated by an oncology surgeon or both an oncology and general surgeon had a
lower risk of death within 5 years of diagnosis, (AHR, 0.81, 95% CI, 0.72, 0.91) and (AHR,
0.72; 95% CI, 0.68, 0.76), than women treated by a general surgeon only.
Socio-Demographic Characteristics
Those who resided in areas where > 15% of the population was college educated were
0.91 times less likely (95% CI, 0.86, 0.97) to die within 5 years of diagnosis, than those residing
in areas where < 15% of the population is college educated.
Treatment
Compared to women received BCS plus RT as their initial loco-regional treatment for
early-stage breast cancer, those who had BCS without RT had a 94% (AOR, 1.94; 95% CI, 1.82,
2.06) and 81% (AOR, 1.81; 95% CI, 1.70, 1.93) increased risk of death within 5 years of
diagnosis.
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Kaplan Meier Estimates
Overall 5-year survival curves for all women with early-stage breast cancer and
according to type of treatment received are shown in Figures 3 & 4 with the number at risk in
366 day intervals. Women who received BCS plus RT had significantly lower probability of
death at all time points within 5 years of diagnosis, than those who had mastectomy or BCS only.
Cohort 3: Guideline-Concordant Care among Women with Stage I, II, & III Breast Cancer
Cohort Characteristics
Among women diagnosed with pathologically staged I, II, and III breast cancer in 2004
to 2009, the average time to death was 1,246.1 days (SD = + 600.8). The majority of women
were diagnosed at age 70-74 years (27.1%), had a comorbidity score = 0 (55.7%), and had a low
frequency of PCP visits (55.1%). More than half of the women were diagnosed at stage I
(56.4%), while about a third were diagnosed at stage II (34.1%), and the rest at stage III (9.5%).
Most women had ER and PR positive tumors (80.0% & 67.3%) moderately differentiated tumors
(44.1%), tumors < 2 cm (38.4%), and were lymph node negative (73.1%). The majority of
women lived in areas with a low density of mammography screening (56.2%) and a high density
of oncology treatment centers (55.0%). About 80% were treated by both an oncology and general
surgeon. Most, women were white (88.2%), lived in metro areas (83.3%), areas where > 15% of
the population was college educated (69.5%), and had an annual income > $35,000 (75.6%).
Treatment
Less than 34% of elderly women with stage I, II, and III breast cancer received GCC. The
vast majority of women had the ER (95.0%) and PR (94.8%) status of their tumors tested and
lymph nodes tested (92.1%). Almost all women had some form of primary surgical treatment
(99.5%), while 74.8% had BCS and 41.7% had mastectomy. Type of surgery adding up to
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greater than 100%, reflects women who had both BCS and mastectomy. About 61% of women
had RT, while only a quarter (25.1%) had chemotherapy. Breaking it down further, 20.8% of the
total sample had timely chemotherapy, while 4.3% didn't have timely chemotherapy.
Group Differences in 5-Year Survival
Most group differences between women who alive or dead 5 years after diagnosis were
significant at the P < 0.001 level, with the exception of density of oncology treatment centers (P
= 0.002), had any surgery (P = 0.172), and had chemotherapy (P = 0.036). Time-to-death was
significantly greater among women who were still living 5 years after diagnosis (M = 2,192.3
days, SD = + 261.0), than those who were not (M = 1016.8 days, SD = + 402.4) (P < 0.001).
Age & Health
Five-year survival rates decreased with increasing age at diagnosis, such that 93.6% of
women age 66-69 years were alive within 5 years of diagnosis, whereas 76.7% of women age >
80 years were still living. Women with a comorbidity score = 0, had higher 5-year survival rates
were higher (90.8%), than those with a comorbidity score = 1 (86.2%), or score > 2 (78.9%).
Women with a lower frequency of PCP visits also had higher 5-year survival rates (89.6%), than
women with a higher frequency of visits (84.9%).
Clinical Prognostic Factors
Five-year survival rates decreased with increasing stage at diagnosis. Women diagnosed
at stage I had a survival rate of 92.6%, where as those diagnosed at stage II and III had survival
rates of 84.5% and 67.7%, respectively. Similarly, 5-year survival rates decreased with
increasing tumor size, such that women with tumors < 1 cm had a 94.1% survival rate, while
those with tumors > 5 cm had a 5-year survival rate of 68.1%. Women with ER and PR positive
tumors had higher 5-year survival rates (89.2% & 89.7%), than those with ER and PR negative
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tumors (79.4% & 82.7%). Those with well differentiated tumors had the highest survival rates
(92.4%), while those with poorly differentiated tumors had the lowest (80.6%). Elderly women
who were lymph node negative had a 5-year survival rate of 90.8%, compared to 78.6% among
women who were lymph node positive.
Oncology Care Resources
Greater 5-year survival rates were observed among women residing in areas with a higher
density of mammography screening centers (88.5%) and oncology treatment centers (88.1%) vs.
low density areas (86.7% & 86.8%, respectively). Women receiving treatment from an oncology
surgeon had the highest 5-year survival rates (89.7%), followed by those treated by both
oncology and general surgeons (88.2%), and then those treated by a general surgeon only
(82.7%).
Socio-Demographic Characteristics
Higher survival rates were observed among white women vs. women of other race
(87.9% vs. 84.8%), women residing in metro areas vs. non-metro areas (87.9% vs. 85.3%), in
areas where > 15% of the population was college education vs. < 15% (88.6% vs. 84.9%), and
areas with an annual income > $35,000 vs. < $35,000 (88.6% vs. 84.3%).
Treatment
Among women who received GCC, 5-year survival rates were 92.8%, while they were
84.9% among women who received GDC. Women who had their ER & PR status tested (87.7%
& 87.7%), than those who did not (83.9% & 84.0%). Likewise, women who had their lymph
nodes tested had higher 5-year survival rates (88.1%), than women who did not have them tested
(80.5%). Five-year survival rates were higher among those who had BCS (90.3%), compared to
those who did not have BCS (79.3%), while survival rates were higher among those who did not
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have mastectomy (92.0%), compared to those who had mastectomy (81.2%). Individuals who
had RT had higher 5-year survival rates (91.1%), than those who did not have RT (81.8%).
Women who had timely chemotherapy had higher 5-year survival rates (87.5%), than women
who did not have chemotherapy in the recommended time period (83.4%).
Risk of Death within 5 Years of Diagnosis
Age & Health
Compared to women diagnosed at age 66-69 years, those diagnosed at age 70-74, age 7579, and age > 80 years were 1.17 (95% CI, 1.04, 1.33), 1.73 (95% CI, 1.54, 1.95), and 2.85 (95%
CI, 2.54, 3.20) times more likely to die within 5 years of diagnosis. In contrast to women with a
comorbidity score = 0, those with a comorbidity score = 1 or score > 2, had an increased risk of
death within 5 years of diagnosis by 38% (AHR, 1.38; 95% CI, 1.27, 1.50) and 209% (AHR,
2.09; 95% CI, 1.92, 2.27). Those with a high frequency of PCP visits had an 18% increased
hazard of death (AHR, 1.18; 95% CI, 1.10, 1.26), compared to women with a low frequency of
visits.
Clinical Prognostic Factors
Compared to women diagnosed at stage I, those diagnosed at stage III had an 81% (AHR,
1.81; 95% CI, 1.48, 2.21) increased hazard for death within 5-years of diagnosis. The hazard of
death increased with increasing tumor size, with women with tumors > 5 cm having the greatest
risk (AHR, 2.30; 95% CI, 1.89, 2.80), compared to women with tumors < 1 cm. Women with ER
& PR negative tumors were 1.48 (95% CI, 1.32, 1.65) and 1.13 (95% CI, 1.03, 1.25) times more
likely to die within 5 years of diagnosis, than women with ER & PR positive tumors. Those with
poorly differentiated tumor grades were 1.49 (95% CI, 1.33, 1.67) times more likely to die within
5 years of diagnosis, compared to women with well differentiated tumors. Being lymph node
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negative decreased to hazard for death within 5 years of diagnosis by 32% (AHR, 0.68; 95% CI,
0.61, 0.76), compared to being lymph node positive.
Oncology Care Resources
Women who were treated by an oncology surgeon or both an oncology and general
surgeon had 26% (AHR, 0.74; 95% CI, 0.62, 0.87) and 22% (AHR, 0.78; 95% CI, 0.71, 0.85)
decreased risk of death, compared to those treated by a general surgeon only.
Kaplan Meier Estimates
Figures 5 & 6 show 5-year survival rates for all women with pathologically staged I, II,
and III breast cancer and by receipt of GCC, with the number remaining at risk in 366 day
intervals. Women who received GCC had a lower probability of death within 5-years of
diagnosis at all time points, than women who received GDC (P < 0.001).
Discussion
Breast cancer mortality has decreased by 34% from 1990 to 2010 among all populations
of women. 3 Simultaneously, long-term overall survival has increased to 89% for 5-year survival
among all women diagnosed with breast cancer, and as high as 100% for women diagnosed at
stage I and 99% for women diagnosed with localized breast cancer (lymph node negative/nonmetastasized). 2,3 Despite these promising statistics, multiple factors remain associated with
differential survival outcomes among elderly with breast cancer. This study began by examining
overall 5-year survival among a broadly inclusive cohort of elderly women with stage I, II, and
III breast cancer and how the risk of death is associated with age, health, clinical prognostic
factors, oncology care resources, and socio-demographic characteristics. A strong association for
increased risk of death within 5 years of diagnosis was observed with increasing age,
comorbidity, and stage at diagnosis. The next survival analysis addressed the controversy with
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differential type of loco-regional treatment among elderly women with early-stage breast cancer
and demonstrated that women who have BCS without RT or mastectomy have a substantially
increased risk of death within 5 years of diagnosis, compared to women who have BCS plus RT.
Study findings from the first cohort analysis were also confirmed. Examination of the link
between treatment patterns and survival was extended in the third cohort analysis to determine
the association between receipt of individual tests and treatments and receipt of GCC, among
women with pathologically staged I, II, and III breast cancer. This analysis observed that women
who did not have RT, chemotherapy, or GCC were at increased risk of death, in addition to the
associations observed by the first two analysis. Overall 5-year survival rates observed among
cohorts ranged from 82% - 88%. A more in-depth discussion of these findings follows.
Age & Health
Across all three study cohorts, age, comorbidity, and frequency of PCP visits were of the
strongest and most consistent predictors of overall breast cancer survival. In all analyses the
hazard of 5-year mortality increased substantially with increasing age. Compared to women age
66-69 years at diagnosis, those who were a 70-74 had a 17% to 24% increased hazard of death,
while those who were age > 80 years had a 3 to 4 fold increased hazard of death. With increasing
age, comes increased comorbidity. Some degree of comorbidity was observed in up to 44% of
women. Compared to women no comorbidity, a comorbidity score = 1 had a 38% to 49%
increased risk of death while women with comorbidity score > 2 had as much as 239% increased
risk of death. The increased hazard of death associated with comorbidity was most likely
reflected in the increased hazard of death associated with a high frequency of PCP visits. Age
and comorbidity are intrinsic risk factors for mortality, regardless of a history of breast cancer.
However, the mortality risk associated with age and comorbidity alone may be amplified given a
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history of breast cancer. Moreover, increasing age and comorbidity are associated with receipt of
less aggressive treatment that may also increase the risk of mortality. Patnaik and colleagues
(2011) observed similar increased 5-year mortality hazard ratios associated with age and
comorbidity among elderly women with breast cancer. 50 Schonberg et al. (2010) also found that
age and comorbidity increased the risk breast cancer specific and other-cause mortality, though
the effect was less pronounced for breast cancer-specific mortality. 51
Clinical Prognostic Factors
Not surprisingly, one of the strongest predictors of overall 5-year survival across all three
study samples was stage at diagnosis. Five-year survival rates ranged from 88% to 93% for
women diagnosed with stage I breast cancer, in contrast to 58% to 68% for those diagnosed with
stage III breast cancer. What is more, the hazard of death as much as 4 times higher among
women diagnosed at stage III, compared to those diagnosed at stage I. Breast cancer prognosis is
very good at earlier stages when the cancer remains localized to the breast tissue and has not
spread to the lymphatic system or metastasized to the rest of the bodily organs. In fact,
Schonberg and colleagues (2011) found that when elderly women are diagnosed at stage 0 or
stage I, they are no more likely to die within 10 years of diagnosis than elderly without a history
of breast cancer. 52 In similar fashion, other clinical cancer characteristics directly associated
with stage at diagnosis, such as tumor size and lymph node status were associated with overall
survival. Increasing tumor size was negatively associated with survival, such that women with
tumors 2-5 cm and > 5 cm had roughly a two-fold risk of death within 5-years of diagnosis. For
women whose cancer had spread into the lymph nodes, the hazard of death increased more than
30%, compared to those who were lymph node negative. A study by Colzani and colleagues
(2011) reported a two-fold increase for hazard of death within 5 years of diagnosis among
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women with 1-3 positive lymph nodes, and almost four-fold increase for those with > 4 positive
lymph nodes. 53 Aside from chemo prevention or prophylactic use of hormone therapy among
women at increased risk for breast cancer, the next best approach to maximizing survival is early
detection by means of routine mammography screening. Unfortunately, the well-documented
decline in routine mammography screening among elderly women decreases the likelihood for
early detection. 54,55 Despite the positive association between age and increased risk, guidelines
for mammography screening make no recommendation for routine screening among women age
> 75 years. 56 Although routine mammography screening among elderly women is associated
with earlier stage at diagnosis and better survival, the debate regarding continued screening
among women age > 75 years persists. 57 The debate revolves around lack of clinical trial based
evidence for continued screening among older women, life-expectancy, competing health
demands, and harms of false-positive and over diagnosis. 58
However, some clinical prognostic factors are unaffected by stage at diagnosis. Factors
with a biological basis, such as tumor grade and hormone receptor status, are also associated
with survival outcomes. Women whose tumors are well-differentiated and are ER/PR positive
have greater survival, than women with poorly differentiated and ER/PR negative. 53,50 Only
about a quarter of women in each cohort had well-differentiated tumors. Poorly differentiated
tumors increased the hazard of 5-year mortality by about 50%. Over 3/4 of elderly had ER
positive tumors, while 65% to 67% had PR positive tumors. Negative ER tumors increased the
hazard of 5-year mortality by 33% to 48%, while negative PR tumors only increased the hazard
by 13% to 19% among elderly women. Breast cancers that are ER and PR negative are often
times more aggressive and fast growing cancers. Since they do not respond to adjuvant hormone
therapy, they tend to be more challenging to treat.
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Oncology Care Resources
Although the risk of death within 5 years of diagnosis was not different based on density
of area-level mammography screening and oncology treatment centers, surgeon specialty was
associated with risk of death. Women who were treated by an oncology surgeon had a 19% 26% decreased risk of 5-year mortality, than women treated by a general surgeon. While women
treated by both an oncology and general surgeon had a 22% - 32% decreased risk of mortality.
Being treated by both specialties might be associated with a lower mortality risk because division
of care may be an indication of high patient volume, a factor associated with increased GCC.59
Also, having an oncologist participate in the woman's cancer treatment may ensure coordination
of guideline recommended care.
Socio-Demographic Characteristics
Women who resided in areas with greater education and income were at somewhat of a
decreased risk of death within 5 years of diagnosis, compared to women residing less educated or
lower income areas. Specialty health care services are generally more common to in areas with
greater education and income. Also, individuals with greater education and income may be more
knowledgeable about breast cancer, be more confident navigating the health care system, and
have a greater propensity to seek health care services. 60-62 In contrast with previous studies, an
association with black race and poorer survival was not observed in this study. This difference in
findings may be due to the way race was categorized by this study (white vs. non-white).
Additionally, some of the poorer survival historically observed among women of black race, may
have already been adjusted for with other socio-demographic characteristics and access to
oncology care.
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Treatment Patterns
The course of breast cancer treatment is most often determined by cancer characteristics
and guided by evidence-based clinical treatment guidelines. In some instances, the course of
treatment may be modified in consideration of patient preferences or health status. Women with
early-stage breast cancer usually have a choice of primary treatment. Breast-conserving surgery
followed by RT is equally as effective for long-term survival as mastectomy for women with
tumors < 5 cm. 12-15 For many women, BCS plus RT is the preferred choice of treatment because
of breast preservation. In spite of that, adjuvant treatments such as RT and chemotherapy often
have adverse short and long-term side effects that may be intolerable for older women
considered to be frail or in poor health, and may be perceived as an unnecessary burden for those
with a short life expectancy. 28-31 In 2004, the NCCN modified guidelines for RT after BCS
applicable to a select group of women age > 70, following results of the CALGB C9343 trial that
found overall survival to be equal between women age > 70 years with early-stage ER positive
breast cancer receiving BCS and tamoxifen vs. BCS plus RT and tamoxifen. 32,33,63 Additionally,
NCCN treatment guidelines make no recommendation for or against chemotherapy in women
age > 70 years, when otherwise indicated, but suggest the decision be made on a case-by-case
basis considering patient health. However, concern has been raised whether the omission of RT
for early-stage ER positive breast cancers when tamoxifen is taken, is actually as effective for
overall survival, since there is a small increase in locoregional recurrence among women who
omitted RT. Moreover, retrospective studies have shown that a large proportion of elderly
women do not receive RT or chemotherapy, raising the question whether more elderly are
omitted from these treatments than should be, and consequently jeopardizing survival.
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Among the sample of elderly women with early-stage breast cancer in this study, 55%
had BCS plus RT, 23% had mastectomy, and 22% had BCS without RT. Notably, elderly
women who were treated with BCS without RT were at almost twice the risk of 5-year mortality,
compared to women who were treated with BCS plus RT. Those who were had mastectomy were
also 1.80 times more likely to die within 5 years of diagnosis, compared to women treated with
BCS plus RT. Findings from the analysis of elderly women with pathologically staged I thru III
breast cancer, also indicate a 53% increased hazard for 5-year mortality among women who did
not receive RT, a 16% increased mortality risk for women who did not have chemotherapy, and a
22% increased risk of death for who did not receive chemotherapy within a timely manner.
Furthermore, women who did not receive GCC had about a 20% increased risk of death within 5
years of diagnosis, compared to women who received GCC. The observed increased risk of
breast cancer specific and overall mortality among women receiving BCS without vs. BCS plus
RT, is corroborated by multiple published studies. 51,64,65 Yood and colleagues (2008) observed
that elderly women treated with BCS without vs. BCS plus RT were 1.86 times the risk of 10year overall mortality, a finding strikingly similar to this study. 65 Additional findings regarding
the receipt of RT, chemotherapy, and GCC may be partially explained by the propensity to use
less aggressive or lengthy treatments among elderly women or women who are already in poor
health or have a short life expectancy. 51,66
Limitations & Strengths
Several limitations should be kept in mind when interpreting the results of this study.
First of all, this study assessed overall survival and not breast-cancer specific survival. While
many of the factors examined in this study have been directly and indirectly associated with
breast cancer specific mortality, the results of this study should not be generalized to breast
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cancer specific mortality, but overall mortality, which includes both breast cancer specific
mortality and all other causes of death. Another limitation is that this study did not look at the
association between more race/ethnicity classifications. Survival disparities among black women
have been well-document, but was not captured by this study. Additionally, when examining the
association between GCC, receipt of individual treatments, and survival, this study did not make
allowances for women age > 70 years to be omitted from treatment, but rather included older
women in the definition of GCC to make comparisons in receipt of aggressive treatment between
younger and older women. Completion of adjuvant therapies was not assessed, only the initiation
of therapy. Also, tumor receptor status was used as a proxy measure of for tumor receptor testing
and does not provide any information regarding the initiation of adjuvant hormone therapy when
indicated. Additionally, several of socio-demographic characteristics examined were aggregate
census level measures, rather than individual level measures. Finally, the SEER individuals
within the SEER database have been found to be of higher income, and higher concentrations of
racial and ethnic minorities, as compared to the U.S. population.67
Despite these limitations, this study holds several strengths that impart credibility to its
findings. First and foremost, this study provides a comprehensive description of how numerous
factors are associated with overall survival, beginning by examining the relationship between
age, health, clinical prognostic factors, oncology care resources, and socio-demographic
characteristics and survival among a large inclusive cohort of women with stage I, II, and III
breast cancer. Additional analysis examined the associations between various aspects of
treatment and survival among more specific cohorts of elderly women with breast cancer.
Moreover, this study examined survival outcomes using a large cohorts spanning 8 years of
relatively recent data. Algorithms were used to identify receipt of GCC based on the

139

recommended course of treatment according to cancer characteristics put forth by the NCCN and
ACSO. Despite containing slightly greater proportions of affluent and minority individuals,
SEER is widely accepted as representative of the U.S. population, making these results
generalizable to the greater population of elderly women with invasive early-stage breast cancer
insured by Medicare.
Significance & Conclusions
In conclusion, despite the twenty-plus year improvement in breast cancer survival and
relatively high survival rates, several factors remain formidable influences on survival. While
certain factors with direct effects on survival, such as stage at diagnosis, are modifiable via
earlier detection, others are non-modifiable. Non-modifiable factors, such as age at diagnosis,
cannot be changed, and may require novel approaches to improving breast cancer survival in
relation to increasing age. This is particularly challenging given the tendency for elderly women
to be undertreated, a finding in of itself associated with an increased risk of death. However, a
factor that is strongly associated with both survival and age, and may be a promising area to
target increased survival among all populations, but especially the elderly, is comorbidity.
Multiple chronic disease and its burden of illness is a growing epidemic in the US and
throughout developing countries, due to increasing obesity rates and lifestyle. The effects of
obesity, lifestyle behaviors, and associated chronic disease are far-reaching. While it would not
eliminate all incidence and mortality from breast cancer, decreasing the prevalence of chronic
disease, by decreasing obesity and improving lifestyle behaviors, would have a meaningful and
positive impact on the incidence and survival from breast cancer.
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Table 1
Characteristics of Elderly Women with Invasive Non-Metastatic Breast Cancer
All Stage I, II, III
SEER-Medicare 2003-2009

All
Time to Death (Days)
Mean(SD)
Alive 5 Years After Diagnosis
Yes
No
Year of Diagnosis
2003
2004
2005
2006
2007
2008
2009
Age at Diagnosis
66-69
70-74
75-79
> 80
Comorbidity Score
0
1
>2
PCP Visits
Low
High
Stage at Diagnosis
I
II
III
ER Status
Positive
Negative
Borderline/Unknown
PR Status
Positive
Negative
Borderline/Unknown
Tumor Grade
Well Differentiated
Moderately Differentiated
Poorly Differentiated
Undifferentiated/Unknown
BCS = breast-conserving surgery

N
53,830

%
100.0

Stage I, II/Local Treatment
SEER-Medicare 2003-2009

N

1247.2 (722.3)
43899
9931
7477
7728
7669
7665
7696
7739
7856

81.6
18.5
13.9
14.4
14.3
14.2
14.3
14.4
14.6
Age & Health

%
45,981

100.0

1410.6 (696.9)

Stage I, II, III/GCC
SEER-Medicare 2004-2009

N
27,883

%
100.0

1246.7 (600.8)

39520
6461

86.0
14.1

24398
3485

87.5
12.5

6667
6527
6418
6494
6564
6629
6682

14.5
14.2
14.0
14.1
14.3
14.4
14.5

―
3885
3726
3873
4025
6151
6223

―
13.9
13.4
13.9
14.4
22.1
22.3

11965
13413
12322
16130

22.2
24.9
22.9
30.0

10331
11741
10731
13178

22.5
25.5
23.3
28.7

6694
7551
6704
6934

24.0
27.1
24.0
24.9

30287
14483
9060

56.3
26.9
16.8

26061
12439
7481

56.7
27.1
16.3

15520
7559
4804

55.7
27.1
17.2

29367
54.6
24834
24463
45.4
21147
Clinical Prognostic Factors

54.0
46.0

15354
12529

55.1
44.9

30153
18196
5481

56.0
33.8
10.2

28931
17050
―

62.9
37.1
―

15731
9514
2638

56.4
34.1
9.5

41840
7904
4086

77.7
14.7
7.6

36364
6301
3316

79.1
13.7
7.2

22298
4136
1449

80.0
14.8
5.2

34894
14377
4559

64.8
26.7
8.5

30504
11766
3711

66.3
25.6
8.1

18762
7463
1658

67.3
26.8
6.0

13093
22957
13856
3924

24.3
42.7
25.7
7.3

12118
20046
10831
2986

26.4
43.6
23.6
6.5

6741
12287
7302
1553

24.2
44.1
26.2
5.6
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Table 1
Characteristics of Elderly Women with Invasive Non-Metastatic Breast Cancer
All Stage I, II, III
SEER-Medicare 2003-2009

All
Tumor Size
< 1 cm
< 2 cm
2 - 5 cm
> 5 cm
Lymph Nodes
Positive
Negative
Mammography Screening Centers
Low
High
Oncology Treatment Centers
Low
High
Type of Surgeon Seen
General Only
Oncology Only
Both

N
53,830

%
100.0

―
―
―
―

―
―
―
―

Stage I, II/Local Treatment
SEER-Medicare 2003-2009

N

%

Stage I, II, III/GCC
SEER-Medicare 2004-2009

45,981

100.0

N
27,883

%
100.0

―
―
―
―

―
―
―
―

8201
10701
7834
1147

29.4
38.4
28.1
4.1

―
―
―
―
―
―
Oncology Care Resources

―
―

7505
20378

26.9
73.1

27783
26047

51.6
48.4

23789
22192

51.7
48.3

15665
12218

56.2
43.8

30146
23684

56.0
44.0

25761
20220

56.0
44.0

12541
15342

45.0
55.0

9613
18.2
8555
3235
6.1
2644
40001
75.7
34782
Socio-Demographic Characteristics

18.6
5.8
75.6

4045
1638
22200

14.5
5.9
79.6

47698
6132

88.6
11.4

41090
4891

89.4
10.6

24594
3289

88.2
11.8

16232
37598

30.2
69.9

13557
32424

29.5
70.5

8493
19390

30.5
69.5

13057
40773

24.3
75.7

10853
35128

23.6
76.4

6806
21077

24.4
75.6

16.7
7686
83.4
38295
Tests & Treatments

16.7
83.3

4660
23223

16.7
83.3

Race
White
Other
Education
< 15% college degree
> 15% college degree
Annual Income
< $35,000
> $35,000
Metro Status
Non-metro
Metro
Loco-Regional Treatment
BCS+Radiation
Mastectomy
BCS Only
Guideline-Concordant Care
Yes
No
ER Status Tested
Yes
No

8965
44865

―
―
―

―
―
―

25067
10768
10146

54.5
23.4
22.1

―
―
―

―
―
―

―
―

―
―

―
―

―
―

9336
18547

33.5
66.5

―
―

―
―

―
―

―
―

26482
1401

95.0
5.02
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Table 1
Characteristics of Elderly Women with Invasive Non-Metastatic Breast Cancer
All Stage I, II, III
SEER-Medicare 2003-2009

All
PR Status Tested
Yes
No
BCS = Breast-Conserving Surgery
Lymph Nodes Tested
Yes
No
Had any Surgery
Yes
No
Had BCS
Yes
No
Had Mastectomy
Yes
No
Had Radiation
Yes
No
Had Chemotherapy
Yes
No
Time to Chemotherapy
Appropriate
Not Appropriate
No Chemotherapy
BCS = breast-conserving surgery

N
53,830

%
100.0

―
―

Stage I, II/Local Treatment
SEER-Medicare 2003-2009

45,981

100.0

N
27,883

―
―

―
―

―
―

26435
1448

94.8
5.19

―
―

―
―

―
―

―
―

25685
2198

92.1
7.9

―
―

―
―

―
―

―
―

27754
129

99.5
0.5

―
―

―
―

―
―

―
―

20865
7018

74.8
25.2

―
―

―
―

―
―

―
―

11636
16247

41.7
58.3

―
―

―
―

―
―

―
―

17023
10860

61.1
39.0

―
―

―
―

―
―

―
―

6992
20891

25.1
74.9

―
―
―

―
―
―

―
―
―

―
―
―

5796
1196
20891

20.8
4.3
74.9
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N

%

Stage I, II, III/GCC
SEER-Medicare 2004-2009

%
100.0

Table 2
Comparison of Characteristics Between Elderly Women Alive and Dead 5 Years After Invasive Non-Metastatic Breast Cancer Diagnosis
All Stage I, II, III
Stage I, II/Local Treatment
Stage I, II, III/GCC
SEER-Medicare 2003-2009
SEER-Medicare 2003-2009
SEER-Medicare 2004-2009
Alive
Dead
Alive
Dead
Alive
Dead
N
%
N
% p-value
N
%
N
%
p-value
N
%
N
%
p-value
All
39520
6461
24398
3485
43899 81.6 9931 18.5
86.0
14.1
87.5
12.5
Time to Deatha
< 0.001***
< 0.001***
< 0.001***
Mean(SD)
2327.2 (357.6) 938.9 (454.1)
2338.7 (361.6)
1055.1 (406.5)
2192.3 (261.0)
1016.8 (402.4)
Year of Diagnosisc
< 0.001***
< 0.001***
< 0.001***
2003
5737 76.7 1740 23.3
5378 80.7
1289
19.3
―
―
―
―
2004
5986 77.5 1742 22.5
5358 82.1
1169
17.9
3188 82.1
697 17.9
2005
6016 78.5 1653 21.6
5344 83.3
1074
16.7
3096 83.1
630 16.9
2006
6044 78.9 1621 21.2
5467 84.2
1027
15.8
3230 83.4
643 16.6
2007
6297 81.8 1399 18.2
5674 86.4
890
13.6
3417 84.9
608 15.1
2008
6691 86.5 1048 13.5
5981 90.2
648
9.8
5591 90.9
560
9.1
2009
7128 90.7
728
9.3
6318 94.6
364
5.5
5876 94.4
347
5.6
Age & Health
Age at Diagnosisd
< 0.001***
< 0.001***
< 0.001***
66-69
10921 91.3 1044
8.7
9690 93.8
641
6.2
6264 93.6
430
6.4
70-74
11954 89.1 1459 10.9
10808 92.1
933
8.0
6956 92.1
595
7.9
75-79
10299 83.6 2023 16.4
9358 87.2
1373
12.8
5858 87.4
846 12.6
> 80
10725 66.5 5405 33.5
9664 73.3
3514
26.7
5320 76.7
1614 23.3
d
Comorbidity Score
< 0.001***
< 0.001***
< 0.001***
0
26091 86.2 4196 13.9
23428 89.9
2633
10.1
14090 90.8
1430
9.2
1
11507 79.5 2976 20.6
10463 84.1
1976
15.9
6517 86.2
1042 13.8
>2
6301 69.6 2759 30.5
5629 75.2
1852
24.8
3791 78.9
1013 21.1
PCP Visitse
< 0.001***
< 0.001***
< 0.001***
Low
24804 84.5 4563 15.5
22008 88.6
2826
11.4
13762 89.6
1592 10.4
High
19095 78.1 5368 21.9
17512 82.8
3635
17.2
10636 84.9
1893 15.1
a = t-test of mean differences
b = cmh chi square test of general association
c = cmh chi square test of location shift using table scores
d = cmh chi square test of location shift using modified ridit scores
e = Pearson's chi square test of association
* p < 0.05; ** p < 0.01; *** p < 0.001
BCS = Breast-Conserving Surgery
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Table 2
Comparison of Characteristics Between Elderly Women Alive and Dead 5 Years After Invasive Non-Metastatic Breast Cancer Diagnosis
All Stage I, II, III
Stage I, II/Local Treatment
Stage I, II, III/GCC
SEER-Medicare 2003-2009
SEER-Medicare 2003-2009
SEER-Medicare 2004-2009
Alive
Dead
Alive
Dead
Alive
Dead
N
%
N
% p-value
N
%
N
%
p-value
N
%
N
%
p-value
All
39520
6461
24398
3485
43899 81.6 9931 18.5
86.0
14.1
87.5
12.5
Clinical Prognostic Factors
Stage at Diagnosisd
< 0.001***
< 0.001***
< 0.001***
I
26632 88.3 3521 11.7
25897 89.5
3034
10.5
14573 92.6
1158
7.4
II
14085 77.4 4111 22.6
13623 79.9
3427
20.1
8038 84.5
1476 15.5
III
3182 58.1 2299 41.9
―
―
―
―
1787 67.7
851 32.3
ER Statusb
< 0.001***
< 0.001***
< 0.001***
Positive
35197 84.1 6643 15.9
31842 87.6
4522
12.4
19897 89.2
2401 10.8
Negative
5687 72.0 2217 28.1
4982 79.1
1319
20.9
3282 79.4
854 20.7
Borderline/Unknown
3015 73.8 1071 26.2
2696 81.3
620
18.7
1219 84.1
230 15.9
PR Statusb
< 0.001***
< 0.001***
< 0.001***
Positive
29617 84.9 5277 15.1
26860 88.1
3644
12.0
16823 89.7
1939 10.3
Negative
10894 75.8 3483 24.2
9633 81.9
2133
18.1
6174 82.7
1289 17.3
Borderline/Unknown
3388 74.3 1171 25.7
3027 81.6
684
18.4
1401 84.5
257 15.5
b
Tumor Grade
< 0.001***
< 0.001***
< 0.001***
Well Differentiated
11537 88.1 1556 11.9
10891 89.9
1227
10.1
6228 92.4
513
7.6
Moderately Differentiated
19231 83.8 3726 16.2
17409 86.9
2637
13.2
10945 89.1
1342 10.9
Poorly Differentiated
10152 73.3 3704 26.7
8681 80.2
2150
19.9
5882 80.6
1420 19.5
Undifferentiated/Unknown
2979 75.9
945 24.1
2539 85.0
447
15.0
1343 86.5
210 13.5
Tumor Sized
< 0.001***
< 1 cm
―
―
―
―
―
―
―
―
7720 94.1
481
5.9
< 2 cm
―
―
―
―
―
―
―
―
9610 89.8
1091 10.2
2 - 5 cm
―
―
―
―
―
―
―
―
6287 80.3
1547
5.6
> 5 cm
―
―
―
―
―
―
―
―
781 68.1
366 31.9
a = t-test of mean differences
b = cmh chi square test of general association
c = cmh chi square test of location shift using table scores
d = cmh chi square test of location shift using modified ridit scores
e = Pearson's chi square test of association
* p < 0.05; ** p < 0.01; *** p <
0.001
BCS = Breast-Conserving Surgery
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Table 2
Comparison of Characteristics Between Elderly Women Alive and Dead 5 Years After Invasive Non-Metastatic Breast Cancer Diagnosis
All Stage I, II, III
Stage I, II/Local Treatment
Stage I, II, III/GCC
SEER-Medicare 2003-2009
SEER-Medicare 2003-2009
SEER-Medicare 2004-2009
Alive
Dead
Alive
Dead
Alive
Dead
N
%
N
% p-value
N
%
N
%
p-value
N
%
N
%
p-value
All
39520
6461
24398
3485
43899 81.6 9931 18.5
86.0
14.1
87.5
12.5
Lymph Nodese
< 0.001***
Positive
―
―
―
―
―
―
―
―
5897 78.6
1877
9.2
Negative
―
―
―
―
―
―
―
―
18501 90.8
1608 21.4
Oncology Care Resources
Mammography Screening Centerse
0.001***
< 0.001***
< 0.001***
Low
22514 81.0 5269 19.0
20317 85.4
3472
14.6
13588 86.7
2077 13.3
High
21385 82.1 4662 17.9
19203 86.5
2989
13.5
10810 88.5
1408 11.5
Oncology Treatment Centerse
< 0.001***
< 0.001***
0.002**
Low
24394 80.9 5752 19.1
21995 85.4
3766
14.6
10890 86.8
1651 13.2
High
19505 82.4 4179 17.6
17525 86.7
2695
13.3
13508 88.1
1834 12.0
b
Type of Surgeon Seen
< 0.001***
< 0.001***
< 0.001***
General Only
7062 73.5 2551 26.5
6675 78.0
1880
22.0
3344 82.7
701 17.3
Oncology Only
2664 82.4
571 17.7
2307 87.3
337
12.8
1469 89.7
169 10.3
Both
33444 83.6 6557 16.4
30538 87.8
4244
12.2
19585 88.2
2615 11.8
Socio-Demographic Characteristics
Racee
< 0.001***
0.092
< 0.001***
White
39028 81.8 8670 18.2
35355 86.0
5735
14.0
21609 87.9
2985 12.1
Other
4871 79.4 1261 20.6
4165 85.2
726
14.8
2789 84.8
500 15.2
Educatione
< 0.001***
< 0.001***
< 0.001***
< 15% college degree
12752 78.6 3480 21.4
11315 83.5
2242
16.5
7211 84.9
1282 15.1
> 15% college degree
31147 82.8 6451 17.2
28205 87.0
4219
13.0
17187 88.6
2203 11.4
Annual Incomee
< 0.001***
< 0.001***
< 0.001***
< $35,000
10085 77.2 2972 22.8
8962 82.6
1891
17.4
5734 84.3
1072 15.8
> $35,000
33814 82.9 6959 17.1
30558 87.0
4570 13.01
18664 88.6
2413 11.5
a = t-test of mean differences
b = cmh chi square test of general association
c = cmh chi square test of location shift using table scores
d = cmh chi square test of location shift using modified ridit scores
e = Pearson's chi square test of association
* p < 0.05; ** p < 0.01; *** p < 0.001
BCS = Breast-Conserving Surgery
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Table 2
Comparison of Characteristics Between Elderly Women Alive and Dead 5 Years After Invasive Non-Metastatic Breast Cancer Diagnosis
All Stage I, II, III
Stage I, II/Local Treatment
Stage I, II, III/GCC
SEER-Medicare 2003-2009
SEER-Medicare 2003-2009
SEER-Medicare 2004-2009
Alive
Dead
Alive
Dead
Alive
Dead
N
%
N
% p-value
N
%
N
%
p-value
N
%
N
%
p-value
All
39520
6461
24398
3485
43899 81.6 9931 18.5
86.0
14.1
87.5
12.5
Metro Statuse
< 0.001***
< 0.001***
< 0.001***
Non-metro
7134 79.6 1831 20.4
6477 84.3
1209
15.7
3975 85.3
685 14.7
Metro
36765 82.0 8100 18.1
33043 86.3
5252
13.7
20423 87.9
2800 12.1
Tests & Treatments
Loco-Regional Treatmentb
< 0.001***
BCS+Radiation
―
―
―
―
23043 91.9
2024
8.1
―
―
―
―
Mastectomy
―
―
―
―
8541 79.3
2227
20.7
―
―
―
―
BCS Only
―
―
―
―
7936 78.2
2210
21.8
―
―
―
―
Guideline-Concordant Caree
< 0.001***
Yes
―
―
―
―
―
―
―
―
8659 92.8
677
7.3
No
―
―
―
―
―
―
―
―
15739 84.9
2808 15.1
ER Status Testede
< 0.001***
Yes
―
―
―
―
―
―
―
―
23222 87.7
3260 12.3
No
―
―
―
―
―
―
―
―
1176 83.9
225 16.1
PR Status Testede
< 0.001***
Yes
―
―
―
―
―
―
―
―
23182 87.7
3253 12.3
No
―
―
―
―
―
―
―
―
1216 84.0
232 16.0
Lymph Nodes Testede
< 0.001***
Yes
―
―
―
―
―
―
―
―
22629 88.1
3056 11.9
No
―
―
―
―
―
―
―
―
1769 80.5
429 19.5
Had any Surgerye
0.172
Yes
―
―
―
―
―
―
―
―
24280 87.5
3474 12.5
No
―
―
―
―
―
―
―
―
118 91.5
11
8.5
a = t-test of mean differences
b = cmh chi square test of general association
c = cmh chi square test of location shift using table scores
d = cmh chi square test of location shift using modified ridit scores
e = Pearson's chi square test of association
* p < 0.05; ** p < 0.01; *** p < 0.001
BCS = Breast-Conserving Surgery
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Table 2
Comparison of Characteristics Between Elderly Women Alive and Dead 5 Years After Invasive Non-Metastatic Breast Cancer Diagnosis
All Stage I, II, III
Stage I, II/Local Treatment
Stage I, II, III/GCC
SEER-Medicare 2003-2009
SEER-Medicare 2003-2009
SEER-Medicare 2004-2009
Alive
Dead
Alive
Dead
Alive
Dead
N
%
N
% p-value
N
%
N
%
p-value
N
%
N
%
p-value
39520
6461
24398
3485
43899 81.6 9931 18.5
86.0
14.1
87.5
12.5

All
Had BCSe
Yes
―
―
―
―
No
―
―
―
―
Had Mastectomye
Yes
―
―
―
―
No
―
―
―
―
Had Radiatione
Yes
―
―
―
―
No
―
―
―
―
Had Chemotherapye
Yes
―
―
―
―
No
―
―
―
―
Time to Chemotherapyb
Appropriate
―
―
―
―
Not Appropriate
―
―
―
―
No Chemotherapy
―
―
―
―
a = t-test of mean differences
b = cmh chi square test of general association
c = cmh chi square test of location shift using table scores
d = cmh chi square test of location shift using modified ridit scores
e = Pearson's chi square test of association
* p < 0.05; ** p < 0.01; *** p < 0.001
BCS = Breast-Conserving Surgery

< 0.001***
―
―

―
―

―
―

―
―

18830
5568

90.3
79.3

2035
1450

9.8
20.7
< 0.001***

―
―

―
―

―
―

―
―

9446
14952

81.2
92.0

2190
1295

18.8
8.0
< 0.001***

―
―

―
―

―
―

―
―

15514
8884

91.1
81.8

1509
1976

8.9
18.2
0.036*

―
―

―
―

―
―

―
―

6068
18330

86.8
87.7

924
2561

13.2
12.3
< 0.001***

―
―
―
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―
―
―

―
―
―

―
―
―

5070
998
18330

87.5
83.4
87.7

726
198
2561

12.5
16.6
12.3

Table 3
Hazard of Death 5 Years After Diagnosis of Invasive Non-Metastatic Breast Cancer in Elderly Women
All Stage I, II, II
Stage I, II/Local Treatment
Stage I, II, III/GCC
SEER-Medicare 2003-2009 SEER-Medicare 2003-2009 SEER-Medicare 2004-2009
Dead vs. Alive
Dead vs. Alive
Dead vs. Alive
All
AOR
95% CI
Sig.
AOR
95% CI
Sig.
AOR
95% CI
Sig.
Year of Diagnosis
2003
1.00
1.00
―
―
―
―
―
2004
0.94 [0.88,1.01]
0.95 [0.88,1.03]
1.00
―
2005
0.88 [0.82,0.94] ***
0.88 [0.81,0.95] **
0.90 [0.81,1.01]
2006
0.87 [0.81,0.93] ***
0.82 [0.75,0.89] ***
0.92 [0.83,1.03]
2007
0.81 [0.75,0.87] ***
0.77 [0.71,0.84] ***
0.92 [0.83,1.03]
2008
0.80 [0.74,0.86] ***
0.78 [0.71,0.86] ***
0.87 [0.77,0.98] *
2009
0.77 [0.71,0.85] ***
0.69 [0.62,0.78] ***
0.82 [0.71,0.95] **
Age & Health
Age at Diagnosis
66-69
1.00
1.00
―
1.00
―
―
70-74
1.24 [1.15,1.35] ***
1.21 [1.10,1.34] ***
1.17 [1.04,1.33] *
75-79
1.86 [1.73,2.01] ***
1.90 [1.73,2.09] ***
1.73 [1.54,1.95] ***
> 80
4.01 [3.74,4.29] ***
3.76 [3.45,4.10] ***
2.85 [2.54,3.20] ***
Comorbidity Score
0
1.00
―
1.00
―
1.00
―
1
1.44 [1.37,1.51] ***
1.49 [1.41,1.58] ***
1.38 [1.27,1.50] ***
>2
2.17 [2.06,2.28] ***
2.39 [2.25,2.55] ***
2.09 [1.92,2.27] ***
PCP Visits
Low
1.00
―
1.00
―
1.00
―
High
1.14 [1.10,1.19] ***
1.15 [1.09,1.21] ***
1.18 [1.10,1.26] ***
Clinical Prognostic Factors
Stage at Diagnosis
I
1.00
―
1.00
―
1.00
―
II
1.82 [1.74,1.91] ***
1.66 [1.57,1.74] ***
1.00 [0.86,1.16]
III
3.95 [3.74,4.18] ***
1.81 [1.48,2.21] ***
―
―
―
ER Status
Positive
1.00
―
1.00
―
1.00
―
Negative
1.36 [1.27,1.45] ***
1.33 [1.23,1.45] ***
1.48 [1.32,1.65] ***
Borderline/Unknown
1.22 [1.02,1.45] *
1.08 [0.87,1.35]
0.72 [0.30,1.74]
PR Status
Positive
1.00
―
1.00
―
1.00
―
Negative
1.19 [1.12,1.26] ***
1.17 [1.09,1.26] ***
1.13 [1.03,1.25] *
Borderline/Unknown
1.09 [0.91,1.29]
1.04 [0.84,1.29]
0.88 [0.59,1.31]
Tumor Grade
Well Differentiated
1.00
―
1.00
―
1.00
―
Moderately Differentiated 1.14 [1.07,1.21] ***
1.15 [1.08,1.24] ***
1.11 [1.00,1.23]
Poorly Differentiated
1.54 [1.44,1.65] ***
1.49 [1.38,1.61] ***
1.49 [1.33,1.67] ***
Undifferentiated/Unknown 1.38 [1.27,1.50] ***
1.09 [0.98,1.22]
1.15 [0.98,1.36]
* p < 0.05; ** p < 0.01; *** p < 0.001
BCS = Breast-Conserving Surgery
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Table 3
Hazard of Death 5 Years After Diagnosis of Invasive Non-Metastatic Breast Cancer in Elderly Women
All Stage I, II, II
Stage I, II/Local Treatment
Stage I, II, III/GCC
SEER-Medicare 2003-2009 SEER-Medicare 2003-2009 SEER-Medicare 2004-2009
Dead vs. Alive
Dead vs. Alive
Dead vs. Alive
All
AOR
95% CI
Sig.
AOR
95% CI
Sig.
AOR
95% CI
Sig.
Tumor Size
< 1 cm
1.00
―
―
―
―
―
―
―
< 2 cm
1.36 [1.20,1.54] ***
―
―
―
―
―
―
2 - 5 cm
1.90 [1.62,2.23] ***
―
―
―
―
―
―
> 5 cm
2.30 [1.89,2.80] ***
―
―
―
―
―
―
Lymph Nodes
Positive
1.00
―
―
―
―
―
―
―
Negative
0.68 [0.61,0.76] ***
―
―
―
―
―
―
Oncology Care Resources
Mammography Screening Centers
Low
1.00
―
1.00
―
1.00
―
High
1.04 [0.95,1.13]
1.03 [0.93,1.15]
1.05 [0.93,1.17]
Oncology Treatment Centers
Low
1.00
―
1.00
―
1.00
―
High
0.96 [0.88,1.04]
0.93 [0.84,1.04]
1.00 [0.89,1.12]
Type of Surgeon Seen
General Only
1.00
―
1.00
―
1.00
―
Oncology Only
0.78 [0.72,0.86] ***
0.81 [0.72,0.91] ***
0.74 [0.62,0.87] ***
Both
0.68 [0.65,0.71] ***
0.72 [0.68,0.76] ***
0.78 [0.71,0.85] ***
Socio-Demographic Characteristics
Race
White
1.00
―
1.00
―
1.00
―
Other
1.00 [0.93,1.06]
0.92 [0.85,1.00]
0.99 [0.89,1.10]
Education
< 15% college degree
1.00
―
1.00
―
1.00
―
> 15% college degree
0.92 [0.88,0.97] **
0.91 [0.86,0.97] **
0.92 [0.85,1.00]
Annual Income
< $35,000
1.00
―
1.00
―
1.00
―
> $35,000
0.94 [0.89,1.00] *
0.94 [0.88,1.01]
1.03 [0.93,1.13]
Metro Status
Non-metro
1.03 [0.96,1.09]
0.99 [0.91,1.07]
1.12 [1.00,1.25] *
Metro
1.00
―
1.00
―
1.00
―
Treatment
Loco-Regional Treatment
BCS+Radiation
1.00
―
―
―
―
―
―
―
Mastectomy
1.81 [1.70,1.93] ***
―
―
―
―
―
―
BCS Only
1.94
[1.82,2.06]
***
―
―
―
―
―
―
Guideline-Concordant Care
Yes
1.00
―
―
―
―
―
―
―
No
1.18
[1.04,1.35]
*
―
―
―
―
―
―
Lymph Nodes Tested
Yes
1.00
―
―
―
―
―
―
―
No
1.09
[0.98,1.21]
―
―
―
―
―
―
* p < 0.05; ** p < 0.01; *** p < 0.001
BCS = Breast-Conserving Surgery
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Table 3
Hazard of Death 5 Years After Diagnosis of Invasive Non-Metastatic Breast Cancer in Elderly Women
All Stage I, II, II
Stage I, II/Local Treatment
Stage I, II, III/GCC
SEER-Medicare 2003-2009 SEER-Medicare 2003-2009 SEER-Medicare 2004-2009
Dead vs. Alive
Dead vs. Alive
Dead vs. Alive
All
AOR
95% CI
Sig.
AOR
95% CI
Sig.
AOR
95% CI
Sig.
ER Status Testede
Yes
1.00
―
―
―
―
―
―
―
No
1.29 [0.43,3.87]
―
―
―
―
―
―
PR Status Testede
Yes
1.00
―
―
―
―
―
―
―
No
1.34 [0.62,2.87]
―
―
―
―
―
―
Had any Surgery
Yes
1.00
―
―
―
―
―
―
―
No
0.73
[0.40,1.34]
―
―
―
―
―
―
Had BCS
Yes
1.00
―
―
―
―
―
―
―
No
1.20
[1.10,1.32]
***
―
―
―
―
―
―
Had Mastectomy
Yes
1.00
―
―
―
―
―
―
―
No
1.10
[0.99,1.23]
―
―
―
―
―
―
Had Radiation
Yes
1.00
―
―
―
―
―
―
―
No
1.53 [1.39,1.68] ***
―
―
―
―
―
―
Had Chemotherapy
Yes
1.00
―
―
―
―
―
―
―
No
1.16 [1.03,1.32] *
―
―
―
―
―
―
Time to Chemotherapy
Appropriate
1.00
―
―
―
―
―
―
―
Not Appropriate
1.22 [1.02,1.46] *
―
―
―
―
―
―
No Chemotherapy
―
―
―
―
―
―
―
―
* p < 0.05; ** p < 0.01; *** p < 0.001
BCS = Breast-Conserving Surgery
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Appendix 1. Claims Codes Used for Identifying Types of Treatment
Type of Treatment
Lymph Node Surgery

ICD-9 Diagnostic

ICD-9 Procedure
40.3, 40.41-40.42, 40.5040.54, 40.59, 85.43,
85.48

Lumpectomy

85.20-85.29

Mastectomy

85.33-85.36, 85.40-85.48

Radiation Therapy

V58.0, V66.1, V67.1

92.20-92.39

Chemotherapy

V58.1, V66.2, V67.2,

99.25, 99.28
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HCPCS/CPT
38500, 38510, 38520,
38525, 38530, 39542,
38720, 38740, 38745,
38792, 78195, 7880078801
19120, 19125-19126,
19160, 19162, 1930119302
19140, 19180, 19182,
19300, 19303-19307,
19200, 19220, 19240,
19260, 19271-19272
77261-77799, G0256,
G0261, G0173-G0174,
G0243, G0251, G0338G03340
96400-96599, C8953C8955, G0355-G0363,
G902-G9032, J0640,
J8510, J8520-J8521,
J8530-J8999, J9000J9999, Q0083-Q0085,
S9329-S9331,

Revenue Center

0330, 0333

0331, 0332, 0335

Appendix 1. Guideline-Concordant Treatment Options by Tumor Size and Lymph Node
Status
Stage

Treatment Option A

Treatment Option B

 Mastectomy
 BCS
• ERST & PRST

LNT
 RT

ERST & PRST
 LNT
Stage I:
 BCS
• CT
 Mastectomy
• CT < 120days
1 cm < T < 2 cm, N-  RT
• CT < 120days
 LNT
• ERST & PRST
 LNT
• ERST & PRST  CT
Stage IIA:
 BCS
• CT
 Mastectomy
• CT < 120days
0 cm < T < 2 cm, N+  RT
• CT < 120days
 LNT
• ERST & PRST
 LNT
• ERST & PRST  CT
Stage IIA:
 BCS
• CT
 Mastectomy
• CT < 120days
2 cm < T < 5 cm, N-  RT
• CT < 120days
 LNT
• ERST & PRST
 LNT
• ERST & PRST  CT
Stage IIB:
 BCS
• CT
 Mastectomy
• CT < 120days
2 cm < T < 5 cm, N+  RT
• CT < 120days
 LNT
• ERST & PRST
 CT
 LNT
• ERST
Stage IIB:
 Mastectomy
• CT < 120days
T > 5 cm, N LNT
• ERST & PRST
 CT
Stage IIIA:
 BCS
• CT
 Mastectomy
• CT < 120days
0 cm < T < 5 cm, N+  RT
• CT < 120days
 LNT
• ERST & PRST
 CT
 LNT
• ERST
Stage IIIA:
 Mastectomy
• CT < 120days
T > 5 cm, N+
 LNT
• ERST & PRST
 CT
Stage IIIB & IIIC
 Mastectomy
• CT < 120days
 LNT
• ERST & PRST
 CT
T = tumor size; N = nodal status; BCS = breast-conserving surgery; RT = radiation therapy; LNT = lymph node
testing; ERST = estrogen receptor status testing; PRST = progesterone receptor status testing; CT = chemotherapy;
Stage I:
T < 1 cm, N-
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Figure 1. Kaplan Meier 5-Year Survival Curve of Elderly Women Diagnosed with Invasive NonMetastatic Breast Cancer, SEER-Medicare 2003-2009
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Figure 2. Kaplan Meier 5-Year Survival Curve of Elderly Women Diagnosed with Invasive NonMetastatic Breast Cancer By Stage, SEER-Medicare 2003-2009

Log-Rank P < 0.0001
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Figure 3. Kaplan Meier 5-Year Survival Curve of Elderly Women Diagnosed with Invasive EarlyStage Breast Cancer, SEER-Medicare 2003-2009
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Figure 4. Kaplan Meier 5-Year Survival Curve of Elderly Women Diagnosed with Invasive EarlyStage Breast Cancer By Local Treatment, SEER-Medicare 2003-2009
Log-Rank P < 0.0001
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Figure 5. Kaplan Meier 5-Year Survival Curve of Elderly Women Diagnosed with Invasive NonMetastatic Breast Cancer, SEER-Medicare 2004-2009
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Figure 3. Kaplan Meier 5-Year Survival Curve of Elderly Women Diagnosed with Invasive NonMetastatic Breast Cancer By Guideline-Concordant Care, SEER-Medicare 2004-2009
Log-Rank P < 0.0001

Guideline-Concordant Care ————

Guideline-Discordant Care
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CHAPTER 5
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CHAPTER 5
Study Review
Epidemiology
Breast cancer is the second most commonly diagnosed type of cancer in the United States
(US) and the first among women.1 It is estimated that in 2014, 232,670 incident diagnoses and
40,000 deaths will be attributed to breast cancer. The average age at diagnosis is 61 years. About
21% of breast cancer cases occur in women age < 50 years, 22% among women age 50 – 59
years, and 57% among women age > 60 years. 2 While breast cancer is the most frequently
diagnosed type of cancer among women in the US, it also has among the highest survival rates,
relative to other types of cancer. Relative to women who have never been diagnosed with breast
cancer, breast cancer survivors have 89% 5-year and 83% 10-year survival rates. 3,4 Moreover,
earlier stage diagnosis is associated with greater survival, such that women diagnosed at Stage I,
II, and III have 100%, 93%, and 72% 5-year survival rates, respectively. 1 Decreasing mortality
and increasing survival rates throughout the years are attributed to improvements in
understanding of the disease and its treatment, alongside earlier detection due to increased
routine breast cancer screening. 5
Disparities in Treatment & Survival
Yet, despite these advancements, disparities in treatment patterns and survival outcomes
persist. The most common disparities in treatment are the omission of recommended treatments
and services or receiving non-preferential treatments. The most commonly omitted treatments
are radiation therapy following breast-conserving surgery or mastectomy when indicated,
chemotherapy, adjuvant hormone therapy, and lymph node sampling. While the course of breast
cancer treatment is determined for each women by her tumor size, lymph node invasion, and
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hormone receptor status, women diagnosed at an early-stage often times have the option for
breast-conserving surgery (i.e. lumpectomy) plus radiation therapy or mastectomy. Breastconserving surgery plus radiation therapy has been found to be an equally effective treatment as
mastectomy for long-term survival of invasive early-stage breast cancer and is usually the
preferred treatment choice due to breast preservation and functional performance. 6-10
While about 60% or more women have BCS, one in four women who have BCS will undergo
additional surgery, and about one in ten will eventually undergo mastectomy after treatment
failure with BCS. 11-15 Whether it is the initial choice of surgery or not, epidemiological studies
have reported an increase in the use of mastectomy in recent years. 12,13,16 Women who elect for
mastectomy when BCS plus RT is an option tend to be younger, have a desire to avoid RT, fear
recurrence, are diagnosed with later stage and more aggressive cancers, have cancers with
clinical characteristics associated with poorer survival, are of lower income, insured by Medicaid
or uninsured, reside in rural locations, have increased travel distances for RT, have a surgeon that
is male surgeon, not trained in the U.S., and less recent training. 12,13, 16-21
In actuality, treatment disparities span across the entire course of breast cancer care, and
lead to disparities in survival. Numerous factors have been associated with treatment and
survival disparities, but several are particularly common among elderly women. Age and
comorbidity are two inter-related factors that are strongly associated with treatment and survival
outcomes. Due to an intolerance to toxic effects of radiation therapy and chemotherapy observed
among some populations of older women, the National Comprehensive Cancer Network
(NCCN) do not make recommendations for or against chemotherapy in women age > 70 years,
but suggest chemotherapy be given on a case-by-case basis, depending on the patient's health.22
Additionally, guidelines specify that radiation therapy following BCS may be omitted among
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women meeting the following requirements: age > 70 years, tumors < 2 cm, node negative,
estrogen-receptor positive, and receiving adjuvant hormone therapy.23 Despite these
recommendations, the decision to omit adjuvant therapies due to old age remains a topic of
debate. What is more, study findings of treatment patterns among elderly women with breast
cancer suggest that more women are not receiving radiation therapy and or chemotherapy than
those who meet exemption criteria or may be too poor of health to undergo treatment. 24-29 In
turn, multiple studies have demonstrated poorer survival among elderly women who do not
receive RT following BCS or chemotherapy when indicated. 30-36
Additional factors associated with treatment and survival outcomes are sociodemographic characteristics, access to specialty oncology services, and clinical prognostic
characteristics. Vulnerable socio-demographic characteristics such as being of non-white race,
publicly insured or uninsured, being or residing in areas of low income, low education, residing
in rural locations, and having greater driving distances to treatment centers are associated with
breast cancer treatment disparities.37-42 Race is also directly associated with survival outcomes.
Black women have markedly worse survival outcomes, as compared to white women, such that
5-year survival for white and black women is 90% and 79%, respectively. 3,43,44 Clinical
characteristics associated with greater survival are earlier stage at diagnosis, smaller tumor size,
less or no lymph node invasion, well differentiated tumor grade, and estrogen and progesterone
positive tumors. 1,45-47
Statement of the Problem
To address gaps in the literature and build upon existing knowledge this series of studies
focused upon the treatment patterns and survival of elderly women with breast cancer, a
population with the highest incidence of the disease, but for whom many are undertreated due to
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age and declining health. Specifically, these studies sought to determine how age, health, clinical
prognostic factors, oncology care resources, and socio-demographic characteristics are
associated with these outcomes. The first study investigated the initial type of loco-regional
treatment received for early-stage breast cancer. Most studies reporting on treatment patterns for
early-stage breast cancer present rates that reflects the end result of multiple surgeries, such that
a woman who first had BCS with or without RT, but eventually had a mastectomy, was classified
as having a mastectomy and not BCS. This study captured, the initial treatment, with the
intention of describing treatment preference and recommendation patterns among elderly women
with early-stage breast cancer, as many women with this diagnosis have a choice of treatment.
The second study sought to determine to what degree women with stage I, II, and III breast
cancer receive GCC according to NCCN and ASCO treatment guidelines, by comprehensively
comparing clinical characteristics and the care received by each women, including individual
diagnostic tests and treatment, using a large, nationally representative dataset. In contrast,
previous studies that have examined GCC in piecemeal fashion by studied narrowly defined
groups of women, focusing on loco-regional or adjuvant therapies, or using smaller and older
dataset. The third study will examine overall 5-year survival among the two previously described
study populations and how each of those study outcomes (initial loco-regional treatment and
receipt of individual tests, treatments, and GCC) and independent variables are associated with
survival. Additionally, overall 5-year survival will be examined among a third, more broadly
inclusive sample of women with stage I, II, III breast cancer, to gain a baseline understanding of
overall survival of elderly women with invasive non-metastatic breast cancer.
In view of these findings, the goal of this dissertation was to 1) examine initial locoregional treatment patterns among elderly women with stage I and II breast cancer, 2) receipt of
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individual tests, treatments, and guideline-concordant care among elderly women with
pathologically stage I, II, and III breast cancer, and 3) overall 5-year survival among a broadly
inclusive group of elderly women with stage I, II, and III breast cancer and among the first two
study samples using the linked SEER-Medicare dataset.
Summary of Findings
The first study sample consisted of 45,981elderly women diagnosed with stage I and II
breast cancer in 2003 thru 2009. Of these women, about 55% received breast-conserving surgery
plus radiation therapy as their primary treatment, while 23% were treated with mastectomy and
22% had breast-conserving surgery only. About 63% were diagnosed at stage I, 23%, 26%, 23%,
and 29% were diagnosed at age 66-69, 70-74, 75-59, and > 80 years, and 57% had a comorbidity
score of zero. Receipt of mastectomy or breast-conserving surgery only, compared to breastconserving surgery plus radiation therapy, shared many of the same predictors with associations
in the same direction. Compared to women who received breast-conserving surgery plus
radiation therapy, those who were diagnosed at older age vs. age 66-69 years, had greater
comorbidity vs. no comorbidity, diagnosed at stage II vs. stage I, of non-white race vs. white,
lived in non-metro areas vs. metro, lived in areas of lower income vs. higher, lived in areas of
lower education vs. higher, were treated by a general surgeon only vs. oncology or both
specialties, and were more likely to receive mastectomy or breast-conserving surgery only. The
second study sample was comprised of 27,883 women diagnosed with pathologically staged I, II,
and III breast cancer in 2004 thru 2009. Among this sample, fewer than 34% of elderly women
received guideline-concordant care as per NCCN and ASCO treatment guidelines. About 56% of
women were diagnosed at stage I, 34% at stage II, and 10% at stage III. Age at diagnosis was
fairly evenly distributed, ranging from 24% - 27% for each age group and 56% had a
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comorbidity score of zero. Ninety-five percent of women had their tumor estrogen-receptor,
progesterone-receptor status, and 92% had their lymph nodes tested, but only 61% had radiation
therapy and 25% had chemotherapy. About 75% of women had breast-conserving surgery and
42% of women initially or eventually had a mastectomy. Perhaps not coincidently, most of the
same predictors of treatment for early-stage breast cancer that were not breast-conserving
surgery plus radiation therapy, were also similarly associated with receipt of guidelineconcordant care among women with stage I, II, and III breast cancer. Older age, greater
comorbidity, later stage at diagnosis, non-white race, residing in lower income areas, residing in
lower education areas, and being treated by a general surgeon only were associated with a
decreased likelihood of receiving guideline-concordant care. In fact, women age > 70 years old,
were less than half as likely to receive guideline-concordant care, than women age 66-69 years at
diagnosis. Women 70 years of age and older were 24%, 37%, and 70% less likely to receive
breast-conserving surgery, radiation therapy, or chemotherapy, respectively. The third study
examined overall 5-year survival among the previously two described study samples and a
broader sample (N = 53,830) of women diagnosed in 2003 thru 2009 with stage I, II, and III
breast cancer. Across the three samples, 5-year survival rates ranged from 82% to 88%, rates that
are similar to those previously reported 89% 5-year survival rate for all women diagnosed with
breast cancer in the US. Women who were diagnosed at age 66-69 years, stage I, had a
comorbidity score = 0, had positive estrogen and progesterone tumor receptors, and well
differentiated tumors had the highest overall 5-year survival rates. Again, many of the same
factors that were associated with less than optimal treatment in the first two studies, were
associated with poorer survival. The risk of death within 5 years of diagnosis increased with
each age category, such that women age > 80 years at diagnosis, were 2.8 to 4 times more likely
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to die. Similarly, women with a comorbidity score > 2 were more than twice as likely to die
within 5 years of diagnosis. Additionally, the hazard of death within 5 years of diagnosis also
increased with increasing stage at diagnosis, increasing tumor size, decreasing tumor grade,
positive lymph node status, and negative estrogen or progesterone receptors statuses. The hazard
of death was also increased for those who were treated by a general surgeon, mastectomy, breastconserving surgery only, did not have radiation therapy or chemotherapy, and did not have GCC.
Discussion & Conclusions
Several common themes can be drawn from these study findings. First of all, many of the
same reasons for health disparities that are prevalent among all women with breast cancer, or
even the population at large, can also be observed among elderly women with breast cancer, who
should in theory have uniform health insurance coverage. Whether it relates to receipt of
preferential or guideline-concordant care, women who are characterized by vulnerable sociodemographic characteristics, such as non-white race, low income, low education, residing in
rural areas, or areas with fewer oncology screening and treatment centers are more likely to
experience health disparities in treatment. Elderly women with early-stage breast cancer of these
characteristics more likely to be treated with breast-conserving surgery without radiation therapy
or mastectomy when the option of breast-conserving surgery plus radiation therapy was an
available option. What is more, vulnerable demographics of elderly women with all stages of
invasive non-metastatic breast cancer were less likely to receive guideline-concordant care.
Consequently, and perhaps for additional reasons, poorer overall 5-year survival rates were also
observed among these same at risk populations. Taken together, these findings suggests that
some women are better equipped to access care, regardless of the oncology service centers in
their area. One cannot be certain why disparities persist among a population of women in the
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presence of equivalent health care coverage. Then again, women of white race, higher education,
higher income, residing in metro areas or closer to oncology services may have more trust in
health care providers, may be more comfortable navigating the health care system, may be more
knowledgeable about breast cancer risk, treatment options, and prognosis, and may generally be
more empowered to pursue and overcome treatment obstacles. These attributes that may lend
themselves to increased mammography screening, thus earlier stage at diagnosis, and more
aggressive and informed health care seeking behaviors. However, it is worth noting that
vulnerable socio-demographic characteristics have additional consequences for overall breast
cancer survival. Race, particularly black race, has been linked to poorer breast cancer survival
due to aggressive types of breast cancer that are more frequently diagnosed among this group of
women for biological reasons. Aside from biology, women who have lived a lifetime with
limited access to health care or with riskier environmental and behavioral exposures may have
poorer health and resiliency in old age that result in an increased risk of breast cancer mortality.
Another common theme that can be discerned from these study findings, is that elderly
women experience unique breast cancer disparities because of their age. This finding is
somewhat alarming because this is the demographic for which incidence of breast cancer is the
greatest, but on the other hand, the under treatment and poor survival experienced by elderly
women is somewhat intuitive given the health and functional declines associated with increasing
age. The reason these findings can be both alarming and intuitive is because it is to be expected
for women who are in too poor of health or functional status to be omitted from taxing
treatments such as radiation therapy or chemotherapy, especially when their life-expectancy is
relatively short. In fact, this is why treatment guidelines make such allowances or advise
discretion in the use of such treatments for women older than 70 years of age. However, with
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that said, when only 34% of women over the age of 65 years receive guideline-concordant care
or a little over half are treated with breast-conserving surgery plus radiation therapy, but almost a
quarter receive breast-conserving surgery without radiation therapy, it seems probable that a
greater number of women are not receiving the standard of care than there are of those who are
actually in too poor of health to endure it. This seems to be a likely conclusion when one
observes that more than two-thirds of the women with no comorbidity did not receive guidelineconcordant care. It is not clear why some women would not receive recommended treatments
when they are healthy enough to do so. Possible reasons for under treatment may be that older
women are more likely to refuse extensive treatments than younger women, it is too burdensome
to arrange travel for repeated treatments, their families or caregivers do not believe it is in their
best interest to undergo some treatments, or their oncologist may believe the benefits of such
treatments do not outweigh their associated harms. Regardless of the reason for under treatment,
the survival of women who could have benefited from aggressive treatment will be
compromised. In addition to patterns of under treatment, the increasing obesity epidemic in the
US and its associated chronic comorbid conditions further compromise the overall survival of
elderly women with breast cancer.
Future Research & Direction
Even though breast cancer treatment and survival have improved markedly over the past
twenty-some years and increased mammography screening has increased rates of early stage
diagnosis, disparities in treatment and survival still exist, with unique disparities affecting the
population with the highest incidence of breast cancer. While there is no logical reason for stage
at diagnosis disparities to exist in the age of routine screening among a group of women with
little out-of-pocket costs for the service, and yet they do exist and have negative impact on
survival. Whether a later stage at diagnosis is attributed to declines in screening that are
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commonly observed among elderly women or for other reasons, health care providers and public
awareness campaigns should emphasize mammography screening persistence among elderly
women. Current screening guidelines put forth by the United States Preventive Services Task
Force do not make recommendations for or against mammography screening after the age of 75
years. However, this should not be taken as an excuse to discontinue screening among older
women. Similarly, treatment guidelines make exceptions for the omission of radiation therapy
and chemotherapy among women older than 70 years, but it appears that more women than those
who would meet this exemption do not receive these and other treatments when they would
otherwise be indicated. Retrospective and secondary-database studies cannot definitively
determine why these disparities exist. Prospective studies that can capture physician and patient
perspective, in additional to clinical measures, are necessary to better understand the nature of
this disparity in order to address it. Patient education and navigation programs available at the
time of diagnosis could be helpful to further address treatment disparities among various
vulnerable socio-demographic populations. These programs have shown to be beneficial for
patients who are less knowledgeable about the disease and its treatment options, as well as,
continuity of care and treatment completion. Beyond patient age and access to care, the other
major factor associated with breast cancer disparities among the elderly is high rates of
comorbidity. Yet, this pervasive problem that effects much of the US population may be harder
to address. While the elderly may experience a wide range of health problems, many can be
linked to obesity and unhealthy lifestyles. This health crisis has been the focus of many
researchers, health care providers, government agencies, and other special interest groups.
Although it is common knowledge that the way to preventing this problem is by being physically
active and eating healthy foods, a mechanism for increasing these behaviors has yet to be
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identified. There will be no quick or easy solution to this problem, but efforts should continue to
raise awareness and motive change to improve health, longevity, and resiliency for the
population as a whole, and for elderly women with breast cancer.
Aside from the issues addressed by the current study, future studies of breast cancer
outcomes among elderly women could investigate whether the improvement in targeted and lowdose radiation therapies increase radiation therapy rates among elderly women, the uptake of
sentinel lymph node biopsy vs. axillary lymph node dissection across different populations of
women, factors associated with repeated lumpectomy and treatment failure resulting in
mastectomy, and factors associated with being treated by a general surgeon vs. an oncology
surgeon.
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